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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Breast Cancer — the Languid Breeze o f Change
*•

The debate on the primary surgical treat
ment of breast cancer is focused now on
the wrong issues. The evidence that con* servative methods of treatment give the
same results as those achieved by more
"* aggressive surgical approaches is now
4 overwhelming and may be summarized as
follows. First, the extent of surgery has
no influence on patient survival. Second,
the extent of surgery has no influence on
* the occurrence of distal metastases.
Third, conservative surgery alone leads to
a higher incidence of local recurrence than
does radical surgery. Fourth, when
* radiotherapy is added to conservative
surgery, the incidence of local recurrence
again equals that following radical
surgery.
The question, therefore, is not which
v operation is best, because we now know
that none is the best, but rather why this
r knowledge is not being incorporated more
rapidly into daily surgical practice. Is it
r not obvious that radical surgery should
only be performed if it benefits the pa
tient, that if the results of radical and conr servative surgery are equivalent then we
should conserve? A recent survey con►ducted by the American College of

Surgeons at their 1983 annual meeting in
Atlanta, Georgia showed that modified
radical mastectomy is still the operation
chosen by 80% of surgeons and the
Halsted radical mastectomy is still per
formed by an astonishing 5% of North
American surgeons. Conservative therapy
is certainly not possible in every case; for
example, the large lesion in the very small
breast and the subareolar lesion usually
require mastectomy. In most centres ex
perienced with partial mastectomy and
radiotherapy, however, the conservative
approach is appropriate in 70% to 80%
of women with breast cancer.
Why then is conservation not more
widely practised in the surgical manage
ment of breast cancer? Some of the possi
ble answers to this question may be ob
vious, some may be more subtle, some
may be rather fanciful, some less than
flattering to the surgical profession and
some frankly offensive. All of them may
be found in the pages of various women’s
publications. Perhaps we should discuss
them rather than ignore them.
It has been stated that surgeons are
reluctant to give up a technique practis

ed throughout their professional lifetime;
that surgeons still desperately want to
believe, in spite o f evidence to the con
trary, that the bigger the operation the
better is the chance of “ cure” for the pa
tient; that we resent being told (in our
perception) what to do by women; that
we consider the psychosocial, emotional
and sexual effects of mastectomy to be
trivial; that we feel a loss of control in the
management of breast cancer; that we are
reacting to Oedipal problems by continu
ing to choose the more mutilating pro
cedures; that we will continue to perform
the more radical procedures so long as
they attract a higher fee; and that there
is a widespread conspiracy among
surgeons to suppress acceptance of the
conservative treatments. Until recently,
radical surgery might have been defend
ed on the basis of all the anecdotal
literature purporting to show that it
brought about better results, but this is
now untenable in view of the multitude
of controlled randomized prospective
trials showing otherwise. The humbling
explanation for the outcome in breast
cancer concerns the nature of the disease
with its early widespread dissemination in

»-
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most cases rather than the aggressiveness
or dexterity of the surgeon.
We should try to analyse our response
to some of these criticisms, rejecting those
that may be preposterous and inappro
priate, but owning up to those that may
have some relevance. It is understandably
difficult for women to see, on the one
hand, the evidence that is becoming
public knowledge and, on the other, the
medical profession apparently ignoring it.
There is, indeed, an enigmatic contrast
between the alacrity with which new ag
gressive technology of unproven merit is
accepted and the reluctance with which
traditional concepts, now proven inap
propriate, are rejected.
One significant problem in the change
to conservative surgery for breast cancer
is that surgeons in practice must learn a
series of techniques quite new and
unknown to most of them. Many separate
centres have learned the necessary techni
ques for p a rtia l m astectom y and
radiotherapy independently so it should
not be necessary to repeat all the
mistakes. For example, lesions in the up
per half of the breast are best excised
through a circum ferential incision,
whereas in the lower half a radial incision
gives better cosmetic results; the breast

tissue should not be sutured to repair the
defect after a partial mastectomy, as the
cosmetic result is better when this step is
omitted; radiotherapy dosage has to be
appropriate and the resulting changes in
the residual breast must be recognized and
managed appropriately.
There are other important questions
relating to the primary management of
breast cancer that remain to be answered.
Are there indications for radiotherapy
alone as the primary treatment? Is there
any advantage to the patient in sampling
the axillary nodes at the time of tumour
excision? It certainly helps in establishing
a prognosis, but whether this information
leads to any change in management that
benefits the patient is still an open ques
tion that several controlled trials are at
tempting to answer. If the answer is
positive, how big is the difference? We
must then decide whether the advantage
justifies the morbidity and cost of pro
phylactic chem otherapy. Should
radiotherapy be given prophylactically, as
is the case in most centres at present prac
tising conservative breast surgery, or
should radiotherapy be withheld and
given subsequently to patients presenting
with local recurrence? The incidence of
local recurrence with partial mastectomy

alone is high, probably around 40%, but
it is known to respond well to
radiotherapy. The corollary to this is that 4
60% of these patients never have local
recurrence and, therefore, would be *
receiving prophylactic radiotherapy quite
unnecessarily. Longer follow-up is
necessary to gather further evidence on ^
this. On the basis of present evidence,
radiotherapy should be given prophylactically because a local recurrence rate of
40% is unacceptable to most women, -«
even if it carries no implications for sur
vival or distant metastases.
Public awareness is growing rapidly.
The questions are pressing. We should re- *
tain control of breast cancer, which is still
one of the primary interests within general
surgery, by acknowledging the evidence .
now available on conservative breast
surgery arid acting accordingly.

C h a r l e s J. W r ig h t ,

m b, ch b , m sc ,

FRCS[C], FRCS, FRCS(EDIN)

Professor of Surgery,
University o f Saskatchewan,
University Hospital,
Saskatoon, Sask.
S7N 0X0
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En doscopic S phincterotom y
In any year more than 5000 persons in
North America are hospitalized for either
residual common-bile-duct stones after
cholecystectomy and common-duct ex
ploration or common-bile-duct stones oc
curring many years after cholecystec
tom y.1Until recently, the standard treat
ment for this condition was choledochotom y and removal of the stones,
associated with a mortality of about
2% .2 In 1974, Classen and Demling3 and
Kawai and associates4 reported their ex
perience with endoscopic sphincterotomy
o f the ampulla of Vater in patients who
had common-bile-duct stones. After this
procedure the stones either passed spon
taneously or were extracted. Since then,
this technique has been performed world

wide with excellent results.5 Further
more, studies of sphincter pressure and
repeat endoscopic retrograde cholan
giography have demonstrated that the
pressures are abolished and that the
sphincterotomy remains patent.6,7 In
some centres, endoscopic sphincterotomy
has been extended to treat patients with
cholelithiasis and choledocholithiasis.
With increased experience, endoscopic
sphincterotom y is associated with
minimal morbidity and mortality and a
success rate of over 90%.8 A comparison
of choledochotomy and endoscopic
sphincterotomy clearly demonstrates the
superiority of the latter in removing
stones from the common bile duct (Table
I). Endoscopic sphincterotomy is the pro

Table l-Choledochotom y versus Endoscopic Sphincterotomy
________________________in the Management of Choledocholithiasis
Procedure
Choledochotomy
Endoscopic sphincterotomy

Morbidity, %

Mortality, %

Estimated cost/patient, $*

5 -7
7

2
0.5-1

5000
1000

'Includes hospitalization and physician's fees.

6

cedure of choice in the initial management
of choledocholithiasis.
H . S. H im a l ,

md,

FRCS[C],

fa c s

Department o f Surgery,
Toronto Western Hospital,
399 Bathurst St.,
Toronto, Ont.
M5T 2S8

*
«
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►

Treatment for Perforated
Peptic Ulcer

To the Editors—I wish to challenge
several statements made in your July 1983
y issue in regard to the treatment of
perforated peptic ulcer.
j,
Dr. Cohen asserts on page 301, “ If,
however, the perforation is recent . . . it
* is best to deal definitively with the ulcer” .
This is a dangerous dogma to propound
as no major centre in the western
hemisphere has followed this unsafe
practice.
Mr. Herman-Taylor has not really
recruited any advocates to his “ nony surgical” philosophy for perforated pep
tic ulcers!
*- In his article (pages 370 to 372) Fong
does not describe any definite method to
ascertain accurately the exact time of per
foration. The history of the patients is
* misleading. In nine of his patients, the
diagnosis was made at autopsy.
Let me emphasize that the reason for
y writing this letter is to keep the facts clear.
The correct treatment of perforated pep
tic ulcer disease is surgical. It is a lifethreatening situation requiring simple
* closure but meticulous toilet o f the
peritoneal spaces. The appropriate policy
* with antibiotics is to give a thirdgeneration cephalosporin at least 1 hour
before operation, to add an aminogly
coside and continue for at least 24 hours.
If other readers disagree with my
►recommendations, I would like to hear
from them.

perforation.1 This view gained accept
ance in the management of perforated
gastric ulcer, but for many years surgeons
continued to patch perforated duodenal
ulcers. The pendulum of surgical opinion
has now swung so far towards definitive
surgery that Sirinek and associates2 felt
constrained to plead for the continued
role of simple closure in elderly patients
seen many hours after perforation. If Dr.
Chaturvedi had read that paper, he would
have discovered that all of its prominent
discussants favoured definitive surgical
treatment.
The old fear that dissection of the
esophagus would result in a high mor
tality from mediastinitis has proved
groundless. Numerous reports from
Europe and the United States have clear
ly documented an acceptable mortality
for definitive surgery in selected patients.
Good judgement in patient selection is
crucial as are the operator’s experience in
gastric surgery and the resources
available. How best to select patients has
not yet been clearly defined. For some
surgeons simple closure will remain the
treatment of choice.
I agree that facts should prevail over
dogma. Unfortunately, Dr. Chaturvedi’s
proposed list of facts is, with one excep
tion, yet another collection of strongly
held opinions (dogma).
M.M.

Cohen,

m b , f r c s ic ], f r c s (e d in )

Member,

Editorial Board.

►

MAHAVIR P . CHATURVEDI, PC, FRCSfCJ,
r
FRCS, FRCS(EDIN)

180 Tulip Ave.,
Floral Park,
''NY 11001

* To the Editors.—Dr. Chaturvedi con
demns definitive surgery for perforated
peptic ulcer as dangerous dogma and con
tends that “ no major centre in the western
hemisphere has followed this unsafe pracr tice” . Thirty years ago some well-known
American surgeons advocated gastrec
tomy as the emergency treatment for

Head,
Division of General Surgery,
Mount Sinai Hospital,
Toronto, Ont.
M5G 1X5

References
1. Cooley d a , J ordan GL jr . Brockman h l , d e Bakey
ME: Gastrectomy in acute gastroduodenal perforation:
analysis of 112 cases. A nn Surg 1955; 141: 840-9
2. Sirinek KR, L evine BA, Schw esing er w h , aust JB:
Simple closure of perforated peptic ulcer. Still an effec
tive procedure for patients with delay in treatment. Arch
Surg 1981; 116: 591-6

To the Editors.—In response to Dr.
Chaturvedi’s letter, the method used in

my study (Can J Surg 1983; 26: 370-2)
to determine the time of perforation was
obtained from the history. As stated in
the methods, the duration of perforation
was the time from the initial symptoms
attributable to the perforated viscus to the
time of operation. C ontrary to
Chaturvedi’s impression, there was good
correlation in most patients between the
history and the findings at operation.
Also, most patients with acute symptoms
of less than 12 hours’ duration had sparse
or no bacterial growth on culture of
material from the peritoneal cavity. I
agree that in elderly, debilitated, immunosuppressed or neurologically defi
cient patients symptoms may be masked
and the duration of perforation difficult
to ascertain, and surgery is usually per
formed late.
In regard to treatment of perforated
peptic ulcer, I agree that early surgery is
the mainstay of treatment and this is
clearly stated in my discussion. There is
no evidence that antibiotics are of value
for acute perforations of less than 12
hours’ duration, as this is primarily a
chemical peritonitis. The antibiotic
regimen of choice for later perforations
has not been studied in this setting. The
combination of a third-generation
cephalosporin and aminoglycoside sug
gested by Dr. Chaturvedi is an expensive
one with overkill that is not necessary.
The same results could probably be
achieved with a cheaper, less-toxic single
agent, such as cefoxitin, which would
cover the usual coliforms (Escherichia
coli, Klebsiella sp. and Proteus sp.), strep
tococci and anaerobes. Even a firstgeneration cephalosporin, such as
cephalothin, would probably be effective
as most of the anaerobes are the moresensitive oral flora, although recent data
suggest that they are becoming more
resistant.
I.W . F o n g ,

m d , frcpic ]

Department of Medicine,
St. Michael’s Hospital,
30 Bond St.,
Toronto, Ont.
M5B 1W8
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Another Use for Surgical Gloves
To the Editor.—Usually, the reduction of
finger fractures is relatively easy, but it
is sometimes difficult to maintain that
reduction.
Skin traction was advocated by
Watson-Jones in 1955.1 Skeletal, pulp
and nail traction have all been used.
Transfixion o f Bennett’s fractures to the
neighbouring metacarpals will ensure
stability, but this is an invasive procedure.
We have circumvented most of the
problems of continuous traction by using
fingers cut from rubber or latex gloves,
gluing them to the skin of the involved
finger; the free, unglued tip of the rub
ber is used for the traction (Fig. 1).

The method is simple and noninvasive.
We still use operative techniques when
necessary.
Method
The only two chemicals needed are a
tube of cyanoacrylate adhesive and
acetone. Local anesthesia is used. A
plaster cast is applied to the forearm and
hand as far as the proximal palmar
crease. A miniature Thomas splint is
made from an umbrella wire (Fig. 1C)
and incorporated into the plaster before
it sets.
The involved finger is painted with
cyanoacrylate up to the distal interphalangeal joint. A latex finger is then put
on the digit. This must be done quickly
and in a single movement.
Reduction of the fracture is then car
ried out and traction is applied (Fig. 1,
A and B). The distal end of the latex rub
ber is folded over the “ V” on the splint
and tied (Fig. 1C). The reduction is main
tained by continuous traction for the re
quired time. The other four fingers are
left free and mobile (Fig. 2). Acetone is
used to remove the latex finger.
We have used this method successful
ly in oblique fractures of the middle and
proximal phalanges and in Bennett’s
fractures.
August P. H ovnanian, md , facs
PO Box 17145,
Euclid,
Ohio 44117

FIG. 1—Application of latex finger for obli
que fracture of proximal phalanx (A, B) with
traction (C).
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Organ Transplantation and Cyclosporin A
The author provides a historical review
of organ transplantation, concentrating
on the modern scientific era, which
began with experiments by Gibson and
Medawar in 1943. They showed that
skin grafts were rejected by an immune
mechanism. Later experiments by
Medawar and his colleagues on neonatal
tolerance stimulated surgeons to seek
ways of transplanting organs to patients
dying of irreversible disease of vital
organs. The kidney was the first organ
to be transplanted therapeutically. After
the surgical technique was worked out,
excellent results were obtained in grafts
between identical twins in whom rejec
tion would not occur.
Control of rejection awaited a practical
form of immunosuppression. This involv
ed the use of the 6-mercaptopurine
analogue azathioprine together with cor
ticosteroids. These have been the basis
of immunosuppression for grafts not only
of kidney but also of liver, heart and
pancreas. Some antilymphocyte globulin
preparations have been found a valuable
adjunct but there was no major improve
ment until the cyclic peptide cyclosporin
A was introduced. Although this drug is
nephrotoxic in man, with careful dose
adjustment, immunosuppression can be
achieved with fewer and less serious
side-effects than azathioprine and
steroids. In the European trials of the
drug, the use of steroids for maintenance
has been avoided and this is regarded as
a great boon by patients.
The author concludes with a few
speculations concerning the future of
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transplantation, pointing out that if im
munosuppression improves to the point
where transplantation is acceptable for
treating patients for whom alternatives
exist, for example in the replacement of
endocrine glands, gonads, bowel and
limbs, then the present shortage of
donor organs would be aggravated, giv
ing rise to serious concerns about organ
procurement and the ethics involved.

L'auteur trace un apercu historique des
greffes d'organes, s'attachant particulierement a I'epoque scientifique moderne
qui commenca avec les experiences de
Gibson et Medawar en 1943. Ceux-ci
demontrerent que les greffes cutanees
sont rejetees par un mecanisme immunitaire. Par la suite, les experiences de
Medawar et de ses collaborateurs sur la
tolerance neonatale devaient inciter les
chirurgiens a rechercher des moyens de
greffer un organe a un patient sur le
point de mourir des suites d'une atteinte
irreversible d'un organe vital. Le rein fut
le premier organe greffe a des fins therapeutiques. Apres qu'eurent ete mises au
point les techniques chirurgicales, d'excellents resultats purent etre obtenus
lors de greffes entre jumeaux identiques
chez qui il ne pouvait y avoir de rejet.
La lutte contre les reactions de rejet
dut attendre une forme pratique d'immunosuppression qui fut obtenue avec
I'azathioprine, un analogue de la
6-mercaptopurine, et les corticosteroldes.
Ces medicaments ont ete £ la base de
I'immunosuppression, non seulement
dans les greffes de rein, mais aussi dans
les transplantations de foie, de coeur et
de pancreas. Certaines preparations de
globulines antilymphocytaires se sont
reveiees comme un appoint th6rapeutique utile, mais il fallut attendre I'arrivee
de la cyclosporine A, un polypeptide
cyclique, avant d'obtenir le premier progres important. Bien que ce medicament
soit nephrotoxique chez I'homme, un
ajustement minutieux de la dose, permet
d'obtenir une immunosuppression avec
des effets secondaires dont la frequence

et la gravite sont moindres que celles de
I'azathioprine et des steroTdes.
Dans des etudes europeennes sur ce
medicament, I'utilisation des steroides en
traitement d'entretien a pu etre evitee,
-4
ce qui est considere comme un avantage
appreciable pour les patients.
*■
L'auteur conclut avec certaines antici
pations sur le futur de la transplantation
*
d'organes. II souligne que si I'immunosuppression s'ameliore au point que Ton
envisage de traiter par greffe des
k
patients pour qui il existe d'autres solu
tions, par exemple, pour remplacer des
glandes endocrines, les gonades, I'intestin ou des membres, la presente penurie
-»
d'organes ira en s'aggravant. L'obtention
des organes pour fins de greffe et les
"
problemes d'ethique deviendront alors
I'objet de serieuses inquietudes.

v

It is a great honour and pleasure to be
selected to give the Gordon Murray
lecture.
When I started research, I remember
reading of Gordon Murray’s work on
dialysis and transplantation. He per
formed one of the first kidney grafts in
man, but his interest extended far beyond
kidney disease. He made notable contributions to orthopedic, cardiac, vascular
and cancer surgery. To have such a
wide field of interest would be very dif
ficult nowadays with the increasing
specialization that is beginning to separate
surgeons into sterile, non-communicating
boxes with their own specialist boards and
private trade-union arrangements, a new
development which I am sure would not
have been pleasing to Gordon Murray.
In this lecture, I shall trace briefly the
history of transplantation from 1954, the
time of Gordon Murray’s experiments in
clinical kidney grafting, to the present and
will venture a few comments on the direc
tion in which future progress might
reasonably be expected.
Historical Review of Transplantation
The concept of replacing a diseased
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organ with a graft from another person
goes back into ancient legend. It is well
t documented in the story of Saints Cosmas
and Damian, the twin patrons of medi* cine who removed a man’s cancerous leg
and replaced it successfully with a leg
removed from a corpse exhumed specially
^ for the operation (Fig. 1). This surgical
miracle is depicted in early European
K churches and there was general ethical ap
proval of the procedure at a time when
«. such operations were restricted to one
specialist team.
The first scientific experiments on
tissue grafting were performed by an
Italian surgeon, Baronio, who published
a monograph in 1800 showing that free
autografts of skin took permanently if the
y surgery was done carefully but allografts
from another individual were destroyed
after a few days (Fig. 2).
In 1943, Gibson and Medawar1 showed that the process of allograft rejection
was an immune reaction, second-set
grafts from the same donor being
f destroyed more rapidly than first grafts.
Exposure to the donor skin caused
specific sensitization analogous to the im
munity to chicken pox that follows infec' tion with the virus. The process was
specific, relating to the donor in question
but not to a third party.
y
In 1956, Billingham and associates2
showed that the immune reaction could
► be prevented if the donor’s antigens were
injected into the recipient in utero or dur
ing the neonatal period before the reticu
loendothelial system had developed. In* jected animals became immunologically
tolerant to donor tissue, accepting grafts
r from the donor as if they were autografts.
Although no direct application could be
made of this work, it served as an impor
tant stimulus to surgeons attempting to
graft organs. The first requirement was
r a reliable method of joining blood vessels
together. This was described by Carrel3
v who, in 1914, used this technique to study
experimental kidney grafts, concluding
* that autografts would be accepted per
manently while allografts, after a period
of function, would always be destroyed.
*
Hume and his colleagues4 reported in
1955 their experience with renal allografts
* in nine patients with terminal renal
failure. Although at that time effective
* immunosuppressive therapy was not
available, some of these kidneys func
tioned for a surprisingly long period; one
y produced urine for 5V4 months. Patients
with chronic uremia or any serious
*• debilitating disease have impaired im
mune defences, which probably explains
h these early results and also those of Gor
don Murray and Holden5 who, in 1954,
described four clinical cases. Although
> studies of renal function were not per
formed, one patient was thought to have
good function in the kidney for a long
a

time. The patient who suffered from
glomerulonephritis recovered.
Joseph Murray and his colleagues6 in
1958 reported from the Peter Bent
Brigham Hospital in Boston on trans
plants between identical twins where the
sick twin was suffering from chronic renal
failure. Some of their early patients still
have functioning transplants 20 to 25
years after operation, showing that when
rejection can be avoided, identical twins
behaving biologically as the same in
dividual, kidney grafts can provide ex
cellent function for at least a quarter of
a century.
Trials of renal allografts using total
body irradiation to damage the immune
system gave disappointing results except
in two cases in which the grafts were be
tween nonidentical twins, suggesting the
advantages of familial donors.
Subsequently, unravelling of the major
histocompatibility complex in man that
governs the most important transplanta
tion antigens has shown that these prod
ucts reside on the sixth human chromo
some and there is a 25% chance that sib
lings will share these products and
therefore have a double haplotype match,
parents being half matched or a single
haplotype match for their children.7' 10
The process of rejection involves in
filtration of the graft with lymphoid cells
which divide rapidly, causing edema and
parenchymal damage. This form of rejec
tion is usually sensitive to high doses of
steroids which often lead to complete
resolution of the damage. The other
method of graft destruction involves
humoral antibodies circulating in the
blood that destroy blood-vessel linings of
the graft and cause irreversible damage.
In 1959, Schwartz and Dameshek11
found that the antileukemic drug 6-mercaptopurine would prevent rabbits from
producing antibodies to foreign protein.

FIG. 1—Reproduction of painting attributed
to Girolamo da Cremona (1463-5) of Saints
Cosmas and Damian transplanting leg from
dead donor to patient afflicted with leg tumor.
(Brook Antiphonal, Society of Antiquaries,
London, England.)

This drug also impaired rejection in renal
allografts in dogs but did not produce a
tolerant state.12,13 Burroughs Wellcome
Laboratories at Tuckahoe, New Y ork,14
produced a series of antimetabolite
analogues of purine bases, and azathioprine, a derivative of 6-mercaptopurine,
was found to be more e ffectiv e.15
A zathioprine com bined w ith c o r
ticosteroids became the sheet anchor of
clinical immunosuppression for patients
receiving organ grafts.
Although corticosteroids had been
studied on a number of occasions with a
view to impairing graft rejection, Zukoski
and associates16 reported the first pro
longation of canine renal allografts using
corticosteroids and G oodw in and
associates17 described a favourable
response to rejection in a patient with a
renal allograft.
The development of long-term dialysis
allowed patients dying of renal failure to
be restored to a state of health sufficient
to withstand renal transplantation and
any temporary graft deterioration. The
pooled results of kidney grafting from the
thirteenth (and final) report of the
Human Renal Transplant Registry18 are
shown in Table I. Patient survival was
better than graft survival since most pa
tients with failed grafts returned to
dialysis and many received further
transplants.
Many agents have been added to aza
thioprine and corticosteroids but, with the
exception of certain antilymphocyte
globulin preparations from the sera of
animals injected with human lymphoid
cells, no combination has been shown to
improve the therapeutic index of
azathioprine and corticosteroids. Potent
drugs usually have side-effects and
azathioprine may damage the bone marTable I—Kidney Transplants
— Functioning Grafts
Percent functioning at

Type of
graft

1 yr

5 yr

Sibling
Parent
Cadaver

75
70
50

60
50
30

FIG. 2—Baronio’s skin autografting experi
ment. Allografts were rejected.
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row and cause leukopenia and throm
bocytopenia. Corticosteroids can produce
the disfiguring appearance of Cushing’s
syndrome and stunt the growth of
children. In some patients, aseptic
necrosis of the femoral head develops,
causing severe hip destruction.
Nevertheless, many patients have sur
vived for long periods after renal
allografting. Several of our patients
transplanted with unmatched cadaver
grafts still have good function after more
than 15 years.
The other two organ grafts that have
become established as therapeutic pro
cedures are liver and heart transplanta
tion pioneered by Starzl and colleagues19
and Lower and associates20 respectively.
Recently, transplantation of heart and
both lungs has been added by the Stan
ford team.21 Transplanting these organs
is more hazardous for the patient because
when the liver, heart or lungs fail there
is no equivalent to renal dialysis to rescue
and maintain the patient in good health
for long periods. The heart is more
susceptible to rejection than the kidney
and antilymphocyte globulin has been
used in most recipients of heart grafts
together with azathioprine and cor
ticosteroids. Nevertheless, some patients
have done well, living for more than 10
years after transplantation of these
organs.22,23
Grafting of pancreas has received much
experimental attention and there have
been a number of clinical trials. It is at
tractive to consider transplanting islets of
Langerhans, but results have been poor
because of the difficulty in obtaining
enough donor islets and because of the
extreme susceptibility of the islet to rejec
tion. Vascularized grafts have the disad
vantage that there is leakage of exocrine
secretion, but there is some evidence that
functioning vascularized pancreatic
allografts will prevent the progress of the
microangiopathy that causes blindness
and renal failure. Only a few patients
have benefited from pancreatic grafting
to date.
There is a shortage of donor organs for
grafting throughout the world. The most
suitable donors are those who have
died from brain trauma, intracerebral
hemorrhage and primary brain tumours,
whose circulation can be maintained by
means of a ventilator while the organs are
removed. From such a donor careful
surgical removal and then storage in ice
will allow preservation for several hours
(48 for the kidney, 10 for the liver and
4 for the heart) permitting transport of
the organ from the institute where the
donor has died to the hospital where the
recipient is waiting.
In our experience more than half the
patients accepted for liver grafting die
before a suitable donor organ becomes
available.
12

Cyclosporin A
The chief stumbling block to improved
results from organ grafting is the inade
quacy of current immunosuppression.
Many new agents have been investigated
but it is only relatively recently that a drug
has become available which appears to
have distinct advantages. Cyclosporin A
is a fungal cyclic peptide of 11 amino
acids. It was investigated as an antibiotic
but found to be ineffective. However,
Borel,24 the chief immunologist for Sandoz Ltd., showed that it had immunosup
pressive properties in vitro and extended
the survival of murine skin allografts.
Cyclosporin A was then shown to be
more effective than any other agent or
combination o f agents in controlling the
rejection o f experim ental organ
grafts.25,26 A cautious pilot study of the
agent in clinical cadaveric renal transplan
tation confirmed its immunosuppressive
action but revealed a nephrotoxic proper
ty not seen in experimental animals. Renal
function can be severely impaired by the
drug and although recovery is usually
rapid when the dosage is decreased or the
drug is changed to azathioprine and
corticosteroids27 it may produce a leaky
capillary syndrome affecting particular
ly the brain or lungs and this makes the
drug difficult to use. Moreover, its ab
sorption is unpredictable. It is fat solu
ble and requires bile in the duodenum
before it can be absorbed. Following ab
sorption it is metabolized and excreted
largely by the liver. It can also be
hepatotoxic. If it produces hepatotoxicity, blood levels may rise rapidly after in
travenous administration and toxic effects
have been observed in such cases and also
in patients with liver allografts when liver
function has been impaired by the
transplant procedure.
Nevertheless, cyclosporin A seems to be
an important therapeutic advance. In our
own experience of cadaveric renal
transplantation using cyclosporin A as the
sole initial immunosuppressive drug,28
there has been a marked improvement in
results.27 The drug has advantages in
liver, heart, heart-lung and segmental
pancreatic grafting.28-33
A multicentre trial has been conducted
by Sandoz Ltd. in which eight transplant
centres participated, four in continental
E urope and four in the U nited
Kingdom.34 Patients who had diuresing
cadaveric renal allografts at 6 hours after
operation were divided at random into
two groups. Those in the control group
were given conventional immunosuppres
sion with azathioprine and steroids accor
ding to the individual centre’s usual
policy. The trial group was given
cyclosporin A, starting with 17 mg/kg
daily. If there was evidence of rejection,
up to six 1-g doses of methylprednisolone

were given over a 14-day period. If the
patient failed to respond, immunosup
pressive therapy was changed to
azathioprine and steroids. More than 200
patients entered the trial and the
preliminary results have been pub
lished.34 It is of interest that patients ex
cluded from the trial because of failure
to diurese at 6 hours and who were treated
with azathioprine and steroids had graft
function that was similar to that of the
control group of patients, treated with
azathioprine and corticosteroids, who did
have diuresing kidneys.
An initial worry of cyclosporin A was
the development in our original series of
three cases of lymphoma.28 Clearly, the
drug is extremely powerful and if other
agents are added overimmunosuppression
can result, causing viral infections and
lymphomas probably associated with the
Epstein-Barr virus.35 Since adopting our
new protocol, we have had no cases of
lymphoma despite the many patients who
have been treated.36
Our deliberate policy has been to avoid
long-term therapy with corticosteroids in
addition to cyclosporin A, but such pro
tocols have been used in the United
States29 and Canada.37 With low-dose
corticosteroid therapy there may be bet
ter allograft survival, although the in
cidence of lymphoma is higher. Of our
patients with functioning renal allografts,
85% are receiving only cyclosporin A and
30% have never received any steroids. By
far the most serious complication has
been nephrotoxicity. Other side-effects
have been increased facial and body hair,
gum hypertrophy, hypertension, tremor,
hepatotoxicity and subclinical marrow
depression, since patients switched from
cyclosporin A to azathioprine will often
not tolerate the full dose of azathioprine
without having leukopenia. Fibroadeno
mas in the breasts, shooting pain in the
limbs and migraine have also occurred.
Most patients, however, do not have
serious side-effects.
The mechanism of action of cyclospo
rin A is not well understood. It appears
to interfere with T-cell function without
actually destroying T cells. It may inhibit
the release or the action of interleukinII, a natural stimulator of T cells.38
Attempts to keep the serum levels in the
therapeutic range have not been fully suecessful. It is very difficult to maintain
serum levels between 300 and 1000 ng/ml,
which are the limits we aim at, and even
within these limits control of rejection
may not be complete, some patients having severe nephrotoxicity. Variations in
serum levels for a given oral dose have
been surprisingly large. Cyclosporin A is
a valuable immunosuppressant as an al
ternative to conventional treatment. Pa
tients can be started on the drug and
switched to azathioprine and pred-
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nisolone or vice versa. Most o f our pa
tients are anxious to receive cyclosporin
► A because it avoids unpleasant cushingoid
effects. The chemists at Sandoz Ltd. have
* succeeded in synthesizing the whole
molecule o f cyclosporin A including a
unique C9 amino acid.39 Analogues can
therefore be produced. It is hoped that
a compound will become available with
the same immunosuppressive properties
as cyclosporin A, or even better, and no
*- nephrotoxicity. In animals, nephrotoxici
ty is not a feature despite excellent
immunosuppression.
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Shortage o f donors and the limits of
current immunosuppression are the chief
obstacles to organ grafting. Education of
the public and the medical profession is
likely to improve organ donation as
would legislation giving presumed consent
for organ donation unless there has been
prior objection. Such a law has helped
with organ donation in France and can
prevent traumatic interviews with be
reaved relatives. If consent were presumed, the possibility of organ donation
would probably be discussed and a deci
sion made before a disaster or accident.
The aim o f immunosuppression is to
allow graft acceptance without having
totally impaired immune defences. It is
likely that in all recipients o f allografts
who do well, natural inhibitory control
o f the immune response does not occur
spontaneously. Suppressor T cells and
humoral enhancing antibodies can play a
part in maintaining a graft. Experimen
tally, specific tolerance has been produced
in adult animals without the use o f im
munosuppressive drugs, but this has not
been achieved in man. Liver allografts in
pigs and certain strains of rats appear to
produce a specific tolerance. The liver
may suffer severe rejection which resolves
spontaneously; then immunosuppressive
factors appear in the serum which can be
transferred to other animals o f the reci
pient strain, allowing them to accept
grafts o f skin or heart for long periods.40
Clinical application of such a mechanism
in a predictable manner would be of great
value, but the phenomenon cannot be
reproduced in all pig liver allografts and
it applies only to certain strain combina
tions in rats. In man and the dog, rejec
tion o f the liver occurs unless immunosuppressive drugs are given.
Better pharmacologic immunosuppression is likely to be the next step in improv
ing the results o f organ grafting. Since
every organ in the body has now been
transplanted experimentally, in the case
o f the brain it is a philosophical point to
decide if the brain is really grafted to the
body or the body to the brain. Since cen
tral nervous reconnections cannot take

place, this frightening prospect can re
main a subject o f theoretical dialogue.
A certain, safe and cheap immunosup
pressive regimen would change the prac
tice o f surgery. Diabetics would receive
grafts o f pancreas and other endocrine
glands could be transplanted. There
would be much debate on the subject o f
gonadal grafts. The child born of a
donor’s germ cells would have the
biologic identity o f the graft and not o f
the pseudoparent. Since peripheral nerve
regeneration will take place, limbs could
be grafted. Patients with deficient bowel
could have intestinal transplants. A possi
ble alternative for some organs would be
mechanical substitutes, such as a pump
to replace the heart and mechanical
joints. In both areas progress has already
been made. In many other instances bio
logic grafts are preferable. But from
where would the extra organs come? Even
if all suitable cadaver grafts were used,
there would still be a shortfall. Perhaps
greater biologic knowledge would allow
grafting between species. One could im
agine healthy organs o f appropriate size
taken from specially bred pigs, but this
would be resented by some and a matter
o f debate by a minority who might feel
that the claim o f pigs for human organs
would be a preferable moral decision.
Perhaps we are lucky that this argument
is not yet relevant because we are ignorant
o f biologic factors that at present prevent
grafting between species.
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This randomized prospective study ex
amines the efficacy of intravenously ad
ministered heparin as prophylaxis against
deep-vein thrombosis, detected
isotopically with iodine 125, in 37 patients scheduled to undergo major ab
dominal procedures. Twenty patients
were given 5000 units of sodium heparin
on opening the abdominal cavity, while
17 patients who did not receive heparin
acted as controls. The effect of heparin
was reversed at the end of the operative
procedure by protamine. Three control
patients had deep-vein thrombosis
postoperatively but only one heparintreated patient did. Complications in the
treated group included excessive blood
loss intraoperatively in one patient and
an incisional hernia postoperatively in
another.
Although the results are not statistically significant, this study suggests that a
single dose of heparin given intravenously during operation is a safe and effec
tive means of prophylaxis against deepvein thrombosis in patients who undergo
general surgical procedures.
Studies are now being carried out to
determine the optimal dose of heparin,
time of administration and duration of
anticoagulation.

Cette 6tude prospective randomisee
y porte sur I'efficacite de I'heparine administree par voie intraveineuse en prophy► laxie des thromboses veineuses profondes; celles-ci avaient 6te d6cel6es a I'aide
r de I'iode 125 chez 37 patients devant subir
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une intervention abdominale majeure.
Vingt patients ont recu 5000 unites
d'heparine sodique des I'ouverture de la
cavite abdominale; 17 patients qui n'ont
pas recu d'heparine ont servi de groupe
temoin. A la fin de I'operation, les effets
de I'heparine ont ete inverses par la pro
tamine. Trois patients temoins ont subi
des thromboses veineuses profondes en
postoperatoire par rapport a un seul des
patients traites a I'heparine. Les compli
cations observees dans le groupe traite
incluent une perte excessive de sang
durant I'operation chez un patient et une
hernie postoperatoire due a I'incision chirurgicale chez un autre.
Bien que ces resultats ne soient pas
statistisquement significatifs, cette etude
indique que ('administration intraveineuse
peroperatoire d'une seule dose d'h6parine est un moyen sur et efficace de pr6venir les thromboses veineuses profon
des chez les patients qui subissent une
intervention de chirurgie generate.
Des etudes sont maintenant en cours
afin de determiner quelle est la dose
optimum d'heparine, le moment d'administration et la duree d'anticoagulation.

in only 7.1% of patients.5 This result is
supported by Spebar and coworkers6
who found that in only 10.5% of patients
did the condition develop after vascular
operations. Why is there such a low in
cidence of deep-vein thrombosis in these
patients postoperatively? One reason may
be that heparin is given routinely during
the course of many vascular surgical pro
cedures. In our previous study,5 each pa
tient received 5000 units o f heparin in
travenously during operation and it is
conceivable that this single dose of
heparin protected them against the
postoperative development of deep-vein
thrombosis. We thought this could be
clarified by a randomized, controlled,
clinical trial in which some vascular pa
tients would not be given heparin in
traoperatively. However, the vascular
surgeons were reluctant to abandon the
use of heparin in elective cases so we
decided to undertake a prospective ran
domized study of patients who underwent
major general surgical procedures to
determine whether a single dose of
heparin intraoperatively would reduce the
occurrence of deep-vein thrombosis post
operatively.

Deep venous thrombosis is a potentially
lethal, but preventable, postoperative
complication. Although the clinical
diagnosis may be difficult, studies of
radioactive-fibrinogen uptake have shown
that the frequency of deep-vein throm
bosis postoperatively in general surgical
patients ranges between 16%’ and 42%.2
Kakkar and coworkers3 found a higher
proportion (45.7%) in patients over 60
years of age and an even greater frequency
(68.4%) in patients with vascular disease
who underwent general surgical pro
cedures. Patients with vascular disease ex
hibit many of the risk factors associated
with the postoperative development of
deep-vein thrombosis.4 However, in a re
cent study of patients who underwent
vascular surgical procedures, deep-vein
thrombosis was detected postoperatively

Patients

Patients over 40 years of age scheduled
to undergo elective m ajor abdominal
surgical procedures were randomized in
to two groups. Patients were excluded if
they had superficial phlebitis, hema
tomas, ulceration, cellulitis or arthritis in
volving the lower limb — conditions that
may produce false-positive results. One
group received heparin intraoperatively
while the other group acted as a control.
Informed consent was obtained from
each patient before entry into the study.
Patients in the study group were given
5000 units of sodium heparin (gutderived) intravenously, 20 minutes after
the start of the surgical procedure, and
on completion o f the procedure the
heparin effect was reversed with pro-
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tamine sulfate. No other prophylaxis
against deep-vein thrombosis was used.
Patients in the control group had no pro
phylaxis against deep-vein thrombosis.
Fibrinogen labelled with iodine 125 was
used to detect deep-vein thrombosis.7
Each patient was given sodium iodide,
100 mg intravenously, to block the uptake
of radioactive iodine by the thyroid and
the same daily oral dosage was continued
postoperatively for 3 weeks. Preoperatively, l25I-fibrinogen, 100 nCi in
travenously, was administered to each pa
tient. The legs were scanned in serial
fashion from groin to ankle at 5-cm in
tervals with a portable gamma counter
(Ibrinator; Amersham Corp., Arlington
Heights, 111.). The initial scanning was
carried out preoperatively, repeated
postoperatively and then daily for 7 days.
Leg counts were expressed as a percen
tage of precordial counts. Readings were
considered to indicate deep-vein throm 
bosis if they were 20% higher than
readings from adjacent sites on the same
limb or from the corresponding site on
the opposite limb. Counts that were
elevated for at least 24 hours were con
sidered to be diagnostic of deep-vein
thrombosis.
Results

At the time of writing, 37 patients had
been entered into the study. The control
group consisted of 17 patients (7 men and
10 women) with a mean age of 65.3 ±
9.8 years. The heparin-treated group con
sisted of 20 patients (9 men and 11
women) with a mean age of 64.1 ± 12.3
years. The age difference was not
statistically significant. Deep-vein throm
bosis occurred postoperatively in three
patients from the control group, a fre
quency of 17.6%. It was bilateral in one
patient. All patients with deep-vein
thrombosis were asymptomatic and, once
the condition was detected, they were
monitored isotopically. In all cases the
thrombosis was confined to the calf and
resolved without anticoagulant therapy.
In the heparin-treated group, only one
patient had deep-vein thrombosis post
operatively, a frequency of 5%. On
postoperative day 4, this patient had a
nonfatal pulmonary embolism proven by
perfusion lung scanning. Intraoperative
blood loss in both groups was comparable
with the exception of the first heparintreated patient who lost 3 L during the
course of an abdominoperineal resection.
One patient in the heparin-treated group
had an incisional hernia. The difference
in the frequency of deep-vein thrombosis
postoperatively between the two groups
is not statistically significant.
Discussion

Pulmonary embolism is the third most
16

common cause of death in the United
States.8 The relation between deep-vein
thrombosis and pulmonary embolism was
described by Virchow in 1846,9 but both
remain common clinical problems. Be
cause deep-vein thrombosis occurring
postoperatively is a preventable cause of
morbidity and mortality, much effort has
been directed towards finding an effec
tive, yet simple, regimen for prophylaxis.
A common prophylactic technique is
that of “ minidose heparin” , which in
volves subcutaneous injection of 5000
units of heparin, two to four times daily.
Although this technique is effective, local
and systemic complications occur in up
to 27% of patients; furthermore, at least
3 to 5 days of therapy postoperatively are
required. T hus, a m ore simple,
straightforward regimen with better or at
least comparable protection, accom
panied by fewer complications, would be
an advantage.
Although peripheral vascular surgeons
have given their patients heparin in
travenously during operation with very
few complications, general surgeons are
sometimes reluctant to do so because of
concern about increased blood loss, a fear
not borne out in this study.
While there may be several mechanisms
by which the incidence of deep-vein
thrombosis in patients who undergo
vascular procedures is reduced, the most
obvious is that of heparin. Although the
exact mechanism by which heparin, given
intravenously, appears to work is not
known, the following have been propos
ed: binding of heparin to antithrombin 3
or to thrombin, release of endogenous
glycosaminoglycans from the vascular en
dothelium, reduced blood viscosity and
reduced platelet adhesiveness.
While this study does not define the
mechanism involved, it does show a
definite reduction in the occurrence of
isotopically detected deep-vein throm
bosis in the heparin-treated patients.
Although the frequency of thrombosis in
the heparin-treated patients and that
found in studies using a miniheparin
regimen10 is similar, we believe the
former has certain advantages. These in
clude a less complicated method — a
single dose given intravenously as oppos
ed to multiple doses given subcutaneous
ly — less expense, avoidance of the local
complications of subcutaneously ad
ministered heparin and a reduction in the
potential complications of intravenous
heparin, which are dose-related. In addi
tion, coagulation studies are not necessary
but may be needed when heparin is given
subcutaneously.
We believe that our results were not
statistically significant because the
numbers of patients involved were
relatively small and the overall incidence
of deep-vein thrombosis was low.

In the majority of cases, deep-vein
thrombosis occurs within 24 hours after
operation. Jennings and associates,11 in
a study of patients who underwent
general or peripheral vascular surgical
procedures, showed that 5000 units of
heparin given intravenously during the
procedure resulted in reduced wholeblood clotting time for more than 24
hours; this may explain the protective effeet of heparin in these patients.
Further studies are needed to clarify the
mechanism of action of heparin in these
patients, as well as the optimal dose, time
of administration intraoperatively and the
need for reversal with protamine sulfate.

4
*
4.

<
■*

*

Conclusion
*

A single dose of heparin given in
travenously during operation appears to
protect patients undergoing major ab- ^
dominal surgery from the development of
deep-vein thrombosis as detected by 125I- «
fibrinogen scanning.
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Reflux Control following Gastric Surgery
*

—

■

► Reflux is a common complication in pa
tients who have undergone gastric
* surgery. These patients have bile reflux,
often associated with gastric disease,
and are resistant to conservative
_ management. In this study the authors
^ have reviewed 124 patients who were
^ treated surgically for reflux that occurred
after gastric operations. They were
V assessed preoperatively by history,
radiologic investigation, manometry with
pH and endoscopy.
Seventeen patients were treated by
* Belsey hernia repair, 42 by partial fundoplication gastroplasty and 65 by total
fundoplication gastroplasty. Thirty-seven
r patients required additional gastric
surgery.
t
Continued reflux was the commonest
problem postoperatively; it was effec
tively corrected by total fundoplication
gastroplasty. Of eight patients who had
persistent bile gastritis, four had had bile
drainage as part of their operation for
reflux.
From this study the authors conclude
that total fundoplication gastroplasty is
the most effective procedure to control
reflux, but it must be carefully tailored to
*■ avoid overcompetence and dysphagia.
Associated gastric problems should be
treated simultaneously.
v

Le reflux est une complication rencontree
frequemment chez les patients qui ont
Y subi une chirurgie gastrique. Ces patients
souffrent de reflux biliaire, souvent
► accompagne de maladie gastrique, resis
tant a un traitement conservateur. Dans
cette etude, les auteurs passent en revue
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124 patients traites chirurgicalement
pour un reflux consecutif a une operation
gastrique. Avant I'intervention, les
patients ont ete evalu6s d'apres leur
anamnese par des examens radiologiques, par manom6trie avec mesure du
pH et par endoscopie.
Dix-sept patients ont 6te traites par
herniorraphie de Belsey, 42 par gastroplastie avec fundoplication partielle et 65
par gastroplastie avec fundoplication
totale. Trente-sept patients ont n6cessit6
des interventions gastriques
additionnelles.
En postop§ratoire, le probleme le plus
frequent 6tait la persistance du reflux,
lequel fut corrig6 efficacement par gastroscopie avec fundoplication totale. Des
huit patients qui ont eu la persistance
d'une gastrite biliaire, quatre avaient eu
un drainage biliaire faisant partie de leur
operation pour reflux.
De cette 6tude, les auteurs concluent
que la gastroplastie avec fundoplication
totale est I'intervention la plus efficace
pour controler le reflux. Elle doit toutefois etre adaptSe avec soin a chaque
sujet pour 6viter une surcapacite et une
dysphagie. Les problemes gastriques doivent etre traites simultanement.

Patients with gastroesophageal reflux
who have had previous gastric surgery
present a particularly difficult manage
ment problem. At least three factors may
affect the results of treatment. Because
of the alkalinity of the reflux bolus, symp
toms do not respond well to acid suppres
sion. Frequently, these patients have both
gastric and esophageal problems with
continued ulcer diathesis despite previous
surgery. Finally, standard methods of
reflux control are often less effective
following gastric surgery.1,2
The described methods of surgical
management often focus on patients who
have been unresponsive to both medical
and surgical treatment. Roux-en-Y
drainage of the stomach or complex
esophagogastric resections have been
advocated.3,4
In this paper we describe our experience
with patients who represent the entire

spectrum of the problem, ranging from
those with a good response to simple
vagotomy and pyloroplasty to those who
underwent multiple gastric and esopha
geal operations, which failed to give
symptomatic relief. This series represents
10.7% of a total experience of 1157
operations for gastroesophageal reflux.
Patients and Methods

Because vigorous medical management
had failed, 124 patients (56 men, 68
women) ranging in age from 19 to 79
years (mean 46.2 years) were treated
surgically for gastroesophageal reflux
and, when necessary, for associated
gastric or duodenal problems.
Patients were investigated preoperative
ly by roentgenography, manometry-pH
determ ination and endoscopy. A
prepared history format was used.
Radiologic studies of esophagus, stomach
and duodenum were carried out and in
cluded water-siphon testing. Manometric
studies used three polyethylene tubes with
side openings (inner diameter 1.19 mm).
A Harvard pump (Harvard Apparatus
Corp., Millis, Mass.) with 100-ml syringes
was used for water infusion at a flow rate
per tube of 2.5 ml/min. Recordings were
made using a Honeywell 1508 U.V.
Visicorder (Honeywell Inc., Denver,
Colo.). A Beckman pH probe and
recorder (Beckman Instruments Inc.,
Schiller Park, 111.) were used for pH
measurements. Fiberoptic endoscopy of
stomach and esophagus was carried out
in all patients.
The surgical management of reflux has
extended over 12 years; in the earlier
phase, management was by standard
Belsey gastroplasty or partial fundoplica
tion gastroplasty. In the past 7 years, the
Nissen gastroplasty or total fundoplica
tion gastroplasty has been used.
Additional gastric surgery was tailored
to the gastric problem and only perform
ed in the presence of poor gastric empty
ing, gastritis and gastric or duodenal
ulceration.
The standard Belsey operation, per
formed in 17 patients, followed the
technique described by Skinner and

VOLUME 27, NO. 1, JAN U ARY 1984 / THE CANADIAN JOURNAL OF SURGERY

17

Belsey.5 Gastroplasty operations were
performed through a left thoracoab
dominal incision because of scar tissue
from previous operations and because
direct-vision dissection in both the chest
and abdomen is necessary. Unless the
esophagus was extremely short, gastro
plasty tubes 5 cm long were cut over a no.
60 French Maloney bougie. Tubes were
closed with continuous 3-0 chromic lock
ing suture and carefully invaginated with
3-0 silk.
The partial fundoplication gastroplas
ty was completed using a 270° fun
doplication below the diaphragm and in
corporating the tube and distal high
pressure zone.6'7 This was carried out in
42 patients.
The total fundoplication gastroplasty,8
performed in 65 patients, will be describ
ed in more detail as this is our preferred
treatment for complex reflux problems.
In preparing the gastroplasty tube, the
greater curvature is mobilized for 15 cm
(four or five short gastric vessels are
divided). Under direct vision the vagi, if
present, can almost always be preserved
and the hepatic branch on the lesser cur
vature usually spared. Care is taken to
preserve the crural peritoneal coverings.
The esophagus is mobilized to the inferior
pulmonary vein laterally and to the aor
ta on its medial and pericardial surfaces
(Fig. 1).
Attention to the details of the fun
doplication technique is essential to the
success of the operation. Past studies9
have demonstrated that the length of the
completion fundoplication is crucial in
reflux control; if it is too long, the patient
will have dysphagia and be unable to burp
or vomit. The intra-abdominal segment
is stabilized by a separate suture line; the
fundoplication is created by using an in
dependent suture line.
The fundus is wrapped clockwise
around the gastroplasty tube and distal
high pressure zone (if the esophagus can
be brought below the diaphragm). The
intra-abdominal segment is fixed with

four to five 2-0 silk mattress sutures from
the stomach to distal high pressure zone
and across the suture line of the
gastroplasty tube (Fig. 2). Gastrogastric
suturing approximates the fundus of the
stomach. The tail of the stomach is nor
mally 2 cm wide and approximated over
1 cm only with three 2-0 silk mattress
sutures. When the stomach is small, the
wrap may be too long and may be reduc
ed to less than 0.5 cm.
Crural sutures are placed before fun
doplication and loosely approximated.
Finally, the fundus is sutured to the
undersurface of the diaphragm to increase
its stability.
Additional gastric procedures consisted
of Billroth 1 and Billroth II gastrectomies,
bile drainage and vagotomy with
pyloroplasty or pyloroplasty alone, and
myotomy. These were added only when
indicated because of gastric or duodenal
problems.
Follow-up was from 1 to 12 years
(mean 5.2 years). Follow-up history is
available in 92.8%, roentgenographic ex
5 cm G astroplasty

Diaphragm

Fundoplication

amination in 90.4% and manometry with
pH in 36%.
Results

^

In this complex group of patients, 225 *
operations had already been performed
before the present procedure (Table I).
The history was similar to that obtained -*■
in 300 patients with reflux uncomplicated
by previous gastric procedures (Table II), *
except for a higher incidence of nausea
and vomiting. Radiologic studies con- *
firmed the presence of a hiatal hernia or
reflux in 106 of the 124 patients (85.5%).
Endoscopy confirmed the presence of
reflux and demonstrated ulcerative
esophagitis or stricture in 38 (30.6%).
Mild gastritis was present in 42 (33.9%),
severe gastritis in 35 (28.2%) and gastric #
or duodenal ulceration was present in 11
(8.9%). An incompetent high pressure
zone was indicated by manometry in 87
(70.2%).10
t
Eighty-seven patients were treated
surgically for control of reflux only. The *
remaining patients underwent additional ^
procedures, including gastric resection,
vagotomy with pyloroplasty, pyloroplasty
alone or bile drainage; in two an extend
ed myotomy was added for diffuse *
esophageal spasm (Table III).
Reflux Control
-f

After the standard Belsey repair, 14 of
17 patients were asymptomatic. Those «
with residual symptoms had persistent
reflux; however, all were improved. None

Distal Esophagus

FIG. 2—Intra-abdominal segment is stabil
ized with separate suture line. Completion fun
doplication is 1 cm long, less than 0.5 cm in
patients who have previously undergone gastric
resection.

No. of
patients

Vagotomy and pyloroplasty
Vagotomy and gastroenterostomy
Esophagogastrostomy
Billroth 1 gastrectomy
Billroth II gastrectomy
Billroth gastrectomy and drainage

Table Ill-Operative Procedures Performed
on the 124 Patients*
No. of
patients (%)

Procedure

Table l-Previous Gastric Operations
in 124 Patients*
Procedure

■4

53
6
1
20
40
4

*66 patients had had previous hiatal hernia
repair in addition to gastric surgery; many had
had multiple repairs (total no. - 101).

Reflux control only
Reflux control plus
Billroth 1 gastrectomy
Billroth II gastrectomy
and bile drainage
Bile drainage
Vagotomy and pyloroplasty
Pyloroplasty
Extended myotomy
(diffuse esophageal spasm)

87 (70.2)
7 (5.6)
1
19
4
4

(0.8)
(15.3)
(3.2)
(3.2)

2 (1.6)

*The previous gastric operation was modified
in 37 patients and tailored to the investigative
findings.

Table II—Preoperative Signs and Symptoms
No. of patients (%)
Sign/symptom

FIG. 1—Esophagus is fully mobilized in
chest and abdomen. No. 60 French bougie is
passed and gastroplasty tube cut. Four or five
short gastric vessels are divided. Left gastric
artery is intact.

18

Heartburn
Reflux to throat
Nausea
Dysphagia

Gastric surgery
(n = 124)
124
101
97
101

(100.0)
(81.5)
(78.2)
(81.5)

No previous gastric
surgery (n = 300)
290
215
139
234

(96.6)
171.5)
(46.3)
(78.0)
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of these patients had had previous gastric
resection and none required additional
Wgastric surgery. One who had previously
undergone vagotomy and gastroenter* ostomy had very mild, persistent gastritis
that occasionally produced symptoms of
reflux.
Of patients treated by partial fundoplication gastroplasty, 18 were asymp♦- tomatic, 11 had moderate, persistent
symptoms and 13 had major residual
Vsymptoms. Of these 13, 8 had had
vagotomy and pyloroplasty, 2 had
undergone Billroth I gastrectomy and 2
a Billroth II gastrectomy. All 24 with
' either moderate or severe symptoms had
.reflux and 4 had gastritis as well.
Those treated by total fundoplication
astroplasty form the largest group. Of
5 patients, 58 were asymptomatic and 7
had moderate, persistent symptoms. All
Krere much improved. Of those with perwstent symptoms, three had moderate
sysphagia and four had bile gastritis;
done had reflux.
n Eight patients had persistent bile
astritis giving rise to mild or moderate
' gymptoms (Table IV). This occurred
I snostly in those who had had previous
tgastric surgery.

i

(45.8970) with a partial fundoplication had
continued reflux. This failure to control
reflux is probably one of the major
reasons for persistent bile gastritis.
Using total fundoplication gastroplas
ty and taking particular care to avoid
overcompetence of the gastroesophageal
sphincter, we have had greatly improved
results. The three patients with persistent
dysphagia were operated upon early in the
series and when this problem was
recognized we reduced the completion
wrap to less than 0.5 cm in patients who
had previously undergone a Billroth II
gastrectomy.
Persistent bile gastritis was present in
8 of the 124 patients. In no case was it
severe enough to merit further surgery.
Four had bile drainage added at the time
of their hernia repair.
The majority of patients with bile
reflux can be effectively handled by a
total fundoplication operation. Clearly,
partial fundoplication is inadequate to
control reflux in this group. Gastric and
duodenal problems should be treated
simultaneously.
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Additional Gastric Procedures
( The various additional gastric pro
cedures are outlined in Table III. By far
^•the commonest procedure was bile
drainage in patients who had previously
undergone a Billroth II gastrectomy.
Gastric resection was used only when
** there was recurrent gastric or duodenal
ulceration.
Four of the eight patients with persis^ tent mild gastritis had bile drainage addT ed to their operative procedure.
Discussion and Conclusions
* Reflux following gastric surgery is one
% of the most difficult esophageal problems
to deal with. In the past it has responded
k inadequately to partial fundoplication.1
In the present study, in the absence of
recurrent hernia, 27 of 59 patients
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“MALLITENE is the first hemostat that combines the high
hemostatic action of microfibrillar collagen with the easy
annlirahilitv
nf Hnth!■
• j f VJm

4

Prof- My|os chvapn, m .d .
Head of Surgical Biology, Department of Surgery, University of Arizona.

MALLITENE’S composition of chemically
pure microfibrillar collagen accounts for its
high hemostatic effectiveness. Its
presentation as a cloth is due to a unique
textile processing which allows for its easy
applicability.
It can easily be cut to the desired size,
folded to increase its hemostatic
effectiveness, sutured to lacerated tissue
(liver, spleen, kidney) or removed in one
piece. It does not stick to instruments and
can be handled by dry gloves.
A comparison of MALLITENE’S hemostatic effectiveness and
handling properties with other hemostatic agents is found
in the graphs below.

Hemostatic Effectiveness +
(Tim e to O b ta in H e m o s ta s is o f S p le n ic B leeding)
Minutes
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Fast Hemostatic Effect due to the large
surface area of the individual fine
collagen fibres of the fleece and the
strong adhesion to the wound.
Does Not Stick to rubber gloves or
surgical instruments. Has no electrical
charge.
Conforms and Adheres firmly to the
bleeding wound.
Can be Sutured to the lacerated wound.
Holds stitches well due to the textile
processing.
Easy to Remove in one piece after
hemostasis is achieved.
Fast Resorbtion in body tissues (avg. rate
of biodegradation: 25 days). Minimizes
risk of adhesions.
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Felt

Collagen
Powder

Gelatin
Sponge

Oxidized
Cellulose

Indications: The co n tro l o f d iffu s e
blood oozing in any tis s u e w here it is
im p ra c tic a l or im p o s s ib le to use
lig a tio n or other conve n tio n a l su rg ica l
procedures.
Contraindications: A fte r h em ostasis
is achieved, M ALLITENE s h ou ld not
be le ft in the wound if used in
in fe c te d or c o s m e tic a lly im p o rta n t
areas. T his applies to all collage n- or
gelatin-based to p ic a l h e m o s ta tic
agents.
Warnings: In p a tie n ts w ith low
p la te le t co u n t or low c lo ttin g fa c to r
a c tiv ity , th e e ffic a c y o f M ALLITEN E is
reduced.

Handling Instructions: Dry
M ALLITEN E o f th e desired size is
app lie d to a bleeding wound, under
m oderate pressure. It is prefera ble
fo r exce s s iv e b lo o d to be removed
from th e b le e d in g s ite before covering
it w ith th e fleece . The cohesiveness
o f the fle e c e a llo w s the a p p lic a tio n by
hand (it does not adhere to d ry rubber
gloves) or by fo rc e p s or clam p. The
fleece can be c u t w ith s c is s o rs or
folde d to th e desire d size. A patch o f
the fle e c e can be sutured over the
bleeding tis s u e if so required. A fte r
a c hievin g hem o s ta s is , the fleece may
be rem oved in one piece leaving little
or no fib ro u s residues. It was
e ffe c tiv e in p a tie n ts treated w ith a n ti
c o a g u la n ts or aspirin.
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t A d apte d from S ilve rste in , M.E. and C h vapil, M., J. Traum a 21: 388-393. 1981.

*

A
1 - MALLITENE is applied to wound in the spleen
under moderate pressure with dry rubber gloves.
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2 - Hemostasis is
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3 - MALLITENE is easily removed with forceps in
one piece.
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MALLITENE texturized collagen fleece is
another new idea brought to life, manufactured
and distributed exclusively by Malliner
Laboratories.

malliner
laboratories inc
“ Bringing new ideas to life.”
10548 - 82nd Avenue, Edmonton, Alberta T6E 2A4
Telephone: (403) 433-8466
- '

M a llin e r Lab ora tories Inc. is a C anadian com pany w h o lly ow ned by Canadians.

C o p yrig h t M a llin e r Lab ora tories Inc. 1983.

P h o to g ra p h s c o u rte s y o f th e U n iversity of S a s k a tc h e w a n ,
D e partm ent o f Surgery.

S.M. Stepkow ski ,

dvm , PH d ; W.R.

D uncan , ph d ; J.P. Sm ith ; H. B itter -Suermann , md

Suppressor Cells in the Thoracic Duct Lymph
of Tolerant, Spleen-Grafted Rats
Vascularized spleen allografts between
two different inbred rat strains induce
specific transplantation tolerance in vivo.
Thoracic duct lymphocytes isolated from
tolerant rats exhibited notable
nonresponsiveness to donor stimulator
cells in the mixed lymphocyte reaction.
In-vitro co-culture experiments indicate
that this nonresponsiveness reflects the
activity of both specific and nonspecific
suppressor cells. Since suppressor cells
are present in tolerant animals, it is
possible that the suppressor cells play an
important role in maintaining spleeninduced transplantation tolerance.
L'allogreffe de la rate vascularisee entre
deux chaines de rats innes produit un
etat de tolerance specifique. Les
lymphocytes preleves du canal thoracique ont demontre la presence de repon
ses rgduites dans la culture mixte de
lymphocyte. La culture mixte de
lymphocytes tolerants avec des lympho
cytes normaux a indique qu'une reduc
tion de la culture mixte de lymphocyte a
reponse reflete I'activite des cellules sup
pressives. II est possible que des cellules
suppressives jouent un role important
dans I'entretien de la tolerance chez le
rat soumis a une allogreffe de la rate.

grafts in dogs and suggested that two dis
tinct processes might occur — the host
responding to the graft (host-versus-graft
response) and the graft responding to the
host (graft-versus-host response).
During the last 10 years, researchers in
our laboratory have been studying the
immunologic consequences of transplan
tation of the spleen in rats. Our initial
results indicated that spleens transplanted
between several different inbred strains
were always rejected 2 to 3 weeks after
grafting, unless the recipient was pretrea
ted with donor lymphoid cells.3 Subse
quently, inbred strain combinations were
found that spontaneously accepted the
allografts without prior treatment or
immunosuppressive therapy.4 The spon
taneous acceptance of spleen allografts
produced a state of transplantation tole
rance, in which the host bearing a spleen
allograft accepted donor skin or pancreas
grafts indefinitely.4,5 The tolerance was
specific, in that tolerant rats always rejec
ted third-party grafts.4
In an attempt to identify the mecha
nism responsible for the tolerance induced
by spleen transplantation, we studied the
in-vitro immune responses of tolerant rats
to donor alloantigens. Lymph-node cells
from tolerant rats exhibited a high degree
of nonresponsiveness to donor stimula
tor cells in the mixed lymphocyte reac
tion, suggesting that tolerant rats lack
donor-specific antigen-reactive cells or
that suppressor T cells are present.6
The present study is an attempt to
analyse further the cellular basis for main
taining transplantation tolerance.
Thoracic duct lymphocytes were used as
a source of tolerant lymphoid cells,
because a large proportion (70% to 80%)
of thoracic duct lymphocytes are T cells,
which migrate spontaneously from lymph
nodes, and some keep recirculating from
blood to lymph. This population,
therefore, should be an excellent source
of suppressor T cells.7

jor histocompatibility complex in the rat.
The microsurgical techniques that we
used for vascularized whole spleen graft
ing and thoracic duct cannulation have
been described previously in detail.3,8 *
Responder cells from normal rats or
rats that had undergone spleen transplan
tation were collected from thoracic duct k
fistulas overnight. Irradiated thymus cells
used as stimulators were obtained from
normal WAG, AGUS and BN rats. The
mixed lymphocyte reaction was performed as previously described.6
Irradiated thoracic duct lymphocytes
from tolerant or normal rats were ex
amined for their ability to suppress nor
mal thoracic duct lymphocytes as
responders in the mixed lymphocyte
reaction.

k

Results

Responses o f AGUS Rats to Mixed
Lymphocyte Reaction 15 to 40 Weeks
After Implantation o f WAG Spleen
Thoracic duct lymphocytes from nor
mal and spleen transplanted AGUS rats
were collected overnight and used as,
responders in a mixed lymphocyte reac
tion with irradiated donor (WAG),
syngeneic (AGUS) and third-party (BN)
stimulators. The results are shown in
Tables I and II. All tolerant animals
In 1910, Carrel1 first reported the trans
demonstrated notably reduced responses
plantation of spleen allografts. He astu
to donor stimulator cells (23% to 87%).
tely noted the possibility of an interaction
Furthermore, their responses to thirdbetween the host and transplanted organ.
party stimulators remained normal in
Simonsen2 also described spleen allomost animals.
From the Laboratory of Transplantation
Suppressor Cells in Tolerant Duct
Biology, Dalhousie University, Halifax, NS
Lymphocytes of AGUS Rats
Presented at the 87th annual meeting o f the
To evaluate further the cellular basis of,
Canadian Association of Clinical Surgeons,
nonresponsiveness to mixed lymphocyte
Eastern Division, Halifax, NS, May 27-28,
reaction, cell mixing experiments were
1983
performed (Table II). Several distinct pat
Supported by a grant from the Medical
terns of suppression were seen. The
Research Council of Canada
thoracic duct lymphocytes of transplanted
rat 313 demonstrated strong suppression
Accepted for publication Nov. 7, 1983
of the normal thoracic duct lymphocyte
Materials
and
Methods
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response to donor (98.6%) and partial *
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the proliferative response of normal
responder cells to both donor (96.5%)
k and third-party (97.1%) stimulator cells.
On the other hand, the responder cell
►population of transplanted rat 33
demonstrated specific suppression of nor
m al responder cells to donor (43.8%) but
no suppression of the response to thirdparty (2.9%) stimulators.

►

Discussion

The results presented in this report sug
gest that spleen allografts induce the for1 mation of suppressor cells, which may
'*■ play an important role in maintaining
transplantation tolerance. Previous
* studies in our laboratory indicated that
the development of tolerance requires the
interaction of a viable donor spleen with

the host lymphoid system. Irradiation of
the donor spleen induces rejection of the
spleen graft rather than tolerance, sug
gesting that cells present in the
transplanted spleen need to undergo divi
sion (i.e., respond to the recipient). Ir
radiation of the host leads to the death
of the recipient as a consequence of the
spleen graft responding to the im
munocompromised host and producing
graft-versus-host disease.4'9,10 Therefore,
host-versus-graft and graft-versus-host
immune responses are required to induce
tolerance. Also, the vascularized whole
organ graft is necessary to induce
tolerance, which fails to develop when
spleen cell suspensions are injected in
travenously. This indicates that the
microenvironment of the donor spleen for
the induction of tolerance is unique.3

Table 1—Mixed Lymphocyte Reaction Response of Thoracic Duct Lymphocytes
from Tolerant and Normal AGUS Rats*
Thoracic duct
Stimulator cells, cpm4
lymphocytes
(responder cells!
BN
AGUS
WAG
of AGUS ratst
46028 ± 3706 (30.5)
681 ± 308
2232 ± 793 (79.13§)
Tolerant, rat 315
66165 ± 7305
10694 ± 1196
895 ± 366
Normal
1527 ± 357
101001 ± 7 8 2 6 (-9 6 .1 |
16302 ± 3 8 94(84.1)
Tolerant, rat 305
51504 ± 4984
2506 ± 1371
102295 ± 15790
Normal
34664 ± 9959 (60.0)
413 ± 232
73859 ± 1603(22.6)
Tolerant, rat 63
86224 ± 1221
342 ± 24
95310 ± 15889
Normal
’ Values are means ± standard deviation.
t2 x 105 cells/well.
44 x 1Q5 irradiated cells/well.
§Percent nonresponsiveness compared with normal control AGUS thoracic duct lymphocytes studied
com of tolerant rat
x 1 UU.
on same day - 1
cpm of normal rat

However, once tolerance has been
established, the transplanted spleen may
be removed without altering the tolerant
state.
Tolerance can be detected in vivo — the
spleen survives and remains vascularized,
whereas the rejecting spleen becomes
ischemic 8 to 12 days after transplanta
tion. Even though the spleen is tolerated,
donor skin grafts are not permanently ac
cepted until 6 to 8 weeks after trans
plantation,4 suggesting that tolerance
may be expressed locally (in the donor
and host spleen) early after transplanta
tion but may take longer to be expressed
peripherally (i.e., in lymph nodes). Fur
thermore, tolerance that develops after
spleen transplantation is specific for
donor-type grafts, whereas third-party
grafts are always rejected.
The results described in this report sug
gest that tolerant thoracic duct lym
phocytes fail to respond to donor
stimulators, but in some tolerant animals
the nonresponsiveness extends to thirdparty stimulators. The results of co
culture experiments suggest that
nonresponsiveness in the mixed lym
phocyte reaction is most likely not the
result of a depletion of donor-specific
antigen-reactive cells but actually reflects
the activity of suppressor cells, as shown
by both specific and nonspecific suppres
sion of normal thoracic duct lym
phocytes. Suppressor cells play a role in
maintaining the tolerant state in vivo.
However, even though in-vivo tolerance
is exquisitely specific, in vitro we can also
detect appreciable nonspecific suppressor
activity.

Table II—Mixed Lymphocyte Reaction Response of and Suppression by Thoracic Duct Lymphocytes from Tolerant AGUS Rats
Thoracic duct
lymphocytes
(responder cells)
of AGUS rats*
Tolerant, rat 323
Normal
Normal
^Normal
Tolerant, rat 313
Normal
Normal
Normal
Tolerant, rat 33
yNormal
Normal
Normal

(

Stimulator cells, cpm4

Co-culture thoracic
duct lymphocytes
of AGUS ratst

BN
36475 ± 25653 (-3 8 .8 )
26273 ± 3902
1083 ± 410 (97.1)
36229
1758

Tolerant, rat 323
Normal

8317
61357
645
45537

WAG
± 3996 (86.5§)
± 23403
± 601 (96.5||)
± 12123

AGUS
808 ± 417
1130 ± 148
384 ± 47
724 ± 30

Tolerant, rat 313
Normal

9557
76050
793
56582

±
±
±
±

2371 (87.5)
23278
351 (98.6)
13036

1257
533
526
556

±
±
±
±

1431
315
408
360

69640
124364
38679
81613

±
±
±
±

5093 (45.1)
39318
15084 (47.5)
1954

Tolerant, rat 33
Normal

50651
105646
47599
84614

±
±
±
±

1517 (52.1)
48508
5977 (43.8)
22224

139
638
2137
1775

±
±
±
±

57
392
592
1413

72828
50229
64369
66248

±
±
±
±

3378 (-4 4 .9 )
7284
11600 (2.9)
6314

*2 x 105 responder cells/well.
- f 2 x 105 co-culture cells/well given 1500 rad in vitro.
44 x 105 stimulator cells/well given 2000 rad in vitro.

, .
cpm of tolerant rat
§Percent nonresponsiveness compared with thoracic duct lymphocytes of normal control AGUS rat studied on same day - 1 - ---------:
x i UU.
cpm of normal rat
v || Percent suppression compared with thoracic duct lymphocytes of normal control AGUS rat studied on same day
cpm with co-cultured cells from tolerant rat
1 — ------------------------------------------ x 1UU.
cpm with co-cultured cells from normal rat
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The evidence that suppressor cells are
involved in transplantation tolerance has
been obtained from other experimental
models. Suppressor cells have been im
plicated in the induction and maintenance
of the tolerant state in neonatally induc
ed tolerance,10 tolerance following the
infusion o f bone marrow cells after total
body11 or total lymphoid irradiation12
and in tolerance following cyclosporin A
treatment.13 Recently, it has been sug
gested that the induction o f neonatal
tolerance is due to the presence of
nonspecific suppressor cells in the spleen
of the neonate.14 Our data (unpublished)
suggest that in this model o f tolerance,
nonspecific suppressor cells also play a
role in the induction and maintenance
phase of tolerance.
Studies are currently under way to

determine the identity of the suppressor
cells — whether they belong to the T-cell
lineage and whether they are derived from
the donor or host.
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Encircling Endocardial Resection for Sustained Drug-Resistant*
Ventricular Tachycardia
Localized endocardial resection guided by
intraoperative mapping has been used
recently to manage patients with drugresistant ventricular tachycardia.
Although not uniformly successful, this
procedure is superior to simple
aneurysmectomy. This report describes
the authors' early experience with en
circling endocardial resection with com
plete removal of endocardial scar in
seven patients with drug-resistant, sus
tained, ventricular tachycardia, as iden
tified by electrophysioiogic studies. In
traoperative mapping was not used.
Although no spontaneous clinical ar
rhythmia occurred after operation, ven
tricular tachycardia could be induced in
one patient, but not after loading with
procainamide. This was the only patient
who required long-term antiarrhythmic
therapy. There were no operative deaths,
but one patient died 2Vi months after
endocardial resection with recurrent ven
tricular septal defects and another died
From the Maritime Heart Center and
Division o f Thoracic and Cardiovascular
Surgery, Dalhousie University, Halifax, NS
Presented at the 87th annual meeting o f the
Canadian Association o f Clinical Surgeons,
Eastern Division, Halifax, NS, May 27-28,
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after 4 months. Our early experience in
dicates that encircling endocardial resec
tion effectively eliminates re-entrant
ventricular tachycardia and identifies
ventricular septal defect as a potential
postoperative complication following ex
tensive septal endocardial resection.
La resection endocardiaque localisee
sous guidage par cartographie peroperatoire a recemment ete utilisee pour traiter des patients souffrant de tachycardie
ventriculaire resistante aux medicaments.
Bien qu elle n'ait pas toujours ete couronnee de succes, cette intervention
s'est averee superieure a I'anevrismectomie. Cet article d6crit I'experience initiate
des auteurs avec une resection endocar
diaque circulaire et ablation complete du
tissu cicatriciel chez sept patients qui
souffraient d'une tachycardie ventricu
laire prolongee, resistante aux medica
ments et identifiee grace a des Etudes
electrophysiologiques. La cartographie
peroperatoire ne fut pas utilisee. Bien
qu'aucune arythmie Clinique spontanee
n'ait ete constatee par la suite, on a pu
provoquer une tachycardie ventriculaire
chez un patient, ce qui ne put etre rea
lise aprfes la prise de procainamide. C'est
le seul patient qui necessita un traitement anti-arythmique ci long terme.
Aucun deces operatoire n'a ete enregistre. Un patient chez qui apparut une nouvelle communication interventriculaire est
decide 2'h mois apres I'operation et un

second apr&s 4 mois. Cette experience
initiate indique qu'une resection endocar- «
diaque elimine efficacement les tachycardies ventriculaires et identifie une com- <
munication interventriculaire comme
complication postoperatoire possible
apres une resection etendue d'une cloison endo-cardiaque.
Sustained ventricular tachycardia is most
frequently associated with ischemic heart
disease and usually is a direct result of
acute myocardial infarction.1 Localized
endocardial resection guided by in
traoperative mapping is currently the
most effective surgical procedure for
eliminating drug-resistant ventricular
tachycardia. Although this method hasv
been more successful than nonguided
surgery, ventricular tachycardia persists
in some patients after operation. We have
modified the localized endocardial resec
tion described by Harken and associates2
and have employed encircling endocardial
resection with complete removal o f en^
docardial scar, without intraoperative
mapping. This report describes our early
experience in seven patients with drugresistant, life-threatening ventricular - <
tachycardia.

Patients and Methods
The seven patients (five men and two
women) ranged in age from 56 to 76 years
(mean 68 years). All had a history o f an
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meq/kg»L ') combined with topical hypo tamine in the early postoperative period.
thermia to reduce myocardial temperature
There were no operative deaths. How
to less than 15°C.
ever, two patients died later. One patient
After establishing cardioplegic arrest, died after 2'A months of chronic renal
we open the left ventricle through the left failure and recurrent ventricular septal
ventricular aneurysm or the previous defects. Five hours after an uncompli
myocardial infarction scar and inspect the cated endocardial resection, acute
left ventricular cavity for thrombus. We pulmonary edema developed with an in
perform ventriculotomy before any other crease in the pulmonary artery oxygen
manipulation to prevent the inadvertent saturation, indicating the presence of a
dislodgement of thrombic material into ventricular septal defect. The defect was
the left ventricular cavity that could result repaired but 2 V4 weeks later a new mur
in subsequent systemic embolization. mur was heard. Initially, the ventricular
Coronary artery grafting is then carried septal defect was not hemodynamically
out on patients who require concomitant significant but gradually over a period of
bypass surgery; we inject the cardioplegic 3 weeks, medically refractive pulmonary
edema and low cardiac output developed.
► Cardiac catheterization and electro- agent through each vein graft after com At operation, the septum appeared to be
pleting
the
distal
anastomosis.
Aneurys
physiologic evaluation were carried out in
healed but there was a ventricular septal
►each patient before operation. The ejec mectomy, which includes removal of the defect in a different region. Following the
entire
sac
except
for
a
small
border
tion fraction was estimated by biplane
second repair of the septum, a further
''angiography and ranged between 20% around the base of the aneurysm, is then spontaneous perforation occurred and she
performed.
We
develop
a
plane
between
^ and 56% (mean 30%). Resting cardiac in
subsequently died of low cardiac output
dex was between 1.5 and 2.7 L/min»nv2 the scarred endocardium and underlying and renal failure. Autopsy demonstrated
muscle and perform the endocardial
* (mean 2.3 L/min«m'2) and the left ven
a third ventricular septal defect in her
tricular end-diastolic pressure at rest rang- resection around the entire circumference muscular septum.
* ed from 15 to 26 mm Hg (mean 19 mm of the left ventricle, including the septum
The second patient died 4 months after
Hg). Ventriculography demonstrated a and extending to a level at which the
♦distinct left ventricular aneurysm in six fibrotic endocardium merges with normal operation. He had suffered from daily
patients; one patient had sustained a left ventricular endocardium. In those pa episodes of ventricular tachycardia re
* myocardial infarction without the forma tients whose endocardial scar involves a quiring cardioversion and overdrive sup
tion of an aneurysm. Coronary arteri portion of the base of the anterior and pression with a transvenous pacing
ography revealed the presence of obstruc- posterior papillary muscles, the papillary catheter. He was discharged without antive coronary artery disease, requiring muscle is partially detached from the tiarrhythmics but was admitted to his
aortocoronary bypass surgery in six underlying myocardium in the region of local hospital 4 months after operation
scar and reimplanted with 4-0 Prolene with shortness of breath and subsequently
► patients.
pledgetted sutures. The sutures are plac died of massive pulmonary embolism. He
Programmed electrical stimulation was ed through the base of the papillary mus
had not had any further episodes of ven
►carried out preoperatively in all patients. cle, brought out through the entire tricular tachycardia after endocardial
Multipolar electrode catheters were in thickness of the left ventricular wall and
resection.
troduced transvenously and were posi secured on the external surface of the
None of the patients in this series had
tioned in the right atrium, the region of heart. Following completion of endocar
the His bundle and in the apex and dial resection, we close the left ventricle spontaneous ventricular tachycardia
following operation. However, we were
outflow tract of the right ventricle, for in the standard fashion.
able to induce ventricular tachycardia
both stimulation and recording. Stimula
Programmed electrical stimulation is with programmed electrical stimulation in
tio n was carried out at twice the diastolic
threshold with single, double and triple carried out as previously outlined 7 to 10 one patient, although he had no spon
days after endocardial resection in an at taneous clinical arrhythmias following en
ventricular extra stimuli being introductempt to induce the preoperative ar docardial resection. The tachycardia
i ed into diastole at various coupling intercould not be induced after loading with
T vals. Induced ventricular tachycardia was rhythmia.
procainamide. This patient had suffered
. terminated in most instances by a profrom recurrent sustained ventricular
v grammed ventricular extra stimulation or Results
tachycardia requiring daily cardioversion.
»by overdrive suppression. In some in
All seven patients underwent encircling He was the only patient in our series who
stances, cardioversion was necessary
► because of hemodynamic instability. In endocardial resection with complete required long-term antiarrhythmic ther
duction of ventricular tachycardia by pro- removal of endocardial scar, which in apy.
► grammed electrical stimulation was taken cluded the left ventricular septum. Par
After a mean follow-up of 10 months,
as evidence that re-entry was the tial reimplantation of the anterior
the remaining five patients are alive and
r mechanism of the arrhythmia. Using papillary muscle of the mitral valve was well with no further recurrence of their
these methods, all seven patients had required in six patients and the posterior
arrhythmias.
reproducible sustained ventricular papillary muscle in two patients.
Reimplantation of the papillary muscles
► tachycardia.
did not result in clinical mitral insufficien Discussion
cy in any of these patients. Aneurysmec
*• Operative Technique
Sustained ventricular tachycardia is
tomy was performed in six patients and
v
Cardiopulmonary bypass was establish six required concomitant aortocoronary most frequently associated with ischemic
ed with standard techniques using core bypass grafting; 11 grafts were placed heart disease and usually follows an acute
V hypothermia to 25°C. The operation was (mean 1.8 grafts per patient). The cross myocardial infarction.1 Although ven
t performed during a single cross-clamping clamping time ranged from 30 to 57 tricular tachycardia may be related to
with myocardial protection being provid minutes (mean 44 minutes). Two patients enhanced automaticity or re-entry, re
ed by a crystalloid cardioplegic agent (20 required inotropic support with dobu- entry is the most common mechanism
acute myocardial infarction and five pa
tients had suffered infarction 3 months
k or less before operation. One patient had
class IV angina (New York Heart Asso►ciation classification) and two patients
had left ventricular failure at rest. Two
*were diabetics; in one the condition was
controlled with an oral hypoglycemic
agent and in the other by diet alone.
^ All seven patients had failed a trial of
at least three conventional antiarrhythmic
►drugs. Frequent cardioversion was ne
cessary in six patients before operation
►and three required insertion of a tem
porary transvenous pacemaker for overdrive suppression.
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responsible for chronic sustained ven
tricular tachycardia.3,4 Re-entrant ar
rhythmias, as opposed to automatic ta
chycardias, may be induced and ter
minated by program m ed electrical
stimulation. Ventricular tachyarrhyth
mias appear to originate in the border
zone between normally perfused myocar
dium and adjacent postinfarction scar
surrounding an infarction.5-6 Wetstein
and colleagues56 have demonstrated that
the border zone consists of regions of nor
mally perfused myocardium interdigitating with areas of ischemia and infarcted muscle. This disorganized array
of myocardium surrounding infarcted
muscle constitutes the necessary electroanatomical substrate required for the
generation o f sustained re-entrant
tachycardia; it provides the requirements
for the re-entry mechanism including dual
pathw ays and varying rates o f
conduction.
Traditionally, patients with sustained
ventricular tachycardia have been man
aged with antiarrhythmic agents alone or
in combination with aneurysmectomy or
resection o f postinfarction scar.7’8
Although earlier papers indicated the ef
ficacy of aneurysmectomy and coronary
revascularization for the control of these
arrhythm ias,7’8 subsequent reports9’10
have indicated that 75% of the patients
may still manifest their ventricular ar
rhythmia following operative interven
tion.
More recently, electrophysiologic
studies have enabled the clinician to iden
tify the ventricular site responsible for re
entry and have resulted in the develop
ment of specific surgical procedures
directed towards ablation of the re
entrant pathway. Localized endocardial
resection guided by intraoperative map
ping was originally described by Harken
and associates.2 Although endocardial
resection has been more successful than
nondirected aneurysmectomy,911 the
Philadelphia experience12 indicates that
localized endocardial resection fails to
eliminate ventricular re-entry in 20% of
patients. That not all patients are cured
by endocardial resection suggests that
either the local resection is inadequate or
that more than one re-entrant pathway is
present. Experience with programmed
electrical stimulation in our laboratory in
dicates that up to 30% of patients will
have more than one morphologically
distinct ventricular tachycardia. This is
not unexpected, considering that re
entrant ventricular arrhythmias arise
from the border zone surrounding an in
farction. This disorganized array of mus
cle may provide the substrate not only for
one re-entrant pathway, but for multiple
sites with the potential for ventricular re
entry. This concept of multiple re-entrant
pathways would help explain the failure
of localized endocardial resection to
26

eliminate ventricular tachyarrhythmias in
some patients.
We have modified Harken’s original
operation and now perform encircling en
docardial resection with com plete
removal of all endocardial scar. We do
not use intraoperative mapping because
ventricular re-entrant arrhythmias are fre
quently difficult to induce in the
operating room and because the mapping
procedure prolongs the operation in pa
tients who are critically ill. More impor
tant, identifying the site of earliest activa
tion does not guarantee that this is the on
ly region responsible for recurring ven
tricular tachycardia. Our results indicate
that complete removal of all endocardial
scar by encircling endocardial resection
will eliminate re-entrant ventricular
tachycardia in most cases. All patients in
this series were free of clinical ar
rhythmias following operative interven
tion, although one patient requires long
term use of procainamide. Before opera
tion this patient suffered from sustained
ventricular tachycardia requiring daily
cardioversion and resuscitation. There
were no clinical arrhythmias following
resection but ventricular tachycardia
could be induced by programmed stimu
lation. The importance of this nonclinical
arrhythmia is uncertain but suggests that
endocardial resection modified but did
not eliminate the re-entrant pathway.
The success of encircling endocardial
resection depends upon complete removal
of all endocardial scar thus eliminating all
ventricular sites in the border zone sur
rounding the myocardial infarction that
have the potential for ventricular re-entry.
The endocardial scar frequently involves
the papillary muscles of the mitral valve.
As long as the scar only involves a por
tion of the base of the papillary muscle,
detachment and reimplantation appear to
be satisfactory treatment and have not
resulted in postoperative mitral insuffi
ciency in our patients. However, if
the entire base of the papillary muscle is
involved with endocardial scar, we do not
recommend complete detachment of the
papillary muscle, which would most cer
tainly result in postoperative mitral insuf
ficiency. Instead, encircling ventricu
lotomy should be carried out around the
base of the papillary muscle in this situa
tion. Encircling endocardial resection was
performed without complication in our
first six patients, but in the seventh pa
tient recurrent ventricular septal defects
developed following extensive septal en
docardial resection. Moran and associates
from Northwestern University13 have
had similar experience with septal per
forations during endocardial resection
and often patch the ventricular septum to
prevent spontaneous perforations postoperatively. Our experience indicates that
a ventricular septal defect is a potential

complication of septal endocardial resec
tion and supports the need for a septal
patch in the region of endocardial resec- *
tion in patients with thin-walled septa. To
prevent this complication, we suggest that 4
septal thickness be measured preoperatively by electrocardiography and that a4
septal patch be applied prophylactically 4
in patients with thin-walled septa follow
ing extensive septal endocardial resection. .,
We thank Laurie A. Quinn for her help in
the preparation of this manuscript.
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Nonsurgical Treatm ent of Common-Bile-Duct Stones
Exploration o f the com m on bile d u c t, th e
tra d itio n a l tre a tm e n t fo r choledocholith ia sis, can o fte n be replaced by n o n 
su rg ica l procedures. Since 1 9 7 6 , 1 4 7
p a tie n ts have been trea te d n o n surg ica lly
w it h an overall success rate o f 8 4 % .
T hre e groups are reported.
In group 1, 8 0 pa tie nts had sto n e e x
tra c tio n under radiologic c o n tro l th ro u g h
th e T-tube tra c t alone. S tones w ere s u c 
ce s s fu lly rem oved fro m th e com m on bile
d u c t in 52 o f 59 patients and fro m th e
intra h e p a tic d u c ts in 12 o f 21 pa tie nts.
T he overall success rate o f e xtra ctio n
th ro u g h the T tu b e w a s 8 0 % .
G roup 2 co m p rise d 58 p a tie n ts w h o
u n d erw e n t end osco p ic s p h in c te ro to m y
a nd stone e x tra c tio n o n ly w ith 8 6 %
success.
T he nine p a tie n ts in group 3 required a
co m b in a tio n o f radiologic and end osco p ic
in te rve n tio n . Six had sto n es " p u s h e d "
b y th e radiologist th ro u g h a pre vio u sly
sp h in ctero to m ize d am pulla o f V a te r and
in tw o the ra d io lo g is t in tro d u ce d sto n e
crushers tran sh e p a tica lly in to th e c o m 
m on duct to break up large stones to a
size capable o f passing th ro u g h the
s p h in c te ro to m y site (1 0 0 % success).
O ne elderly p a tie n t had a cholec y s to s to m y under local anesthesia fo r
su p p ura tive c h o le c y s titis , and subse
q u e n tly m ultiple co m m o n -b ile-d u ct
s to n e s were rem oved by th e ra d io lo g ist
th ro u g h the gallbladder and c y s tic d u c t
a nd by the e n d o sco p ist th ro u g h th e en 
d o sco pic sp h in c te ro to m y site.
A ll procedures w ere carried o u t under
lo c a l anesthesia, and m ost required a
h o s p ita l stay o f 1 day or less. C om plica-
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tio n s w ere m inim al and there w e re no
deaths.
T-tube e xtra ctio n and e n d oscopic
sp h in cte ro to m y are e ffe c tiv e , relative ly
safe, nonsurgical procedures fo r the
rem oval o f co m m o n -d u ct stones.

L'exp lo ra tio n du choledoque, tra ite m e n t
trad itio n n e l de la choledolithiase, peut
so u ve nt etre rem placee par des in te rv e n 
tio n s non chirurgicales. Depuis 1 9 7 6 ,
147 m alades o n t ete traite s de fa co n
non chirurgicale avec un ta u x de succes
global de 8 4 % . On d e crit les resu lta ts de
trois groupes.
Dans le groupe 1, 8 0 pa tie nts o n t subi
('e xtra ction des calculs par un tu b e en T
sous co n tro le radiologique. Les calculs
o n t ete enleves avec succes du ch o le d o 
que chez 52 p a tie nts sur 5 9 , et des
canaux intrahepatiques chez 12 p a tie nts
sur 2 1 . Le ta u x global de succ&s pour les
e xtra ctio n s par un tube en T fu t de
80% .
Le groupe 2 com prenait 5 8 pa tie nts
qui o n t subi une sp h in ctero to m ie endoscopique et ('e xtra ctio n des calculs avec
8 6 % de succds.
Dans le groupe 3, neuf pa tie nts o n t
necessity une com binaison d 'in te rve n tions radiologiques et endoscopiques.
Chez six pa tie nts, les calculs fu re n t
"p o u s s e s " par le radiologiste dans une
ampoule de V a te r prealablem ent sphincterotom isee et chez deux autres, le rad io lo 
giste in tro d u is it par voie transhepatique
de quoi ecraser les gros calculs dans le
choledoque ju s q u 'a ce q u 'ils aient et£
su ffisa m m e n t reduits pour passer a travers un p o in t de sp h in ctero to m ie (1 0 0 %
de succes). Un pa tie nt age su b it une
ch o le cystosto m ie sous anesthesie locale
pour une ch o le cystite suppurative; de
nom breux calculs fu re n t alors e x tra its du
choledoque par le radiologiste en passant
par la vesicule biliaire e t le canal c ystique e t par I'en d o sco p iste en passant par
le p o in t de sp h in ctero to m ie
endoscopique.
Toutes ces inte rve n tio n s fu re n t pratiquees sous anesthesie locale et la plupart n 'o n t necessity qu'u n e h o sp italisa 
tion d 'u n e journee ou m oins. Les c o m p li

cations fu re n t m inim es e t il n 'y e u t
aucun deces.
L 'e xtra ctio n par un tu b e en T e t la
sp h in ctero to m ie endoscopique so n t des
in te rve n tio n s non chirurgicales e ffica ces
et relative m e n t sures pour I'en le ve m e n t
des calculs dans le choledoque.

-<

In the past, the conventional management *
of retained stones in the common bile
duct depended on the type and timing of
previous treatment. If the patient p
presented in the early postoperative
period with a T tube in the common bile >
duct, various options were available.
Flushing of the T tube with fluids such
as saline, heparinized saline,1 various
bile acids2’3 and even ether and olive oil4 "*
has been reported. More recently, the instillation of mono-octanoin into the com
mon bile duct has produced encouraging t
results of stone dissolution.5’6 Often, the
patient was sent home to allow the retain- f
ed stone to pass spontaneously through
the ampulla, with subsequent confirma- *
tion of its passage by repeated T-tube
cholangiography. If the duct could not be 4
cleared by these methods of irrigation, re- ^
exploration was required.
If the patient presented with symp- ^
tomatic choledocholithiasis a considerable
time after the original cholecystectomy, V
reoperation was recommended. Such pro
cedures, whether performed immediate- V
ly after exploration or later, have ap
preciable mortality and morbidity and are *
not always successful.7’8
Since 1973, common-duct stones have
been extracted safely and effectively ,
through the T-tube tract by radiolo
gists.911 In addition, the endoscopist has
aided the surgeon by performing en
doscopic sphincterotomy to remove gall- *
stones in patients without T tubes.12-15
This paper reports the experience in the
nonoperative management of choledo
cholithiasis of one radiologist and one
surgeon-endoscopist over a 7-year period
at the Toronto General Hospital.
m

v
Patients and Methods

Between 1976 and 1983, 147 patients
were seen at the Toronto General
VOLUME 27, NO. 1, JA N U A R Y 1984 / THE CANADIAN JOURNAL OF SURGERY

Hospital by one or both authors. All pa
tients presented either with proven
► common-bile-duct stones or with symp
toms that later investigation at this institu► tion confirmed as choledocholithiasis.
The 147 patients were classified retrospec* tively into three groups according to the
treatment, which was primarily radiologic, primarily endoscopic or a combina
tion of the two.
Group 1: Radiologic Extraction
Eighty patients, 32 men and 48 women,
with a mean age of 59 years (range from
25 to 90 years) presented after commonbile-duct exploration with stones
*■ demonstrated by postoperative T-tube
cholangiography. If patients presented
* within 4 weeks of operation, they were
^sent home with the T tube in place to
allow the tract to mature. They were
^ brought back as outpatients and the
radiologist extracted the stones through
* the T-tube tract under local anesthesia.
The technique of removal has been
* described previously.16 If the T-tube
diameter was less than no. 14 French, the
* tract was often dilated using red rubber
A or steerable catheters to a point where the
appropriate baskets could be used for
removing the stones. In patients who had
multiple stones, up to eight sessions were
» needed to clear the duct. After each ses
sion, a red rubber catheter was left in the
► common duct to keep the tract open for
future procedures. Complete removal was
r confirmed by catheter cholangiography,
whereupon the tube was removed.
Fifty-nine patients in this group had
^ common-duct stones and 21 patients had
intrahepatic duct stones, which are con» siderably more difficult for the radiologist
to evacuate,
r
r Group 2: Endoscopic Removal
Fifty-eight patients, 28 men and 30
* women, with a mean age of 54 years
(range from 23 to 94 years), underwent
* endoscopic retrograde cholangiopan
creatography (ERCP) to confirm the
presence of common-duct stones seen at
► previous intravenous cholangiography, or
to investigate symptoms suggestive of
choledocholithiasis. The Olympus JFB 3
sideviewing flexible fiberoptic duodenor scope (W. Carsen Co., Don Mills, Ont.)
was used to opacify the common duct;
lidocaine throat spray and intravenous
t diazepam were used as anesthetic pre
paration for the endoscopy. Buscopan
»- (Boehringer Ingelheim [Canada] Ltd.,
Burlington, Ont.), 20 mg to 40 mg, was
*• given intravenously in all cases to decrease
duodenal motility. When the patient prov ved to have stones at endoscopic cholangiography, a Seuberth papillotome
(Hildegarde Seuberth Co., Forchheim,
Germany) was then inserted into the
**

r
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lower end of the duct, and the sphincter
divided slowly using a combination of
coagulation and cutting cautery. In most
patients, stones were then allowed to pass
spontaneously. Few attempts were made
to remove stones immediately with a
basket because of the fear of inciting
cholangitis, pancreatitis and bleeding. En
doscopic retrograde cholangiopan
creatography was carried out on an out
patient basis, but if sphincterotomy was
necessary, the patient was usually admit
ted overnight for observation. The pro
cedure lasted approximately 20 to 30
minutes; broad-spectrum antibiotics were
administered intravenously, then orally
for 5 days. Repeat ERCP to confirm the
spontaneous passage of stones or to in
dicate the need for removal of residual
stones with a Dormia basket was carried
out on an outpatient basis 3 to 4 weeks
after the sphincterotomy.

Group 3: Combined Radiologic and
Endoscopic Treatment
Nine patients, four men and five
women, mean age 67 years (range from
48 to 91 years), were treated with a com
bination of the radiologic and endoscopic
methods.
In six patients the conventional T-tube
extraction technique was insufficient to
clear the duct because of impacted stones
or floating stones that could not be
retrieved with the Dormia basket. En
doscopic retrograde cholangiopan
creatography and endoscopic sphinc
terotomy were then carried out, and
stones were either pushed through the Ttube tract by the radiologist using a
steerable catheter or allowed to pass spon
taneously. Cholangiography was later
performed.
Two patients had been treated with en
doscopic sphincterotomy first, but
because of the large size of the commonduct stones, extraction with a basket was
impossible by the endoscopic route, even
after several attempts. The radiologist
was then able to place a Dormia basket
into the common duct via the per
cutaneous transhepatic route. Per
cutaneous transhepatic cholangiography
was performed in the conventional man
ner using a 23-gauge needle with a
20-gauge Teflon sheath. A 0.625-mm
guide wire was then inserted through the
sheath into the common duct, and both
the sheath and the guide wire were ad
vanced further into the biliary tree. The
transhepatic tract was then dilated over
the guide wire with a no. 9 French Kifa
catheter. A Dormia basket could then be
introduced into the common duct, basket
the stones, and crush them to a size small
enough to pass through the sphinc
terotomy. No such crushing technique
could be used by the endoscopic route
/

because of the length of instruments.
Chronic cardiopulmonary disease
prevented conventional treatment of sup
purative cholecystitis in the ninth patient,
an 86-year-old woman. Cholecystostomy
was performed under local anesthesia,
and all stones were removed from the
gallbladder. A good backflow of bile was
obtained from the common duct through
the cystic duct. A large cholecystostomy
tube was left in place; a postoperative
cholecystostomy tube cholangiogram
revealed multiple common-duct stones.
The radiologist steered a catheter through
the gallbladder and cystic duct and
withdrew several stones. However, com
plete clearance of the duct could not be
achieved. At this point, with the patient’s
general condition much improved 3 weeks
after operation, an endoscopic sphinc
terotomy was carried out. Subsequent
cholecystostomy tube cholangiograms
were done.
Six of the nine patients were treated as
outpatients (except for the observation
period after endoscopic sphincterotomy);
the others were treated as inpatients.
Results

Radiologic intervention or endoscopic
sphincterotomy, or both, was successful
in 123 of the 147 patients so treated —
a success rate of 84%.
Group 1
Fifty-nine of the 80 patients had
common-duct stones and in 52 (88%), Ttube extraction was successful. The other
21 had intrahepatic stones as shown on
postoperative T-tube cholangiograms. Of
these, 12 (57%) had successful clearance
of the duct. Therefore, a major operation
was avoided in 64 (80%) of the 80 pa
tients. Most of the failed cases had re
exploration of the common or intra
hepatic duct, or both.
Group 2
Fifty-six of the 58 patients had a suc
cessful endoscopic sphincterotomy. Two
attempted sphincterotomies failed. In one
the papilla was inaccessible at the apex of
a diverticulum in the second portion of
the duodenum, and in the other a large
impacted stone at the ampulla prevented
insertion of the papillotome. Of the 56
patients who had successful sphinc
terotomy, stones passed spontaneously in
39 during the ensuing 2 weeks. Passage
was either asymptomatic or marked by a
sudden, typical but brief recurrence of
right upper quadrant pain. Eleven other
patients required stone removal by basket
at subsequent ERCP, and all 50 had com
plete clearance of the duct, confirmed by
subsequent endoscopy.
Six patients, however, despite suc-
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cessful sphincterotom y, needed a
laparotomy because of incomplete
clearance of the common duct. Two pa
tients had numerous small stones im
pacted throughout the duct system form
ing a virtual common-bile-duct “ cast” .
Long, arduous procedures using en
doscopic baskets and irrigation had fail
ed to clear the common duct adequately.
Instillation of mono-octanoin through
nasal tubes introduced at the time of
ERCP into the common duct also failed
to dissolve the stones.
In two of the early cases, stones were
too large to extract by the endoscopic
route and had to be approached
surgically.
One patient had successful extraction
with a basket of a stone lying transverse
ly at the lower end of his common bile
duct, but the basket became trapped at
the sphincterotomy. Since it could not be
retracted or pushed back into the duct to
release the stone, laparotomy became
necessary to remove both basket and
stone.
The sixth patient had acute suppurative
cholangitis after a cholecystectomy for
acute cholecystitis; when the endoscopic
sphincterotomy was performed, a large
amount of pus drained from the common
bile duct. Despite aggressive medical
management and apparently adequate
drainage through the ampulla, the patient
continued to have fever, which necessi
tated laparotomy and choledochotomy.
All six patients who underwent laparo
tomy had successful evacuation of their
stones and did well.

treated conservatively. One patient had
bile peritonitis related to breaking of the
T-tube tract and had to have an explora
tion and drainage. A fourth patient
underwent surgical removal of a basket
trapped in the common duct. There were
no deaths.
Group 2
Three patients had notable complica
tions. Two had pancreatitis, which was
managed conservatively with nasogastric
suction and intravenous administration of
fluids. Both recovered quickly. The third

patient suffered a retroperitoneal perfora
tion of the duodenum after the sphinc
terotomy was performed through an am- 4
pulla situated at the edge of a duodenal
diverticulum. The patient felt well in the i
initial postoperative period, but a retro
peritoneal abscess developed that eventU-*
ally required surgical drainage; she re
covered well. No patient had bleeding at *
the site of the sphincterotomy.
Group 3

„

There were no serious complications in
this group.
4
<

Fig. lb

Group 3
Nine patients treated by a combination
of radiologic and endoscopic methods
had successful endoscopic sphinc
terotomy and with additional radiologic
procedures all nine were cleared of
common-duct stones without operation.
In both patients who underwent transhepatic crushing of common-duct stones,
complete passage of the crushed particles
through the previous sphincterotomy site
was confirmed. Serial films of one of
these two patients are shown in Fig. 1.
The patient who had a cholecystostomy, removal of common-duct stones
through the cholecystostomy tract and en
doscopic sphincterotomy, all performed
under local anesthesia, was eventually
well and free of stones. Serial roent
genograms of her biliary tract are shown
in Fig. 2.
Complications

Fig. lc

Group 1
Four patients in this group of 80 had
serious complications. Suppurative
cholangitis developed in two and was
30

Fig. Id

FIG. 1—(a) Endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy
(note air in biliary tree). Stone (arrow) is too large to basket endoscopically. (b) Dormia basket 4
(arrows) introduced by percutaneous transhepatic route grasps stone, (c) Basket and crushed
particles (arrow) are introduced through sphincterotomy into duodenum, (d) Final percutaneous a
transhepatic cholangiogram. Duct (large arrow) is clear and flow into duodenum (small arrow)
is excellent.
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Discussion
The treatment of common-bile-duct
* stones has changed radically over the last
. 10 years. Laparotomy and conventional
exploration of the common bile duct can
^ now often be replaced by procedures car
ried out by the radiologist or endoscopist,
k or both.
The best treatment for cholelithiasis
and choledocholithiasis is still formal
^ cholecystectomy and exploration of the
common bile duct. However, interest has
►grown in the radiologic and endoscopic
procedures, which have been employed
v more frequently even on patients with
gallbladders in situ.15 In patients who are
* old, have intercurrent illnesses or who are

Fig. 2c
V

too ill for operation, percutaneous
drainage of the biliary tree or, in some
cases, endoscopic sphincterotomy have
been employed to “ tie over” unstable pa
tients until their condition is good enough
for definitive therapy.
All of our patients but one had had a
previous cholecystectomy.
In the group that had T tubes in place,
the radiologist had greater success with
stones situated in the common bile duct
than in the intrahepatic ducts. Some of
the patients had impacted intrahepatic
stones, and frequently these proved to be
extremely difficult to remove even at
subsequent operation. It is questionable
whether newer techniques of stone
dissolution, extraction, or treatment with

Fig. 2d

FIG. 2—(a) Postcholecystostomy cholangiogram, showing stones in cystic and common
hepatic ducts (arrows), (b) After radiologic removal of common-duct stones through gallblad► der, stone remains at lower end o f common bile duct (arrow), (c) Endoscopic sphincterotomy
performed at this stage. One stone (arrow) remains in common duct, (d) Final cholecystostomy
tube cholangiogram shows clear biliary tree, including gallbladder, with good flow into duodenum.

ultrasonography or lasers17 will be more
successful in removing these intrahepatic
stones.
Endoscopic sphincterotomy is a
reasonably simple procedure for an ex
perienced endoscopist. However, judge
ment about when the procedure has fail
ed is important, as prolonged endoscopic
manipulation of the common bile duct
from below can be dangerous; cholangitis
may result. The two patients who had
countless stones in the biliary tract and
extensive manipulation after endoscopic
sphincterotomy, also had endoscopic in
sertion of long nasal tubes for instillation
of m ono-octanoin. (Zimmon and
associates18 reported a death in a case
such as this.) During this irrigation,
however, sepsis developed and both pa
tients had to have operative evacuation
of their ducts. The two patients with
stones too large to extract by the en
doscopic route were treated early in our
series, and now would likely be treated
by transhepatic crushing. When better
crushing baskets become available for en
doscopic use, this will not be such a
problem.
The problem of suppurative cholangitis
and its drainage through the ampulla is
a difficult one. True suppurative
cholangitis is life-threatening and the
abscess must be drained. In our patient,
although pus poured freely from the duct
into the duodenum, laparotomy 3 days
later demonstrated that a large stone from
higher in the common duct had become
impacted at the sphincterotomy site. The
patient did well with adequate surgical
decompression of his bile duct.
The relative safety of a laparotomy and
choledochotomy, as opposed to the
various “ less invasive” techniques, is a
subject of constant debate.19,20 The mor
tality associated with laparotomy and
common-bile-duct exploration after
previous surgery is generally accepted to
be 3% to 8%.7,8,20 The complication rate
of T-tube extraction is 5°7o, with negligi
ble mortality,11 and the corresponding
figures for endoscopic sphincterotomy are
8% and 1% to 2°7o.14,15 In our 147 pa
tients, there were no deaths among the
123 patients who avoided laparotomy for
their common-duct stones, the 24 patients
whose stones were not cleared immediate
ly by these methods or in the 3 patients
(2 patients in the T-tube extraction group
and 1 in the endoscopic sphincterotomy
group) who had a laparotomy for a com
plication of their less-invasive procedure.
Many patients in all groups were at con
siderable risk with laparotomy; all 80 pa
tients in group 1 had had recent opera
tions and so were at greater risk. Seven
teen of the patients in group 2 were older
than 70 years, and many of them had
medical problems that would have
rendered laparotomy dangerous. The
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average age of group 3 patients was 67
years, with four patients over 70 years
(one 91 years). It is impossible to ^
speculate about the morbidity and mor
tality in the 123 patients who were spared 4
laparotomy, but we believe that both rates
were appreciably lowered by using less-4
invasive procedures.
^

SESAP IV Question

Conclusions

32. The most satisfactory operation for patients with chronic pancreatitis and
duct ectasia with multiple areas of stenosis is

(A)
(B)
(C)
(D)
(E)

pancreaticoduodenectomy
distal pancreaticojejunostomy
longitudinal pancreaticojejunostomy
near-total pancreatectomy
sphincteroplasty

For the incomplete statement above select the one answer that is best of the
five given. For the critique of Item 32 see page 94.

(Reproduced by permission from SESAP IV Syllabus: Surgical Education and
Self-Assessment Program No. 4. For enrolment in the Surgical Education and
Self-Assessment Program No. 4, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)

One antiemetic may be
all you need on the ward

"STEMETH
prochlorperazine

to stop nausea and calm the patient
RHONE POULENC
PHARMA Inc.

8580 Esplanade
Montreal, Quebec
®authorized user
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We conclude from our experience in
147 patients that a combined radiologic *
and endoscopic approach is a safe and ef
fective way o f handling retain ed ''
common-duct stones. Laparotomy was
avoided in 84% of patients, and 16% (24
patients) subsequently had definitive ,
surgical treatment. Complications of both
procedures are potentially lethal but were -t
acceptably infrequent in our experience
and there were no deaths.
An aggressive nonoperative approach
to common-duct stones is recommended,
but early and appropriate surgical in- k
tervention is required if procedures are
unsuccessful or if sepsis develops.
k
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Principles of an Oncology Data Base for Small Computers
It is now possible to store large amounts
of data, which can be rapidly retrieved
and cross-referenced, on relatively inex
pensive computers. This study was done
♦ to determine if a small computer could
be used to store detailed data on patients attending an oncology clinic in
such a manner that personnel inex
perienced in the use of computers would
1 be able to enter or access information
without training or the need for
4 reference literature.
Ninety items can be entered on each
J
patient under 1 1 options (demography,
diagnosis, laboratory, tumour markers,
investigations, surgery, chemotherapy,
radiotherapy and immunotherapy, comr plications, clinic visits and palliative
care). The data can be retrieved rapidly
on any individual or group of patients
r and cross-referenced to two or more
variables and can be updated, corrected
► or transmitted by an automated print-out
in letter form.
The study illustrates basic principles in
program design that will function on any
*
"hom e" computer.
Y

* II est maintenant possible de conserver
sur un ordinateur relativement peu couteux des masses importantes de donnees
y
auxquelles on peut rapidement avoir
acces ou faire les renvois desires. Cette
t etude a ete effectuee afin de determiner
si un petit ordinateur pouvait etre utilise
►pour conserver des informations detaillees sur les patients d'une clinique d'ony
cologie, de facon a ce qu'un personnel
peu experiments dans le domaine des
*
ordinateurs puisse faire des entrees et
Y
des sorties de donnees sans formation
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speciale ou la necessite de s'en referer a
la literature.
Pour chaque patient, 90 items peuvent
etre entres sous 1 1 options (demographie, diagnostic, epreuves de laboratoire,
marqueurs tumoraux, examens, chirurgie,
chimiotherapie, radiotherapie et immunotherapie, complications, visites et soins
palliatifs). Ces donnees peuvent etre
recouvrees rapidement pour chacun des
patients ou groupe de sujets et des ren
vois peuvent etre faits a deux variables
ou plus. Les donnees peuvent etre mises
a jour, corrigees ou transmises sous
forme de document a I'aide d'une
imprimante.
Cette etude illustre les principes fondamentaux de programmation qui s'appli
quent a tous les ordinateurs
"domestiques."

The computer has made it possible to
store, retrieve and cross-reference large
amounts of data quickly. When a large
computer is used, a team of experts is re
quired to plan and write an appropriate
system. The physical and financial
resources needed for this are of a
magnitude that often discourages the use
of a computer. The rapid development of
the small computer with its everincreasing capacity for handling informa
tion has made it possible to consider these
relatively inexpensive “ home” machines
as suitable alternatives.1’2
This is a report of the creation on a
small computer of a system to store and
manipulate information on patients at
tending an oncology clinic in a medium

Table I—Oncology Data Base Directory
1.
2.
3.
4.
5.
6.
7.
8.
9.

Do
Do
Do
Do
Do
Do
Do
Do
Do

you
you
you
you
you
you
you
you
you

need
wish
wish
wish
wish
wish
wish
wish
wish

instructions?
to enter information?
to retrieve?
to correspond?
to update?
to archive files?
to scratch files?
a census?
to quit?

Your choice (1 to 9)

sized community hospital. There were
three objectives: (a) to determine if a
small computer has the capacity to store
the items of information needed for a
tumour registry; (b) to make the informa
tion input simple for an inexperienced
operator and (c) to design the system so
that any information entered would be
linked to the previous data on an in
dividual in a manner that would prevent
duplication or accidental loss.
M ethod

A microcomputer (Commodore CBM
Model 8032) with 32 000 (32 K) characters
of accessible memory and two disc
storage devices, each with a storage
capacity of 512 K characters, was used for
the study. The system included a printer
connected to the computer for program
verification and correspondence.
The following four functions usually
used in a tumour registry were selected as
the basis upon which to construct the
system: (a) storage and retrieval of data;
(b) a capability to abstract information
from storage on any patient; (c) the ability
to monitor the changes in an individual
patient or the disease, or both, over an
extended period and (d) the ability to cor
rect, update, erase or place in archives the
stored records of either individuals or
groups o f data.
The system was co nstructed in
modules, each composed o f 18 relatively
small routines accessed by a separate
directory. The directory program (Table
I) presents a list of nine choices. When
the choice is to enter inform ation, the
computer asks the user to enter the pa
tient’s last name. A similar request ap
pears if a patient summary or cor
respondence is chosen. On the other
hand, a request for information retrieval
is answered by a message indicating the
site of the primary tumour. Once that
choice is made, various options are
offered.
Once the user enters the last name, a
search is initiated automatically. If the
name is found, the following facts about
that patient are displayed on the screen:
first name, initials, birth date, address
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(including city and postal code) and social
insurance number. This permits iden
tification of a specific patient among
those with identical last names. If the
name is not found, the search program
then displays names with the same first
three letters as the name requested by the
user. This phase of the search serves to
display names that may have been
misspelled. Finally, if no name is found,
the search program lists all names with
the same first letter and includes a record
number beside each name. The record
number may then be used to locate fur
ther information on that particular
patient.
A demographic program is initiated if
there is no previous record on a particular
patient. The screen displays 20 items of
importance to the registry (Table II). The
information may be entered in sequence
or not. Any incomplete items can be fill
ed in later.
Whether a name has been found or a
new name entered, the program next
displays an “ option” menu (Table III),
allowing the user to choose which par
ticular section of information is to be
entered. When each section is complete,
the program automatically returns to the
list of options so that other choices can
be made or permits an exit to the menu
program. In this manner, the user can
start and stop the process at any time.
As the program operates between the
user’s option and the data entry, three
automatic data files are working to main
tain a link between entries on any in
dividual — (a) a file to assign numbers
to each new record; (b) a file to link the
patient by name to each entry and (c) a
key file that stores the record number, pa
tient name, date and particular option.
This last file is important because it per
mits rapid retrieval of information.
The system is designed to operate two
discs simultaneously. One disc contains
all the programs and link files, the other
is the data disc. All the information is
stored on this disc, in a random fashion
independent of the sequence in which in
formation is entered. The interaction of
the record number in the key file with the
record number in the data file permits
rapid access.
Information is retrieved by using the
site of the primary tumour. A list of 43
possible anatomical sites is displayed and
the user selects one. A table of 10 choices
for cross-reference and statistical evalua
tion is then shown on the video screen.
These are similar to the options available
for data entry, namely diagnosis,
laboratory results, tumour markers, in
vestigations, surgical procedures,
chemotherapy, radiotherapy and im
munotherapy, complications, clinic visits
and palliative care. When the user selects
two or more of these choices, the screen
34

will display all of the information such
as dates, results and treatments in the data
file that refers to the selected items. If
statistical analysis, printed output or
graphic displays are required, the infor
mation is stored on a separate disc for
later study.
Discussion

The system has many attractive
features for those interested in creating
a data bank of clinical information. It is
written entirely in BASIC language, a
computer language easily written and
understood by most computer users. It is
completely flexible and can be modified
to suit individual needs with regard to the
type of information to be stored. Because
it is written for a small computer system,
it can be operated in a small clinic setting
at reasonable cost. Included within its
program are many routines designed to
minimize human error. Each item is
specified as to length and location of en
try. Any attempt to do otherwise is
automatically erased and the user is re
quested to re-enter the information. At
the completion of entry of any item there
is opportunity to correct mistakes. The
program displays messages at various
points to permit the user to change a deci
sion or to exit and start again.
It is possible to maintain a chronologic
record of an individual patient by the use
of the “ link” files. This is especially at
tractive in an oncology clinic where it is
necessary to maintain records over a long
period. The program also permits the
storage of data in an archive file for pa
tients no longer receiving treatment or
who have died.
One critical requirement of any record
storage system is the ability to update or
correct files on any patient. This is ac
complished by the use of an “ update”
routine. This displays an abstract of cur
T a b le II— D em o g rap h ic P rogram
1 . Id e n tific a tio n no.
2 . L a s t nam e

1 1 . M a le lfe m a le ?
1 2 . Attending physician
1 3 . R eferring physician

3 . F irs t nam e
4 . In itia ls
5 . B irth d a te
6 . A ddress

1 4 . Fam ily p hysician
1 5 . Admission diagnosis
1 6 . A dm ission d a te

7 . C ity
8 . P o s ta l code

1 7 . D is c h a rg e d a te
1 8 . 1 s t clinic

9 . Social insurance no. 1 9 . E n try d a te
1 0 . Health insurance no. 2 0 . H e ig h t (cm )

T a b le Ill- O p t io n s

1.
2.
3.
4.
5.

D iagnosis
6.
7.
L a b o ra to ry
T u m o u r m a rk e rs
8.
In v e s tig a tio n s
9.
S u rg e ry
10.
1 1 . T o e xit

C h e m o th e ra p y
R a d io th e ra p y
C o m p lic a tio n s
C linic v is its
P a llia tiv e c a re

rent information on any individual and
permits the user to alter or delete outdated
information.
4
Another attractive feature is the “ cor
respondence” routine. It is possible to 4
communicate with referring physicians
and others interested in the patient’s pro- 4
gress automatically. The printer is an integral component of the system and can
type reports in sequence on from 1 to 10 ^
patients. These reports contain informa
tion spanning 1 year of observation and +
are produced in triplicate.
The capacity of the system is con--«
siderable although not as great as that
available on larger machines. The system *
used for this study can store and retrieve
information on 400 patients. However, *
since storage depends entirely on the
capacity of the disc, storage can be ex
panded by using other available systems
capable of storing data on several thou
sand patients.
-1
To study disease in a clinical setting,
it is necessary to maintain complete *
records. It is also vital that the informa
tion be readily accessible and easily k
analysed. The computer is capable of this ^
because it is able to perform repetitive
tasks with great speed and because it has v
a great memory capacity. The small com
puter now offers the opportunity for clini
cians to maintain records and to study pa
tients more effectively.
•*
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Thoracic Outlet Compression

*• In a review of his experience with
thoracic outlet compression, the author
* attempts to define factors that will help
^select patients for operation.
Fifty-three patients underwent 59
transaxillary resections of the first rib. In
almost all cases the diagnosis was
*. clinical, based mainly on the history.
Aortography was useful only when in4 trinsic vascular disease was suspected.
Nerve-conduction studies were not
* helpful and were used only to confirm a
t diagnosis of peripheral nerve
compression.
Of 44 patients followed up, 33 had
good or excellent results. Of the 11 par tients with poor results. 8 complained of
persistent neck and shoulder pain.
►
The author concludes that the
diagnosis of thoracic outlet compression
* is clinical and is based mainly on the pa
tient's history. Transaxillary resection is
* safe and effective, particularly for pa^ tients whose symptoms are mainly in the
hand and arm. It is not effective for
r those whose predominant complaint is
neck and shoulder pain.
* A la revue de son experience des syndro^ mes des defiles cervico-axillaires, I'auteur
tente de definir les facteurs susceptibles
r de contribuer aux choix des patients
aptes a I'operation.
► Cinquante-trois malades ont subi 59
resections transaxillaires de la premiere
*"cote. Dans la plupart des cas, il s'agissait d'un diagnostic clinique base surtout
sur I'histoire du malade. L'aortographie
^ etait utile seulement quand une maladie
vasculaire intrinseque etait soupconnee.
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Les etudes de conduction nerveuse
n'etaient pas contributives et elles ne
furent utilisees que pour confirmer un
diagnostic de compression nerveuse
peripherique.
Des 44 patients ayant fait I'objet d'une
surveillance post-therapeutique, 33 ont
beneficie de resultats bons ou excellents.
Des 11 patients chez qui les resultats
furent mediocres, 8 se plaignaient de
douleurs persistantes au cou et a
I'epaule.
L'auteur conclut que le diagnostic du
syndrome des defiles cervico-axillaires
est clinique et qu'il repose avant tout sur
I'histoire du patient. La resection transaxillaire est sure et efficace, particulierement chez les patients dont les symptomes affectent principalement la main et
le bras. Elle n'est pas efficace chez les
patients qui se plaignent de facon predominante de douleur au cou et a I'epaule.

There have been sporadic reports, dating
back to the middle of the 19th century,
of gangrenous fingers due to a cervical
rib.
In 1931, Telford and Stopford1 de
scribed three patients whose gangrenous
fingers recovered following removal of
the cervical rib. They also discussed the
anatomy of the condition that is now call
ed thoracic outlet compression and sug
gested that neurovascular compression
may be present even with a normal first
rib.
Adson and Coffey2 drew attention to
the importance of the scalenus anticus
muscle and described how to divide this
muscle to relieve the symptoms. Naffziger
and Grant3 reviewed the neurologic com
plications of thoracic outlet compression.
In 1945, Wright4 examined 150 asymp
tomatic army recruits and noted that the
radial pulse could be abolished by
manipulating the shoulder in 82%. This
was confirmed by Roos5 who described
a number of abnormalities of insertion of
the scalene muscles that might cause
neurovascular compression in the absence
of bony abnormality.
A major advance in our understanding
of the condition came in 1966 when

Roos6 pointed out that the uppermost
rib invariably forms one jaw of the com
pressing vice although the second jaw can
be a variety of structures. He also describ
ed the transaxillary approach for removal
of the first rib.
The evaluation of patients who present
with pain in the neck, shoulder, arm and
hand remains difficult. Many published
series claim good to excellent results in
80% to 90% of patients who undergo
operation, but they provide little help in
selecting patients for operation.
In this paper I attempt to draw some
conclusions from my personal experience
with transaxillary resection of the first rib.
Patients and Methods
A review of the charts of 53 patients
who underwent transaxillary resection of
the first rib between 1974 and 1982 reveal
ed that 6 patients underwent staged,
bilateral operations making a total of 59
such procedures performed in this period.
Forty-five patients (85%) were women.
The age of the patients ranged from 16
to 51 years; the majority were in their 3rd
or 4th decade.
The predominant symptoms were pain
in the neck, shoulder, arm or hand (82%)
and numbness or tingling (82%). Less
common symptoms were swelling (24%)
and cyanosis (12%).
Manipulation of the arm obliterated
the radial pulse or caused a bruit to be
heard in the infraclavicular fossa in 80%
of patients. None had gross signs of cer
vical disc disease, muscular or tendinous
disease aro u n d the sh o u ld er or
acromioclavicular joint or of ulnar or me
dian nerve compression at the elbow or
wrist. Roentgenograms of the chest were
done in all patients and of the cervical
spine in most. Early in the study, it was
found that arch aortography was unhelp
ful and on one occasion was frankly mis
leading. Accordingly, arteriograms were
obtained only when there was a palpable
aneurysm or evidence of intrinsic vascular
disease, such as peripheral gangrene, or
a major difference in blood pressures bet
ween the two arms at rest.
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Nerve conduction studies were not
useful in diagnosing thoracic outlet com
pression, although Caldw ell and
associates7 and Urschel and Razzuk8
have advocated them as a diagnostic test,
an objective investigation for follow-up
and a guide for therapy. Conduction
studies are, however, unquestionably
valuable to confirm carpal or cubital tun
nel compression.
Results

No patient died. The average hospital
stay of patients, including the six who
underwent staged, bilateral operations,
was 6.5 days.
There were three major complications.
One patient suffered a massive hemo
thorax in the recovery room due to a
small tear in the axillary vein. Following
a second operation to suture the tear, her
recovery was smooth. Two other patients
had pneumothoraces on the evening of
the operation and chest tubes had to be
inserted.
Minor complications occurred in 17 pa
tients. In 12, the pleura was torn during
the operation. In all, the wound was clos
ed over a rubber catheter, which was
removed after the lung had been inflated
by the anesthetist. Two patients had
wound infections, two (both heavy
smokers) had pneumonia postoperatively and one patient needed intermittent
catheterization for urinary retention for
16 days after operation. No organic cause
for the urinary retention was found.
At follow-up, 33 of 44 patients were
either symptom-free or complained of
m inor symptoms, m ost frequently
anesthesia in an area on the inner aspect
of the arm due to division of the intercostobrachial nerve.
Nine patients were not better and two
were worse. Eight of these 11 patients
complained of persistent neck and
shoulder pain. Three had multiple com
plaints. One patient, taking propranolol,
complained o f Raynaud’s phenomenon.
This resolved when the propranolol was
discontinued. Only one patient was judg
ed to have a recurrence of her thoracic
outlet compression.
Discussion

Although the predisposing cause for
thoracic outlet compression is nearly
always congenital, the fact that the ma
jority of patients present in the 3rd and
4th decades o f life suggests that life-style
and posture are important factors in pro
ducing disabling symptoms.
Since the classic signs of compression
depend, in early cases, on the demonstra
tion of a bruit or abolition of the radial
pulse and since these signs can be elicited
in normal, asym ptom atic m en,4 it
follows that the history is the most im36

portant feature in making the diagnosis
and in offering appropriate advice for
treatment.
Many patients suffer pain in the neck,
in the area of the trapezius muscle, the
shoulder, arm and hand. Frequently, the
cause is not obvious or several possible
causes including thoracic outlet compres
sion may be suspected. Some patients
may need lengthy and detailed history
taking and review on several occasions
before any decision on their management
can reasonably be made. Shoulder exer
cises may be harmless over this period of
6 to 12 weeks, but in our practice they
have seldom proved beneficial for pa
tients who have unequivocal and in
capacitating symptoms of thoracic outlet
compression.
The symptoms are related to the posi
tion of the arm, and pain or neurologic
symptoms produced by such activities as
hair-drying or hanging out clothes are
suggestive of thoracic outlet compression.
If the degree of compression is severe,
typing or driving a car may produce pain.
Pain or paresthesia brought on by carry
ing, vacuuming or scrubbing floors may
be due to any of a variety of causes.
The classically described physical signs
lack both sensitivity and specificity.
However, the elevation-stress tests
wherein the patient’s shoulder is abducted
to 90°, the elbows bent 90° and the
fingers are then opened and closed rapidly
may be helpful if there is a gross dispari
ty in the exercise tolerance of the two
limbs.
The least common manifestation of
thoracic outlet compression is axillary
vein thrombosis. In view of the danger of
pulmonary embolism, it is justifiable to
be reasonably aggressive in advising pa
tients whose predominant symptoms are
of swelling or cyanosis related to posture
to undergo surgical treatment.
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Palliation of Advanced Head and Neck Cancer with
Radiofrequency Hyperthermia and Cytotoxic Chemotherapy
Fourteen patients with recurrent malig
nant tumours of the head and neck were
treated with radiofrequency hyperthermia
and chemotherapy after conventional
therapy had failed. After 2 to 11 treat
ment courses and a foilow-up of 30
weeks, the neoplasms in three patients
had completely regressed and one had a
partial response. Of eight patients who
died, two had partial responses initially;
a third patient died of complications
relating to surgical resection of the
tumour after a partial response. Three of
five patients whose tumours were
unresponsive to methotrexate responded
when this drug was given with radiofre
quency hyperthermia. There were seven
minor skin burns in six patients. Further
studies of radiofrequency hyperthermia
and chemotherapy for palliation of head
and neck cancer are planned.
Quatorze patients souffrant de recidives
de tumeurs malignes de la tete et du cou
ont ete traites par hyperthermie a ondes
hertziennes et chimiotherapie apres
I'echec des traitements conventionnels.
Apres de 2 a 11 cures et une periode
d’observation post-therapeutique de 30
semaines, trois patients avaient vu leur
tumeur regresser completement et un
avait eu une remission partielle. Des huit
patients qui sont decedes, deux avaient
eu une reponse partielle initialement; un
troisieme est mort des complications
d'une resection chirurgicale de la tumeur
apres avoir obtenu une reponse partielle.
Trois des cinq patients dont les tumeurs
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etaient resistantes au methotrexate ont
reagi quand le meme medicament fut
administre en association avec I'hyperthermie a ondes hertziennes. II y eut sept
brulures cutanees mineures chez six
patients. D'autres etudes de I'hyperthermie a ondes hertziennes en association
avec la chimiotherapie dans le traitement
palliatif des cancers de la tete et du cou
sont projetees.

Patients with recurrent cancer of the head
and neck following operation and max
imal irradiation present a formidable
therapeutic challenge. The extent of
disease often precludes further operation
and the role of radiotherapy is limited.
Chemotherapy may offer some palliation
for recurrent unresectable tumours;
methotrexate, cis-platinum, cyclophos
phamide and bleomycin, given individual
ly, may produce short-lived responses in
20% to 50% of cases but do not improve
survival.14 Combination chemotherapy
produces tumour regression in a greater
proportion of patients but is associated
with a notably higher frequency of
toxicity. 2,4,5
Hyperthermia is toxic to neoplastic
tissue and has been employed locally,
regionally and systemically to treat hu
man malignant tumours. Thermotherapy
is most efficacious when combined with
radiotherapy or chemotherapy.611 Local
hyperthermia with ultrasonic or microwave therapy produces tumour regression
when applied to superficial neoplasms.12,13
At the Toronto General Hospital and at
other centres,14‘17regional radiofrequen
cy hyperthermia has been used for deep
ly situated cancers and is showing par
ticular promise in patients with unresec
table hepatic metastases from colorectal
adenocarcinom as.17 Regional thermochemotherapeutic infusion through
the external carotid artery has been used
in patients with tumours of the head and
neck with some success, but it requires a
surgical procedure under general
anesthesia.18 The use of systemic hyper
thermia to treat human cancers is limited

by toxicity to the liver and central nervous
system and is prohibitively expensive.19
"Since August 1981, radiofrequency
hyperthermia combined with cytotoxic
chemotherapy and adjuvant administra
tion of metronidazole has been used to
treat patients with incurable malignant
tumours at the Toronto General Hospital.
Metronidazole was added to the protocol
in April 1982 because of its toxic effect
on hypoxic cells and its role as a
radiation-sensitizing agent.20 Initial ex
perience suggests that metronidazole
facilitates elevation of tumour temper
ature with radiofrequency hyperther
m ia.16 The preliminary results obtained
with this regimen in patients with recur
rent, unresectable tumours of the head
and neck are reported here.
Patients and Methods
To date, 421 patients with malignant
disease have been treated with radiofre
quency hyperthermia and chemotherapy
at this centre. Of these, 20 patients had
tumours of the head and neck. Six of
these patients were excluded from further
study; three were lost to follow-up and
three did not complete a full treatment
course. The 14 patients remaining includ
ed 8 men and 6 women, ranging in age
from 30 to 69 years (median 54 years).
Histologic types and sites of origin of the
primary lesions are detailed in Table I.
All patients had received one to three
courses of radiotherapy (4000 to 6500 rad)
and 12 had been operated upon (one to
seven operations each) before referral. Six
patients had failed to respond to cytotoxic
chemotherapy; six others had been judg
ed unsuitable for treatm ent with
chemotherapy by a medical oncologist or
tumour review board. Previous treatment
is summarized in Tables II to IV. All pa
tients had recurrent, unresectable (stage
IV) tumours that were not amenable to
further irradiation. One patient (with
adenoid cystic carcinoma) had multiple
pulmonary metastases.
Twelve of the 14 patients had systemic
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cytotoxic chemotherapy during radiofre
quency hyperthermia treatment. Four pal tients received methotrexate alone and the
rest multiple agents, either sequentially or
f in combination (Table V). Three doses of
metronidazole (500 mg orally or in^ travenously) were given before and dur^ ing each session of radiofrequency hyper
thermia. Analgesics and mild sedatives
were given during treatment as required.
Hyperthermia was administered with
^ either of two capacitive radiofrequency
machines (IIMS-100 model; International
►Institute of Medical Science, New York,
NY). These machines generate radiofre*" quency energy at 13.56 MHz with up to
500 W of power through each of three
^ channels. The energy produced through
each channel is delivered through a pair
of electrodes (“ paddles” ) positioned on
the body surface so that the tumour mass
lies between them. In our 14 patients, only
► one channel was used, as the surface area
of the head and neck is too small to app* ly more than one pair of paddles. These
tumours were superficial and could be
* heated quite easily.
^
The paddles currently used were design
ed at this institution and have been
t described previously.17 They are
malleable and have an internal cold-water
circulation system to protect the skin sur
face from burns. These paddles can be inr dividually made on short notice — an im
portant advantage in treating head and
* neck cancer as the contour of an in
dividual tumour is often unique. This is
* especially true for tumour recurrences
y following major surgical resection. Areas
to which radiofrequency hyperthermia
v was applied included the cheek and max
illa (five patients), neck (four), temporal
► region (three) and mandible/pterygoid
region (two).
* The treatments were given on an out
patient basis whenever possible. All pa
tients gave informed consent before enterr ing the treatment program. Courses,
given every 3 to 6 weeks, consisted of two
y to three consecutive daily sessions lasting

72 to 120 minutes (median 109.5
minutes). Total treatment time for each
course was 272 ± 47 minutes (range from
200 to 348 minutes, median 268 minutes).
Machine power was maintained at a level
compatible with patient comfort and
varied between individuals. On average,
137 ± 38 W of power were used (range
from 63 to 230 W, median 136 W).
Systemic temperature was measured at
the beginning and end of each session.
Tumour core temperature was monitored
in 13 patients with either of two electronic
thermometry systems: the Bailey In
struments TM-10 Clinical Thermometer
with flexible wire thermister (Bailey In
struments, Saddle Brook, NJ) or the Luxtron Model 1000B Biomedical Fluoroptic Thermometer with the Luxtron GMA
Table II—Previous Operative Treatment in
11 of 14 Patients with Head and Neck
Tumours Referred for Radiofrequency
Hyperthermia with Chemotherapy
No. of
Type of operation
operations
Primary
Wide local excision
3
Commando procedure
1
Partial glossectomy
1
Parotidectomy
1
Radical laryngectomy
1
Radical neck dissection
1
Sleeve resection of
external auditory canal
1
Secondary — for subsequent
regional metastasis or
local recurrence
Wide excision
Local recurrence
8
Neck recurrence
3
Commando procedure
1
Ethmoidectomy
1
Maxillectomy
1
Partial resection of temporal bone
1
Radical neck dissection
Unilateral (including
parotid gland)
1
Bilateral
1
Total
26

Fluoroptic Temperature Probe (Luxtron
Corp., Mountainview, Calif.). The ther
mister or probe was inserted percutaneously under local anesthesia into
the tumour mass through a no. 18
Angiocath (Deseret Co., Sandy, Utah).

Results
Survival and Response
To date, the 14 patients under con
sideration have received from 2 to 11
courses of radiofrequency hyperthermia
(median 3 courses). The objective
responses, as assessed by physical ex
amination using conventional criteria, are
summarized in Table VI. The three pa
tients with complete tumour regression
have been followed up for 21, 35 and 55
weeks respectively from the time of the
initial radiofrequency hyperthermia treat-

Table Ill-Previous Radiotherapy in 14 Patients
with Head and Neck Tumours Referred for
Radiofrequency Hyperthermia with Chemotherapy
No. of
Type of
courses
radiotherapy
Primary
External (4 0 0 0 -6 5 0 0 rad)
Irridium implant
Secondary — for recurrence
External (2 5 0 0 -6 0 0 0 rad)
Total

11
i
8
20

Table IV—Previous Chemotherapy in 6 of 14
Patients with Head and Neck Tumours Referred
for Radiofrequency Hyperthermia with
Chemotherapy
No. of
Type of
chemotherapy
patients
Primary
0
Secondary — for occurrence
Methotrexate (intravenously)
5
5-fluorouracil
2
6*
Total
*1 patient received both agents.

►
Table I--Origin of Primary Tumours in 14 Patients
Histologic type
Squamous cell carcinoma

Site of origin
Larynx
r
Buccal mucosa
Floor of mouth
►
Anterior tongue
Posterior tongue
Ethmoid/sphenoid sinuses
Mastoid*
External auditory canal
Facial skin over zygoma
Basal cell carcinoma
Facial skin over nasal complex
Adenoid cystic carcinoma
Minor salivary gland of oral cavity
x Chondrosarcoma
Maxilla
Parotid gland
Mucoepidermoid carcinoma
* Post-mastoidectomy for chronic sinusitis.

No. of
patients
2
1
1
1
1
1
1
1
1
1
1
1
1

Table V-Systemic Cytotoxic Chemotherapy
Given with Radiofrequency Hyperthermia in
12 of 14 Patients
No. of
patients
Agent
9
Methotrexate
6
5-fluorouracil
5
Mitomycin C
1
Bischloronitrosourea
1
Vinblastine
1
Vincristine
23*
Total
*2 patients received 2 agents. 2 patients
received 3 agents during different courses. 1
patient received all 6 agents during different
courses.
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ment. The patient followed up for 55
weeks had marked reduction in tumour
size at 35 weeks and underwent excision
of residual tumour at that time. Tumour
nodules developed postoperatively which,
after two further courses of radiofrequen
cy hyperthermia and methotrexate, disap
peared completely. The patient followed
up for 35 weeks had pulm onary
metastases at the time of the initial treat
ment. His head and neck tumour regress
ed completely and his lung lesions remain
stable and asymptomatic. The patient
whose tumour partially responded had
complete regression after two courses of
radiofreq u en cy h y pertherm ia and
chemotherapy. His tumour recurred when
treatment was stopped for 8 weeks but
when radiofrequency hyperthermia and
methotrexate therapy were resumed, his
tumour regressed once again.
Of the 10 patients whose tumours pro
gressed, 2 had partial responses initially.
The response was only transient in one
but lasted 33 weeks in the other. Both
have since died of their disease. One pa
tient died from a surgical complication
following partial tumour regression.
After three courses of radiofrequency
hyperthermia and chemotherapy, his
tumour was removed en bloc with the
right carotid artery; arterial reconstruc
tion was carried out using autologous
saphenous vein. Wound sepsis developed
and he died of hemorrhage from his
carotid graft 16 days after operation.
R adiofrequency hypertherm ia was
discontinued after two courses in one of
the two living patients whose tumours
progressed, and cis-platinum, bleomycin
and VP-16 without hyperthermia were
given systemically. Her tumour complete
ly regressed with this therapy.
Three of the five patients who failed to
respond to methotrexate alone before
referral did respond to methotrexate with
radiofrequency hyperthermia. Two had
partial regression; one has since died of
his disease, the other was the man who
died of delayed hemorrhage following ex

cision of his tumour. The third patient
had complete regression of his tumour at
21 weeks’ follow-up. Neither of the two
patients who received radiofrequency
hypertherm ia without concomitant
chemotherapy obtained any objective
tumour regression. One of these patients
had been treated with methotrexate
before starting hyperthermia.
In summary, 8 of 14 patients (57.1%)
died. The duration of survival was 24 ±
14 weeks (range from 10 to 51 weeks, me
dian 22 weeks). The follow-up for the six
patients (42.9%) still alive on May 1, 1983
was 36.5 ± 1 1 .0 weeks (range from 21 to
55 weeks, median 36 weeks).
Toxicity
There were no major adverse effects at
tributable to the use of cytotoxic
chemotherapy or metronidazole, nor was
there any systemic toxicity due to
radiofrequency hyperthermia in these pa
tients. Local toxicity due to hyperthermia
consisted of seven superficial burns in six
patients. These healed well and in no case
did the skin break down or ulceration oc
cur. There was no morbidity associated
with insertion of thermisters or probes for
monitoring tumour temperature.
Systemic and Tumour-Core Temperature
Systemic temperature rose 0.7 ± 0.3°C
during treatment sessions, a clinically in
significant increase. The results of
monitoring systemic and tumour-core
temperatures are shown in Fig. 1. In con
trast to our experience with hepatic
tum ours,17 there was modest but signifi
cant (p < 0.005, simple linear regression
± ratio) correlation between machine

power and tumour-core temperature in
the 13 monitored patients (Fig. 2).

*
Discussion
The results of this preliminary study
suggest that patients with head and neck
tumours that have recurred despite max
imal conventional therapy can be given
effective and safe palliation with radiofre
quency hyperthermia and chemotherapy.
Furthermore, tumour responses to this
treatment may be of longer duration than
those seen with chemotherapy alone. The
small number of patients and relatively
short follow-up does not allow objective
assessment of the effect of this regimen
on survival.
It has been shown in vitro that
methotrexate-resistant tumour cells will
become sensitive to this drug if the ambient temperature is elevated.21 Further
more, an additive effect of methotrexate
and hyperthermia against the VX2 car
cinoma in rabbits has been demonstrated
in vivo.22 In this series, three of the five
patients whose tumours had not responded to methotrexate obtained regression
when radiofrequency hyperthermia was
added.
The patient with local recurrence and
pulmonary metastases had complete
regression of his local disease and no ap
parent effect on his pulmonary nodules.
Since local disease is the cause of most
morbidity and death even when distant
metastases are present, any local pallia
tion obtained is a major benefit, as it was
for this patient.
The proportion of superficial burns in
these patients was substantially higher
than that found in the total patient
population treated with radiofrequency
hyperthermia at this centre.17 Patients
with head and neck tumours were unique
in th at they received high-dose
radiotherapy before treatment with
hyperthermia. Probably the skin is less
able to withstand the stress of heat follow-
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FIG. 1—Tumour-core temperature and
systemic temperature (°C) versus radiofrequen
cy hyperthermia treatment time (minutes) in
13 monitored patients. RFHT = radiofrequen
cy hyperthermia; bars = ± standard error.

FIG. 2—Scattergram of tum our-core
tem perature versus machine power in j
13 monitored patients. There is significant
positive relationship between machine power 4
and tumour temperature (a = 35.01, b =
0.048, r = 0.70, p < 0.005).
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ing irradiation. Alternatively, decreased
sensation in skin flaps as a result of
A surgical denervation may have com
promised the ability to feel burning early
^ enough to prevent skin injury.
In patients with hepatic tumours there
was marked variation in machine power
^ required to achieve therapeutic tumourtemperature elevation and minimal cor►
. relation between power and tumour
tem peratu re within and between
► individuals.17 This was not the case in
the 14 patients considered here; the more
h superficial location of these lesions may
account for the reduced variability and
amount of power required to heat tumour
^ tissue in the head and neck region
adequately.
y
The results so far have been encourag

ing. We are continuing to use radiofre
quency hyperthermia and methotrexate in
combination in patients with recurrent,
unresectable head and neck tumours. In
addition, we propose to study in the near
future the efficacy of combination
chemotherapy (cis-platinum, bleomycin
and VP-16) in the treatment of these
cancers, both alone and with radiofre
quency hyperthermia.
We acknowledge the assistance of Mrs.
Carolyn Anderson in preparing this
manuscript.
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Chronic Pancreatitis: a 5-Year Experience

k

Of 81 patients with chronic pancreatitis
admitted to the Ottawa Civic Hospital
over a 5-year period. 40 had conditions
that were thought to be amenable to
various operations. Good results were
obtained in 70%. Of note were the 75%
good results of pancreaticojejunostomy.
Several patients needed further operations. The proportion of good results
leaves no room for complacency, but it
is difficult to envisage how a damaged
gland can be expected to make a full
recovery from either internal or external
drainage procedures. Two patients died
of carcinoma within 2 years of their
initial operation and may have had car
cinoma of the pancreas from the outset,
although their mode of presentation and
results of investigation were those of
chronic pancreatitis. Alcohol abuse was
thought to be responsible for the condi
tion in 72% of these patients.
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Au cours d'une periode de 5 ans, sur les
81 patients recus a I'hopital civique
d'Ottawa souffrant de pancreatite chronique, 40 avaient des affections que I'on
croyait susceptibles d'etre gueries par
diverses interventions chirurgicales. De
bons resultats furent obtenus dans 70%
des cas. II est a noter que 7 5 % des bons
resultats sont dus a la pancreaticojejunostomie. Plusieurs patients ont
necessite des interventions supplementaires. Le pourcentage de bons resultats
ne permet pas d'etre complaisant, mais il
est difficile d'imaginer qu'on puisse esperer la guerison complete d'une glande
endommagee par un drainage interne ou
externe. Deux patients sont morts d'un
cancer du pancreas dans les 2 ans qui
suivirent et peuvent avoir ete porteurs
d'un cancer du pancreas des le debut,
bien que leur tableau clinique et les
resultats de leur examens aient ete ceux
de la pancreatite chronique. On croit que
I'abus de I'alcool etait responsable de la
maladie chez 72% des patients.

To audit the efficacy of operations per
formed to ameliorate the course of
chronic pancreatitis, 81 patients who were
treated for chronic pancreatitis at the O t
tawa Civic Hospital during a 5-year
period were studied. No attempt was
made to relate the results to whether or
not the alcoholic patients stopped drink
ing, because of the high rate o f recidivism
in such patients and because the
statements of alcoholic patients and other

witnesses are not dependable enough to
be considered evidence. Hence, the results
are presented as a random sample of what
may be expected in a group of patients
with chronic pancreatitis o f mixed
etiology, who undergo operations to cor
rect an anatomic lesion.
Patient Data
During the 5-year period 1977 to 1981,
81 patients (56 men, 25 women) were
treated for chronic pancreatitis at the O t
tawa Civic Hospital. The diagnosis of
chronic pancreatitis was based upon the
following criteria: recurrent attacks of
acute pancreatitis, chronic abdominal
pain, radiologic changes in the pancreas,
the presence of pancreatic pseudocysts or
recurrent pancreatic abscesses, the find
ings on endoscopic retrograde cholangio
pancreatography, and endocrine and ex
ocrine pancreatic insufficiency.
Forty-five patients underwent endo
scopic retrograde cholangiopancreato
graphy. The findings were unequivocal
ly those of chronic pancreatitis in 67%;
in 16%, findings were equivocal.
Treatment
Operative
Forty of the 81 patients underwent 57
operations (Table I). The operations for
pseudocysts were those performed on pa
tients who had recurrent or chronic pan
creatitis; patients with pseudocysts aris
ing from acute pancreatitis were exclud-
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ed. Two of the cholecystectomies were
performed in association with exploration
of the pancreas. The choledochostomies
were performed in some patients who also
had external drainage. The external
drainage procedures were usually for pan
creatic abscesses, or infected pancreatic
pseudocysts. Included in “ exploration”
were seven patients thought to have car
cinoma of the pancreas but found at ex
ploration to have chronic pancreatitis.
The 12 pancreaticojejunostomies were
performed using a Roux-en-Y segment of
jejunum, a long opening of the pancreatic
duct and a mucosa-to-mucosa suture in
two layers between the jejunum and the
duct, preserving the spleen. The five distal
pancreatectomies included splenectomy.
Complications. —Postoperatively, two
patients who had undergone pancreaticojejunostom y had pseudocysts and
abscesses, which were drained external
ly. Two patients died in the postoperative
period; one had had external drainage of
a recurrent pancreatic abscess — death
was from sepsis; the second patient, with
chronic alcoholic pancreatitis and hepatic
cirrhosis, died of hepatic failure
51/2 weeks after external drainage of a
chronic pancreatic abscess.

FIG. 1—Pseudocyst of head of pancreas.
T tube is in place after internal drainage.

Follow-up (Table II).—Since some pa-

tients had more than one procedure, the
most definitive operation is recorded in
Table II for follow-up purposes. Followup ranged from 17 to 60 months. Patients
who were lost to follow-up were classified
as “ worse” . Overall, the results of opera
tion were good in 70% of the patients. Of
the 12 patients who underwent pancreaticojejunostomy, 9 had a satisfactory
outcome. Two patients died of carcinoma
of the pancreas 2 years after their initial
operation. It is likely that the carcinoma
was present at the time of the original
operation. In one case the original operation was internal drainage of a pseudocyst
into the duodenum; in the other case it
was a pancreaticojejunostomy. There
were no distinguishing characteristics of
cystadenoma or cystadenocarcinoma
either at operation or at autopsy. Figs. 1
and 2 show pseudocysts and dilated ducts
respectively in these two patients. Both
patients had had intermittent pain and
jaundice for several months before they
underwent operation and histories more
typical of chronic pancreatitis than of car
cinoma of the pancreas. It is not known
whether the carcinoma arose in the
chronically inflamed pancreatic tissue or
the clinical features of chronic pancreatitis were due to the carcinoma from
the outset.
Medical
Forty-one patients were not considered
candidates for operation and were
therefore treated medically. Seven had no
symptoms, 8 were improved, 13 had
disabling symptoms, 5 died and 8 were
lost to follow-up.

Table 1— P ro c ed u re s P e rfo rm e d
P ro c ed u re

No.

P a n c re a tic o je ju n o s to m y

12
5
7

D is ta l p a n c re a te c to m y
E x p lo ra tio n (2 w it h c h o le c y s te c to m y !
B ilia ry bypass (1 w ith c h o le c y ste cto m y )

3
4
14

P a n c re a tic o g a s tro s to m y
P s e u d o c y s t o p e ra tio n
E x te rn a l d ra in a g e (includes
c h o le d o c h o s to m y )

11
1

S p h in c te ro to m y

FIG. 2—Pseudocyst of head of pancreas.
Pancreatic duct and biliary tree (arrows) are
dilated.

Im p ro v e d

W o rs e

Died

2

1 (ca rc in o m a
o f p a n c re as !

2

-

4

E x te rn a l d ra in ag e
C h o le c y s te c to m y

3
3

-

-

E x p lo ra tio n
C h o le d o c h o d u o d e n o s to m y
S p h in c te ro to m y a nd
e x te rn a l d ra in a g e
D is ta l p a n c re a te c to m y

2
1

—

—

42
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4
*
'
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x

4
"*
4

5

1 (cause
unknow n!
1

-

1

—

3

~

-

—
-

1

2
1
3

-

1 (renal
failu re)
_
—

1
_

Seventy-two percent of the patients suffered from alcoholism, which was pro- n
bably responsible for their chronic pan
creatitis. Diabetes mellitus was present in •»
16% and steatorrhea in 12%. Gallstones
and familial pancreatitis were likely
etiologic factors in 11%.
t

P a n c re a tic o je ju n o s to m y

B ilia ry bypass
In te rn a l d ra in ag e
P a n c re a tic o g a s tro s to m y
C h o le c y s te c to m y and
b ilia ry bypass
In te rn a l d ra in ag e and
b ilia ry bypass

^
^

•*

R esu lt

P ro c e d u re

A

Associated Conditions

T a b le II— F o llo w -u p a fte r O p e ra tio n

No
s ym p to m s

4

—

1 (ca rc in o m a
o f p a n c re as )

Conclusions
The treatment of chronic pancreatitis,
whether medical or surgical, leaves much y
to be desired, but when a pancreaticoje
junostomy can be performed, the results M
are satisfactory in approximately 75%.
When chronic pancreatitis is due to
gallstones, even better results can be ex- „
pected. Multiple operations may be re
quired to achieve a satisfactory result. «
There is a danger of overlooking a small
carcinoma as a cause of chronic pancreatitis, a large pseudocyst or ectasia of
the main pancreatic duct. Cystadenocar- -*
cinoma or cystadenoma are readily j
suspected and diagnosed. During the
period of study, three such lesions were 4
diagnosed and treated and are not includ
ed in this group. ■
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A Single Preoperative Dose of Cefazolin Prevents
Postoperative Sepsis in High-Risk Biliary Surgery
To test the ability of cefazolin, given in a
single dose preoperatively, to prevent in
fection in high-risk patients after biliary
tract surgery, the authors conducted a
double-blind, prospective, randomized,
controlled study. Of 92 patients operated
on for acute cholecystitis or bile-duct
disease, 46 were given 2 g of cefazolin
intravenously before operation. Bile was
contaminated with bacteria in 36% to
50% of patients with acute cholecystitis,
obstructive jaundice, bile-duct disease
without jaundice, or over 50 years old
compared with only 5% of patients with
chronic cholecystitis or under 50 years
of age. Postoperative sepsis was eight
times more frequent in patients with
contaminated bile than in those without.
Only 1 patient who received cefazolin
had a wound infection, but 9 of the 46
patients in the control group did. The
bacteria causing wound sepsis were
similar to those in the contaminated bile.
The authors conclude that a single dose
of cefazolin given intravenously before
operation provides effective prophylaxis
against infection in high-risk biliary tract
surgery.

chez les patients a risque elevd qui
subissent une chirurgie des voies biliaires, les auteurs ont mene une etude
prospective, randomisee, controlee et a
double-insu. Parmi 92 patients operes
pour une cholecystite aigue ou une
affection des canaux biliaires, 46 ont
recu 2 g de cefazoline par voie intraveineuse avant I'intervention. Une contami
nation bacterienne de la bile a ete observee chez 36% d 50% des patients qui
souffraient de cholecystite aigue, d'ictere
par obstruction, d’atteinte des canaux
biliaires sans ictere et chez ceux qui
etaient ages de plus de 50 ans, comparativement a seulement 5% des patients
souffrant de cholecystite chronique ou
ages de moins de 50 ans. Les sepsies
postoperatoires ont ete huit fois plus frequentes chez les patients qui avaient une
contamination biliaire que chez ceux qui
n'en avaient pas. Un seul des patients
qui ont recu de la cefazoline a eu une
infection de plaie comparativement a 9
des 46 patients du groupe temoin. Les
bacteries responsables des infections de
plaie etaient les memes que celles qui
contaminaient la bile. Les auteurs concluent qu'une seule dose de cefazoline
administree par voie intraveineuse avant
I'operation assure une protection efficace
contre I'infection dans la chirurgie des
voies biliaires a risque eleve.

them beyond the day of operation.
Strachan and coworkers9 recommended
just one dose of cefazolin given pre
operatively; the Medical Letter on Drugs
and Therapeutics10 has endorsed this ap
proach. However, the population studied
by Strachan and coworkers included few
high-risk patients. We undertook the pre
sent study to determine whether a single
dose of cefazolin given intravenously
before operation provides effective pro
phylaxis against infection in high-risk pa
tients who undergo biliary operations.
Patients and Methods

Patients at the Queen Elizabeth
Hospital, Montreal, scheduled for opera
tion on the bile ducts and for cholecystec
tomy for acute cholecystitis entered the
trial. Those who had received antibiotics
in the 48 hours preceding operation or
were known to be sensitive to cephal
osporins were excluded. A diagnosis of
acute cholecystitis was made clinically and
confirmed by abdominal ultrasonography
and by demonstrating cystic duct obstruc
tion using technetium-99m 2,6-dimethylphenylcarbamoyl methyliminodiacetic
Dans le but de tester la capacite de la
acid (99mTc-HIDA) scanning. The pa
cefazoline, administree en dose unique
tients were randomly assigned by sealed
avant 1'operation de prevenir I'infection
envelope technique to receive cefazolin,
2 g intravenously, or an identically labell
From the Department o f Surgery, Queen
ed placebo immediately before operation.
Elizabeth Hospital and McGill University,
Montreal, PQ
The age, sex, weight and height of each
When
used
properly,
antibiotics
provide
patient
and the duration of operation
Presented at the 87th annual meeting of the excellent protection against infection were noted. Ideal weight for height and
Canadian Association of Clinical Surgeons,
Eastern Division, Halifax, NS, May 27-28, following biliary tract surgery.1'4 But body build values were obtained from
controversy persists as to which patients standard tables.11 A risk index of wound
1983
should receive them and when they should infection was calculated as suggested by
*Associate Professor of Surgery, McGill
be given. Chetlin and Elliott5 defined Davidson and associates.12 This index
University
four categories of patients at high risk of relates the risk of wound infection
infection after biliary tract operations. postoperatively to the age of the patient,
t Assistant Professor of Surgery, McGill
University
Others6 7 have expanded the risk groups duration of operation, wound class and
but the overall risk correlates closely with the presence or absence of organisms on
XAssociate Professor o f Surgery, McGill
the presence of bacteria in bile samples culture of the subcutaneous fat at the end
University; Surgeon-in-Chief, Queen
taken from the gallbladder or bile ducts of operation. The total blood lymphocyte
Elizabeth Hospital, Montreal, PQ
at operation.5'6 Administration of an count was obtained preoperatively by
Accepted for publication July 7, 1983
tibiotics must be started before multiplying the total leukocyte count by
operation;4 when to stop them is less cer the percentage of lymphocytes seen on
Reprint requests to: Dr. R. T. Lewis, The
tain. Stone and associates8 have shown differential smears. This value provides
Queen Elizabeth Hospital, 2100 Marlowe
Ave., Montreal, PQ H4A 3L6
that there is no advantage in continuing a simple measure of host resistance.13
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Results

The serum bilirubin, alkaline phospha
tase, glutamic pyruvic transaminase and
P lactate dehydrogenase levels were deter
mined preoperatively by standard meth^ ods using the Bichromatic autoanalyser
^ (Abbott Laboratories, Diagnostics Div
ision, Toronto, Ont.). At operation, a
i. culture was obtained from the inner sur
face of the gallbladder and from the sub► cutaneous fat of the abdominal wound
before skin closure.

Ninety-two patients completed the pro
tocol — 46 received cefazolin and 46 the
placebo.
The patients in both groups were
similar with respect to mean age, bloodlymphocyte count preoperatively, David
son risk index and percent actual of ideal
weight for height (Table I). Fewer men
and more women received cefazolin than
the placebo, but the difference was not
statistically significant. Table II compares
the two groups with respect to wound
class, clinical diagnosis confirmed at
operation and by gross and microscopic
findings and with respect to results of
culture of bile samples taken at operation.
The groups were evenly matched.
The clinical risk factors selected
predicted correctly the increased risk of
bile contamination (Table III). Patients
with chronic cholecystitis and choleli
thiasis without jaundice or bile-duct
disease and those under 50 years of age
generally had uninfected bile, but cultures
positive for bacteria were obtained in the

After operation, patients were follow* ed up carefully by infection control per
sonnel for development of wound or
*- intra-abdominal infections. A wound in
fection was diagnosed when pus drained
V from the wound; a sample of the pus was
then sent for culture. Wounds that were
*■ indurated, reddened or tender were
followed until the condition resolved or
there was drainage. A further report was
*. obtained 1 month after operation from
the patient’s physician.
A
Statistical evaluation was carried out
4 where indicated by Student’s f-test and
X 2 analysis.

36% to 50% of patients older than 50
years, those with acute cholecystitis,
obstructive jaundice or bile-duct disease
without jaundice.
Although the frequency of positive bile
cultures was similar in the treatment and
control groups, a wound infection de
veloped in only one patient who received
cefazolin, compared with nine patients
who had the placebo. Two of these also
had intra-abdominal abscesses and two
others an intra-abdominal abscess and
drain-site abscess respectively (Table IV).
The association between positive bile
culture and postoperative sepsis is shown
in Fig. 1. The difference in rates of in
fection between patients with negative bile
cultures and those with positive cultures
is significant (p < 0.0002). Sepsis occur
red in over 50% of patients with positive
bile cultures who received the placebo,
compared with only 5% of those who
were given cefazolin (p < 0.005) (Fig. 2).
By contrast, postoperative sepsis was
equally infrequent in treatment and con
trol patients with negative bile cultures (p
= 0.14). Table V compares results be-
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BILE CULTURE

FIG. 1—Bile culture and postoperative in
fection. There is eightfold difference in rates
of infection between patients with negative bile
cultures and those with positive cultures.
Numbers in brackets indicate number of
patients.
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tween treatment and control groups in
each high-risk category. Although the
number of patients in each category is
small, differences were significant in pa
tients with obstructive jaundice and in
those over the age of 50 years. The
bacteriologic findings demonstrated a
close similarity between organisms grown
from the bile and those producing
postoperative infection (Table VI).
The mean postoperative stay of pa
tients who had infections was 17.5 ± 2.9
days, but was only 8.5 ± 0.3 days for
those who did not (p < 0.0005).
Discussion
Indiscriminate or prolonged use of an
tibiotics prophylactically may encourage
antibiotic-resistant organisms, superinfec
tion or toxicity.13 An appropriate an
tibiotic given as prophylaxis to selected
patients in a single intravenous dose is
therefore attractive. The results of this
double-blind, prospective, randomized,
controlled trial confirm that the high risk
of postoperative infection in biliary
operations is due to contaminated bile,
that selected clinical criteria predict this
increased risk correctly and that a dose
of cefazolin given before operation
reduces the risk considerably. Indeed,
among the patients given the placebo, a
positive culture of the bile implied a ten
fold increase in the risk of infection com
pared with sterile bile (Fig. 2). A single
dose of cefazolin abolished this risk.
Our findings with respect to risk fac
tors in contaminated bile confirm those
previously rep o rted .5’6 Their even
distribution between the treatment and
control groups is important in evaluating
the role of antibiotics.
In a study of 201 patients who under
went elective cholecystectomy, Strachan
and coworkers9 showed that a single
dose of cefazolin reduced the risk of in
fection postoperatively. However, that
study was single-blind, excluded patients
with acute cholecystitis and jaundice, in
cluded few elderly patients and only 29

Table V-Postoperative Infection: Diagnosis versus Cefazolin
Patients with infection!
total no. of patients
Placebo
Cefazolin

Diagnosis
Acute cholecystitis
Obstructive jaundice
Bile-duct disease, no jaundice
Chronic cholecystitis, normal
bile duct
Age over 50 yr
'Statistically significant difference between

5
6
7
CEFAZOLIN

PLACEBO

FIG . 2—C efazolin, bile culture and
postoperative infection. There is significantly
(p < 0.005) higher rate of infection in control
patients with positive bile cultures. Black bars
= positive bile culture, white bars = negative
bile culture.
46

1124
0111
1(7

1120
6/11
2!8

0.7
<0.0005*
0.7

0/3
1(34

0I7
9/40

NS
<0.002*

treatment groups.

Bacteria according to culture site
Grouplpatient
with infection
Cefazolin
1

4

PLACEBO

P
value

Table VI—Bacteriology of Postoperative Infection

Placebo
1
2
3

CEFAZOLIN

By contrast, the present study deals
with patients at increased risk of infec
tion postoperatively due to bile con- 4
tamination. The study shows that this risk
is similar in the treatment and control 4
groups; following a single dose of
cefazolin, it demonstrates reduced infec- ^
tion postoperatively in patients with ^
positive bile cultures but not in those with
sterile bile; it confirms a close correlation A
between the organisms in the bile and
those producing infection.
The choice of antibiotic for prophylac
tic use is governed by the organisms *
found in the biliary tree, primarily coliforms and streptococci. Many of these
organisms are now resistant to ampicillin
and tetracycline.16 Gentamicin, to which
most are sensitive, has been recommend- A
ed by Keighley and colleagues,3 but there
are theoretical objections to its routine use ^
for prophylaxis, and it is not effective
against enterococci. Cotrimoxazole,14 *
rifamide17 and cefamandole18 have also
been used because they attain high con- '
centrations in the bile. However, in the

who underw ent choledochotom y.
Moreover, of the 17 patients who had
wound sepsis, 7 discharged pus from
which no organism was grown, and in on
ly 5 of the remainder was the organism
obtained from the wound similar to that
in the bile or subcutaneous fat at opera
tion. More recently, in a double-blind
study, Morran and associates14 found
wound sepsis in 10 (21 %) of 47 control
patients, but in only 2 (4%) of 48 who
received a single dose of cotrimoxazole in
travenously before elective cholecystec
tomy. However, only 18% of patients in
each group had positive bile cultures, and
7 of the 10 wound infections in the con
trol group were due to organisms unre
lated to bile contamination. In fact, the
bacteria most commonly grown from the
wound infections were Staphylococcus sp.
This is similar to our findings in simple
elective cholecystectomy15 where only
10% to 15% of patients had con
tam inated bile and staphylococci,
although never grown from the bile, were
the common cause of wound infection.

8
9
10
11

Bile
Streptococcus group D

Wound abscess
Streptococcus viridans,
Staphylococcus aureus

No growth

S. aureus

S. aureus
Escherichia co li

—

£ coti, Klebsiella sp,
Morganella sp
No growth
£. coli, S. aureus
Klebsiella sp,
Clostridium sp
Streptococcus sp
Streptococcus sp
£ coii, Klebsiella sp

Intra-abdominal or
drain-site abscess

S. aureus

£ coli, Peptostreptococcus
sp
£ co li
Enterococcus sp,
S . aureus
£ coli, S. aureus
Klebsiella sp
Streptococcus sp
Streptococcus sp
£ coii, Streptococcus
group 0, Bacteroides sp

—

£ co li
—
Streptococcus sp

—
S. aureus

£ coli, Enterobacter sp,
Streptococcus group
0, Klebsiella sp
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presence of biliary disease, especially
obstruction, antibiotic levels in the bile
are variable; in treating and preventing in
fection in biliary surgery, it appears that
serum and tissue antibiotic concentrations
are far more important than concentrations of antibiotics in the bile.17
Cefazolin attains high concentrations
in the bile in non-jaundiced patients
within 1 hour of injection19 and also in
serum.20 Its relatively broad spectrum
with few specific indications in
treatment21 makes it a suitable antibiotic
for prophylaxis. Its efficacy has now been
demonstrated repeatedly in biliary tract
surgery.4'9'22 The present confirmation of
its efficacy in prophylaxis when given as
a single dose affords the added advantages of decreased likelihood of bacterial
resistance and reduced cost. At our
hospital, the cost per patient of a single
2-g dose of cefazolin for prophylaxis is
$4.60, whereas the minimum cost per pa
tient due to postoperative sepsis in this
study averaged $2600.

*

Summary and Conclusions

*
►
*
„
*

*
^
►
»•
v

*
We have performed a double-blind,
A prospective, randomized, controlled trial
of single-dose cefazolin prophylaxis in pa
tients requiring biliary tract operations

who are at high risk of postoperative
infection.
The study confirms the increased risk
of infection postoperatively in patients
with contaminated bile; the main site at
risk is the operative wound. It also shows
that clinical diagnostic criteria will cor
rectly predict those patients who are at in
creased risk. Finally, it establishes the ef
ficacy of a single dose of cefazolin given
intravenously before operation in prevent
ing postoperative infection due to con
taminated bile.
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Dalacin C Phosphate
is part of the “Gold Standan
in the treatment of
polymicrobial abscesses
1. Staphylococci; 2. Bacteroides fragilis; 3. Polymorphonuclear Leukocyte

Polymicrobial Abscess
A Potential Post-Surgical Complication

Dalacin C Phosphate Sterile Solution

(clindamycin phosphate)

.. .the standard to which
others are compared.
*

- • Provides excellent penetration into infected
’
abscesses.2
►

* • Highly effective against gram-positive aerobes
‘
including penicillinase - producing Staphylococci.
4 • Highly effective against gram-positive and gram!
negative anaerobes, in particular Bacteroides fragilis.
• After 10 years of clinical use, resistance development
’
to Bacteroides fragilis is as low as 2% .3
/ • Has never been associated with any carcinogenic or
»
mutagenic activity.
• May enhance the natural host defense system; has
,
been shown to concentrate within polymorphonuclear
*
leukocytes in vitro. These neutrophils in turn may act
as an important antibiotic delivery system to the site of
/
infection.4
►
^
►

►
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Dalacin C Phosphate Phosphate S.S.
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also
by causing a reduction in the rate of synthesis of nucleic acids.

Indications: D alacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infec
tions where the o ral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections d ue to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species and m icroaerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections d ue to sensitive Gram-positive organisms
(staphylococd, including penicillinase-producing staphylococci, streptococci and pneum ococa) when
the patient is intolerant of, or the organism resistant to o ther appropriate antibiotics.

Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated
in patients previously found to be hypersensitive to this com p ou nd , the parent com pound, clinda
mycin, or dindamycin palmitate. Although cross-sensitization with Lincoan® (lincomydn hydrochloride)
has not been dem onstrated, it is recom m ended that Dalacin C Phosphate not be used in patients
w h o have demonstrated lincom ydn sensitivity.
Until further dinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn
(infants below 30 d ays of age), o r in pregnant women.

Warnings: Some cases of severe and persistent diarrhea have been reported during or after ther
apy with Daladn C P hosphate (clindamycin phosphate). This diarrhea has been occasionally asso
ciated with blood a n d m u cus in the stools and has at tim es resulted in acute colitis. When endos
co py has been p erform ed, som e of these cases have shown pseudom em brane formation.
If significant diarrhea occurs d uring therapy, this d ru g should b e discontinued or, if necessary, con
tinued o nly with close observation. Significant diarrhea occurrin g up to several weeks post-therapy
should be managed as if antibiotic-associated.

Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate
(clindamycin phosphate) were followed with clinical laboratory tests, including complete h e m ato log y^
urinalysis and liver and kidney function tests. Som e of these tests were abnormal initially and r e tu rn ^
ed to normal during therapy with Dalacin C Phosphate, while others were normal initially and became
abnorm al during therapy. Overall evaluation of clinical laboratory values in these patients does n jf
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renai
systems. Transient elevations of serum transaminases have occurred in some patients, but other liver
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase a n d t
there have not been clinical signs of d rug-induced hepatic toxicity.
Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. N o ^
specific antidote is known. Doses as high as 1200 m g every six hours (4800 m g/day) by infusion for
five days have been given without adverse effects
.
DOSAGE A N D ADMINISTRATION
*

Adults
Intramuscular Injection: 600 m g/day in 2 equal doses.

Severe infections: 1200 to 2400 m g/day in 2 ,3 or 4 equal doses. Intramuscular injections of m o re ^
than 600 m g into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) m ust be diluted prior-*
to I V. administration to a dilution of 300 m g in 50 ml of diluent (6 m g/m l) or more, and infused in not
less than 10 minutes. Administration of m ore than 1200 m g in a single 1 hour infusion is not recoo^m ended. Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.

If colitis is suspected, e nd osco p y is recom m ended. M ild cases showing minim al mucosal changes
may respond to sim ple d ru g discontinuance. Moderate to severe cases, including those showing
ulceration or pseudom em brane formation, should be m a n ag ed with fluid, electrolyte, a nd protein
supplementation as indicated. C orticoid retention enem as a nd systemic corticoids may be of help
in persistent cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other causes
of colitis should be considered.

Moderately severe infections: 900 to 1800 mg/day by continuous d rip or in 2 or 3 equal doses, e a c h ^
infused over 20 minutes or longer.

Studies indicate a toxin(s) p roduced by Clostridia (especially Clostridium difficile) may be a princi
pal ca use of clindam ycin a nd other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancom ycin. When 125 m g to 500 m g of vanco
mycin w ere administered orally tour tim es a day for 5 - 1 0 or m ore days, there was a rapid observed
disappearance of th e toxin from faecal sam ples and a coincidental recovery from the diarrhea.

Dilution and infusion rates:

Severe infections: 1800 to 2700 m g/day by continuous d rip o r in 3 o r 4 equal doses, each infused
over 20 minutes or longer. In life-threatening infections, doses of 2700 to 4800m g/day by co n tin u o u s *
d rip or in 3 or 4 equal doses each infused over 20 minutes or lo nger may be given.

It shou ld be noted that serious relapses have occurred u p to one month after apparently successful
treatment. A relatively p rolonged period of continuing observation is therefore recom m ended.

Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed
with caution in atopic individuals.
Dalacin C Phosphate m ust be diluted for intravenous administration. (See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organism s - particularly
yeasts. Should superinfections occur, appropriate m easures should be taken as dictated by the clin
ical situation.
A s with all antibiotics, perform culture and sensitivity studies in conjunction with d rug therapy.
Since abnormalities of liver function tests have been noted occasionally in anim als a nd man, peri
o d ic liver function tests should be perform ed during p rolonged therapy. Blood counts should also
be m onitored during extended therapy.
Dalacin C Phosphate m ay be used in anuretic patients. Since the serum half-life of clindam ycin in
patients with im paired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate shou ld be appropriately decreased. Hemodialysis and peritoneal dialysis are
not effective means of removing the com pound from the blood. Periodic serum levels should be deter
m ine d in patients with severe hepatic a nd renal insufficiency.

A d verse

R e action s: Local.

(a) Intramuscular Injections: Of 404 patients treated with Dalaan C Phosphate (dindamycin phosphate)
intramuscularly (with a solution containing 150 m g/m L), six (1.5%) demonstrated local reactions as
follows: Two complained of pain at the injection site, two dem onstrated induration at the injection site
a n d two developed sterile abscesses.
(b) Intravenous Infusions: O f 192 patients treated with Dalacin C Phosphate by intravenous infusion,
14 (7.3% ) demonstrated local reactions. Eleven patients developed superficial throm bophlebitis and
o ne patient developed both superficial and deep throm bophlebitis. The majority of these cases
d eveloped in conjunction with the use of indwelling I.V. catheters a nd it is difficult to know how m uch
the d ru g contributed to the irritation. Two patients developed localized erythema, swelling a nd pain
at the site of the infusion.

Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as follows:

Number of Patients
R a s h .....................................................................................................................................
7
U rtic a ria ........................................................................................................................................................... ...
P r u r it u s .....................................................................................................................................
1
Fever, Leucocytosis...........................................................................................................................................1
Nausea, with or without v o m itin g ..................................................................................................................1
Dia rrhea (See also u n d e r ‘W a rn in g s ').........................................................................................................4
H yp o te n sio n ...............................................................................
1
H y p e rte n s io n ....................................................................................................................................................1
Shortness of Breath ........................................................................................................................................ 1
S u p e rin fe ctio n*................................................................................................................................................. 4
C a rd ia c a rre s t* * ............................................................................................................................................... 1
B ad or bitter taste in m o u th ........................................................................................................................... 5
‘ Superinfection is a com plication of antibiotic therapy in general and is not necessarily a true
side effect of clindam ycin phosphate.
‘ D ue to underlying m yocarditis in this patient.
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Dose

Diluent

Time

300 mg
600 mg
900 mg
1200 mg

50 ml
100 ml
150 ml
200 ml

10 min.
20 min.
30 min.
45 min.

♦
4

Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed
by continuous I.V. infusion as follows:

To maintain serum
clindamycin levels

Rapid
infusion rate

Maintenance
infusion rate

◄

A bove 4 mcg/ml
Above 5 mcg/ml
A bove 6 mcg/ml

10m g/min. for 3 0 min.
15m g/min. for 3 0 min.
2 0m g/m in. for 3 0 min.

0.75mg/m in.
1.0 0 mg/min.
1.25 mg/min.

*

-4

Children: (Over one month of age)
Intramuscular injection: 10 to 15 mg/kg/day in 2 ,3 or 4 equal doses.
Moderately severe infections: 15 to 20 m g/kg/day in 3 or 4 equal doses.
Severe inlections: 20 to 3 0 m g/kg/day in 3 or 4 equal doses.

■i

Intravenous Administration:
Moderately severe infections: 15 to 25 m g/kg/day by continuous d rip or in 3 or 4 equal doses, each -4
infused over 20 minutes or longer. In severe infections, it is re com m ended that children be given no
less than 300 m g/day regardless of bod y weight. (Dilute Dalacin C Phosphate Sterile Solution in the
sam e m anner as for adults.)
Dilution and Compatibility:

^

4 ml (600 m g) Dalacin C Phosphate when diluted with 1000 ml of the following com m only used in
fusion solutions was found to be physically com patible and dem onstrated no significant change in
pH or antim icrobial potency over a period of 24 hours:
^
S odium chloride injection
Dextrose 5 % in water
Dextrose 5 % in saline
Dextrose 5 % in Ringer’s Solution
Dextrose 5 % in half-strength saline plus 40 mEq potassium chloride
Dextrose 2 1/2% in Lactated Ringer's Solution (Hartmann's Solution).

-f
^

Dalacin C Phosphate was not stable when added to Dextrose 5 % in water plus vitamins. Therefore
it is not recom m ended that Dalacin C Phosphate be mixed with any infusion solution containing B
vitamins.

4

Supplied:
Dalacin C Phosphate contains the following per ml of sterile solution:
Clindam ycin phosphate equivalent to clindamycin base 150 m g
Benzyl alcohol 5 mg
Disodium edetate 0.5 mg
Water for injection q.s.

^

^

When necessary the pH is adjusted with sodium hydroxide a n d /o r hydrochloric acid to maintain a
pH range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.

NOTE: Do not store below 15°C.
Product M onograph available upon request,
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Surgical Management of Primary Bile-Duct Carcinoma
Primary bile-duct carcinoma is a rare le
sion, causing death from hepatic failure
due to biliary obstruction. Between 1976
and 1983, 22 patients with this tumour
were treated at the Sunnybrook Medical
Centre in Toronto. Thirteen patients had
unresectable proximal bile-duct car
cinoma of the high type. Distal bile-duct
carcinomas in three patients were not
resected because of metastatic disease.
Three proximal bile-duct carcinomas of
the low type and three distal bile-duct
carcinomas were resectable.
A new method of internal biliary
decompression is presented, for palliation
in patients with proximal bile-duct car
cinoma of the high type. An intraluminal
polyethylene stent has produced
satisfactory quality of life with a mean
survival of 16 months in eight patients;
two others are alive with disease, 9 and
19 months after placement of a stent.
Satisfactory palliation of distal,
unresectable lesions can be achieved by
biliary intestinal anastomosis in some
cases.
Le cancer primitif des canaux biliaires est
rare; il cause la mort par insuffisance
hepatique consecutive a une obstruction
des voies biliaires. Entre 1976 et 1983,
22 patients porteurs de cette tumeur ont
ete traites au Sunnybrook Medical Centre
de Toronto. Treize patients avaient un
cancer non resecable de la partie proximale des canaux biliaires, de type haut.
Chez trois patients, un cancer de la partie distale des canaux biliaires n'a pas
ete rdsdque, la maladie s'etant metasta-
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see. Trois cancers de la partie proximale, de type bas, et trois de la partie
distale etaient resecables.
Une nouvelle methode de decompres
sion interne des voies biliaires est
decrite, permettant un traitement palliatif
des cancers de la partie proximale des
canaux biliaires, de type haut. L'introduction d'un tube de polyethylene dans la
lumiere du canal biliaire a produit chez
huit patients une qualite de vie satisfaisante pendant une survie moyenne de
16 mois; deux autres vivent encore avec
leur maladie, de 9 et 19 mois apres la
pose du tube.
Un traitement palliatif satisfaisant des
lesions distales non resecables peut etre
obtenu dans certains cas par anastomose
des canaux biliaires et de I’intestin.

Hepatic failure due to obstruction of the
bile duct from untreated bile-duct car
cinoma will inevitably cause death 3 to 4
months after diagnosis. However, the
primary neoplasm remains localized, is of
small size and has an inherently slow
growth rate with late metastatic spread.
The location of the tum our usually
precludes curative resection when this rare
neoplasm involves the hilar structures of
the liver, but resection may be possible
in more distal lesions when the diagnosis
is made early, through the aggressive use
of current investigative methods.
This report, presenting a new anatomic
classification of these lesions and cor
relating it with surgical treatment, is based
on our experience with 22 patients with
primary bile-duct carcinoma seen at the
Sunnybrook Medical Centre, Toronto,
between 1976 and 1983.
Classification
Primary bile-duct carcinomas most
commonly occur in the hilar region. Most
series do not differentiate between two
types of lesion at this location. It is im
portant to define those lesions that can
be considered for curative resection as op
posed to those in which intrahepatic ex
tension precludes cure even with radical
surgery.

The classification presented is based on
radiologic definition of the bile-duct
anatomy as determined by percutaneous
transhepatic cholangiography. This
method, which defines the proximal ex
tent of the obstructing lesion, is superior
to endoscopic retrograde cholangio
graphy, which identifies the distal, but
not always the proximal, tum our limit.
Proximal bile-duct carcinomas can be
subclassified into a high type (Fig. 1) in
which the obstruction involves the junc
tion of the right and left hepatic ducts
with possible extension into either duct in
its intrahepatic portion, and a low type
(Fig. 2) in which the common hepatic duct
is involved between the junction of the
hepatic ducts and the cystic duct. Distal
bile-duct carcinomas (Fig. 3) involve the
common bile duct beyond the cystic duct.
This classification has clinical impor
tance in planning the surgical manage
ment of patients presenting with bile-duct
strictures.
Patients and Methods
Since 1976, 22 patients have been
treated surgically for primary bile-duct
carcinoma. The diagnosis was establish
ed by surgical biopsy or at autopsy.
Thirteen patients were women. Ages
ranged from 28 to 78 years (mean 56

FIG. 1—Transhepatic cholangiogram show
ing proximal bile-duct carcinoma o f high type.
There is obstruction (arrow) at junction of right
and left hepatic ducts.
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years), investigation included liverfunction studies and abdominal ultraso
nography followed by percutaneous
transhepatic cholangiography. Per
cutaneous transhepatic biliary drainage
was not performed preoperatively in any
case.
In each case, the surgical procedure was
determined following operative explora
tion of the liver, biliary tract and regional
lymph nodes, noting the presence of local
tumour extension and lymph-node or dis
tant metastases.
In all cases follow-up (ranging from 4
to 66 months) included standard
biochemical liver-function studies and ab
dominal ultrasonography to assess the
degree of bile-duct dilatation. If these
studies demonstrated recurrent obstruc
tion in patients who were otherwise well,
without widely disseminated disease,
nuclear biliary (HIDA) scanning was per
formed to assess hepatocellular excretory
function and bile flow from the treated
lobe. Thereafter, percutaneous trans
hepatic cholangiography was done to
determine the pathologic anatomy and
plan subsequent secondary decompres
sion.
Proximal Bile-Duct Carcinoma
High type.—In 13 cases the tumour in
the proximal bile duct was of the high
type. In two cases it extended widely at
the liver hilum infiltrating the paren
chyma of the right and left lobes. In these
cases the obstructed duct was dilated from
below after opening the common bile duct
distal to the tumour. A latex T tube for
combined internal and external drainage
was used for palliation. In a third case the
tumour had obstructed the portal vein,
causing cavernous malformation of the
portal tributaries, which precluded
surgery directly on the bile duct. In this
case, a peripheral cholangiojejunostomy
was performed from a duct in the right
lobe of the liver.
In 10 cases the tumour was not
metastatic but was considered unresectable because of its high location in the
hilum. In these cases an endoprosthesis
of firm yet malleable polyethylene tubing
was passed through the tumour from
below and into the right or left hepatic
duct above the obstruction; the lower end
was placed in the normal-sized common
bile duct distal to the tumour. No exter
nal drainage accompanied the placement
of this endoprosthesis (Fig. 4). The en
doprosthesis has an internal diameter of
4 mm at its distal end and 2 mm at the
intrahepatic end. This allows impaction
of the tube and prevents migration. The
endoprosthesis facilitates free flow of bile
from the treated hepatic lobe only.
Low type.—Three patients had local
ized bile-duct tumours involving the main
hepatic duct; the hepatic parenchyma and
52

hilar blood vessels were free of tumour.
All these tumours could be resected by a
choledochectomy without pancreatico
duodenectomy. Reconstruction in these
three cases required a Roux-en-Y
hepaticojejunostomy, using the mucosal
graft technique of Lord Smith.1
Distal Bile-Duct Carcinoma
In three patients with carcinomas
located in the common bile duct, the
regional lymph nodes were also involved.
One patient also had involvement of the
duodenum. Curative resection was
thought to be impossible and palliation
was provided by a choledochojejunostomy at the dilated proximal com
mon bile duct or common hepatic duct.
Three patients presented with a tumour
localized to the distal common bile duct.
In one who had previously undergone
resection of the colon for carcinoma 2
years before, local resection was perform
ed for tumour control and relief of the
distal duct obstruction. The other two pa
tients were treated by radical pancreati
coduodenectomy. Standard biliary, pan
creatic and gastric reconstruction was per
formed in both cases.

type of proximal bile-duct tumour and
three with distal bile-duct tumour. One
patient in the group with proximal
tumours died and one patient is alive and
free of disease in the distal group. Of 16
patients who had palliative decompression, survival of those with the high type
of proximal bile-duct carcinoma, using
the simple endoprosthetic stent, compares
favourably with those who had distal bileduct tumour and underwent a more ex
tensive choledochojejunostomy for palliation.
Simple T-tube decompression in two
patients with high-type proximal tumours
did not provide satisfactory palliation.

Results of Treatment

Survival following the various pro
cedures for the three types of bile-duct
carcinoma is indicated in Table I. Six pa
tients were considered to have had
curative resection — three with the low

FIG. 3— Distal bile-duct carcinom a.
Obstruction of common bile duct (arrow) is
distal to its junction with cystic duct.

FIG. 2—Proximal bile-duct carcinoma of
low type. Obstruction (arrow) is between origin
of common hepatic and cystic ducts.

FIG. 4—Operative cholangiogram demon
strates retrograde flow through endoprosthesis
stenting proximal bile-duct tumour (arrows) in
right hepatic duct.
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The only complication was biliary sep
sis; this occurred in the two patients with
* T tubes, which provided external drainage
as well as a tract for infection.
► Reoperation for replacem ent of
obstructed endoprostheses was unsuc
cessful in two patients because of tumour
^extension in the hilum.
Recently, we have considered the place
k of percutaneous external drainage in pa
tients who present with recurrent obstruc
ts. tion. This has been converted to internal
drainage by means of a peripheral
cholangiojejunostomy to prevent the in
evitable septic complications of longk standing external drainage tubes.2 The
deaths in all cases were due to recurrent
^ bile-duct obstruction and progressive
^ hepatic failure. Autopsy failed to show
widespread dissemination of tumour in
itnost cases. Metastases were limited to the
liver parenchyma and adjacent peripor►tal nodes and vessels.
A

Discussion

4

Most primary bile-duct carcinomas
(arise in the hilar region of the liver. In an
effort to appreciate better the treatment
* and survival data for the tumours in this
location, it is imperative to subdivide the
lesions, defining the group without in
volvement of either hepatic duct and with
* a tumour-free segment of the proximal
K part of the common hepatic duct, that is,
the low type of proximal bile-duct car
cinom a. Only this lesion is potentially
curable by radical resection. Because this
►tumour is intrinsic to the bile-duct wall
and localized to a small segment of the
*■affected duct, a choledochectomy of the
common hepatic duct and proximal com* mon bile duct with cholecystectomy and
.regional node resection will be adequate
to effect cure in non-metastatic lesions.
t Radical resection of the high type of
proximal bile-duct carcinoma, including
►extended central hepatic resection, hepatic
lobectomy or total hepatectomy with
* transplantation, has failed to produce a

substantial number of long-term survi
vors.3'6 Therefore, palliative treatment is
indicated to prolong survival with good
quality of life in patients who present with
this type of proximal duct carcinoma as
shown by transhepatic cholangiography.
Distal bile-duct carcinoma is less com
mon. This may be due to confusion of the
radiologic picture with the common
primary carcinoma of the head of the
pancreas. Histologic differentiation of
these lesions is not always clear. Never
theless, radical pancreaticoduodenectomy
for distal bile-duct carcinoma is the pro
cedure of choice to effect cure. In our ex
perience the distal lesion presents with
more advanced regional metastatic
disease. Three of our six patients with
distal duct carcinoma presented with
metastases to lymph nodes, pancreas or
duodenum. Palliative choledochojejunostomy was effective in maintaining
liver function until death occurred from
disseminated intra-abdominal metastases.
Our single experience with local resection
for a distal bile-duct carcinoma showed
that it was inadequate for cure although
palliation was successful for 24 months.
Patients in our series who underwent
curative resection did not receive
chemotherapy or radiotherapy.
Palliative relief o f hepatobiliary
obstruction from bile-duct carcinoma
should be the aim in all patients with
metastatic tumour and in all patients with
proximal bile-duct tumour of the high
type. A lth o u g h biliary intestinal
anastomosis is the procedure of choice
and ensures the longest duration of un
compromised bile flow, it is rarely feas
ible to consider such a technique for the
proximal lesions.
The newer invasive radiologic pro
cedures for external and internal biliary
drainage and endoscopic biliary drainage
techniques demand attention when con
sidering the aims of palliation in this slowgrowing neoplasm, which causes morbidi
ty and death from bile-duct obstruction
rather than from disseminated disease.

►

Table -Results of Treatment for Primary Bile-Duct Carcinoma

Tumour location
Proximal bile duct
' High type

Low type
Distal bile duct

Treatment
Internal stent
T-tube decompression
Cholangiojejunostomy
Resection and
hepaticojejunostomy
Local resection
Whipple resection

-

Choledochojejunostomy

Result
8
2
2
1
2
1
1
1
1
2
1

died
alive with disease
died
alive with disease
alive, disease free
died
died
died
alive, disease free
died
alive with disease

Duration of
survival or
follow up, mo
16
9,
4,
21
46,
30
24
32
12
6,
16

imeanl
19
6
66

24

Ideally, the quality of life should be
nearly normal, without iatrogenic com
plications or the need for additional
operative intervention.
Techniques for percutaneous trans
hepatic biliary drainage have improved
progressively in the past 5 years.7'9 Com
plication rates have been reduced to 5%
to 8%. However, death still occurs in 1%
to 3%. Param ount in considering pallia
tion is the duration of survival. Anicteric
palliation by percutaneous transhepatic
external drainage rarely exceeds 3
months. Once patients have been dis
charged from hospital with external
drainage catheters in place, the frequen
cy of complications rises appreciably and
all patients will have a septic event within
the first 2 months of drainage.9 In our
opinion this procedure has limited ap
plication as the only palliative procedure
for primary bile-duct carcinoma. Instead,
it should be considered as “ secondprocedure management” and used on a
short-term basis while planning a method
of biliary intestinal decompression.
With the development of percutaneous
endoprostheses, inserted under radiologic
control, the risks of external infection
have been reduced. However, the paten
cy of these prostheses is maintained for
only a short period and jaundice recurs
within 60 to 90 days.10-11
Palliation by endoscopic sphinc
terotomy, with or without concomitant
biliary stenting, is applicable only to distal
lesions. Failure to define the lesion
histologically and inability to stage
metastatic disease by endoscopic methods
may result in losing an opportunity for
possible curative resection. Therefore, we
do not encourage this method of pallia
tion for distal bile-duct carcinoma.
Palliative surgical procedures to relieve
obstruction of the high type of proximal
duct tum our or locally advanced lesions
of the low-type tend to achieve anicteric
survival ranging from 12 to 24
m o n th s.1215 The operative m ortality
associated with extended hilar procedures
with resection is high,4'6 but perioper
ative deaths are uncommon with most
palliative procedures not associated with
resection.
Param ount in palliative procedures
without resection is the transluminal
dilatation of the duct in the area of the
tumour required to relieve the obstruc
tion. Differences in techniques then relate
to methods of drainage or tum our
stenting.
Terblanche and associates12 described
the U-tube technique which combines ex
ternal and internal drainage but requires
a permanent external appliance. The
recurrence of obstruction is managed by
changing the U tube. However, external
intubation has been mentioned as a
source of septic complications. Survival
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using this method ranges from 14 to 30
months, yet reoperation may be required
up to five times during the period of
palliation.
Cameron and colleagues13 used a
transhepatic tube with a single external
limb for irrigation purposes. Twelve of
14 patients had palliation of from 3 to 31
months with a mean survival of 12
months. Septic com plications and
reoperation rates were notably reduced in
this series. Simple internal-external
decompression after dilatation using a
T tube alone in 26 cases was described by
Lees and associates.14 Survival, com
plication rate and reoperative re
quirements were similar to those reported
by Cameron’s group.13
Palliation of bile-duct obstruction by
permanent internal biliary stenting has
not been readily accepted because of the
inaccessibility of the prosthesis with an
ticipation of only short-term relief of
jaundice. H ow ever, N ilo ff and
Hinchey15 recently reported median sur
vival of 18 months in 11 patients with bileduct carcinoma following placement of
rigid Vitallium prostheses. Migration of
the prosthesis required reoperation on one
occasion. No obstruction occurred due to
biliary concretions. In our series 10 of 13
patients with the high type of proximal
duct carcinoma were stented internally,
using a firm yet malleable polyethylene
stent. The stent followed the contour of
the previously dilated right or left intrahepatic duct, allowing more proxi
mal intrahepatic decompression. The
greater distal diameter of the stent
prevented tube migration. There were no
septic complications in the 10 patients
with endoprostheses. Gradual extension
of tumour occluded the prostheses in 8
of the 10 patients, leading eventually to
death from hepatic failure. These patients
had a mean survival of 16 months. In
two, reoperation to repeat the dilatation
and stenting was unsuccessful because of
the hilar tumour mass. Two of the 10 pa
tients are still alive with disease 9 and 19
months after operation.
Freedom from hepatobiliary infection
in patients without external drainage
tubes helps to prevent stone formation
from increased lithogenicity associated
with cholestasis and sepsis.
The quality of life in this group of pa
tients with prolonged survival has been
satisfactory. The operative technique is
simple and the reoperation rate is low.
Longer survival may be realized with
secondary procedures directed to the
peripheral hepatic ducts when the tumour
obstructs the prosthesis.
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NOTICES
Call for Abstracts,
Second International Conference
on Clinical Factors and
Mechanisms Influencing
Bone Growth
The second international interdisciplinary
conference, to be held at the University
of California, Los Angeles, in early
January 1985, will be a follow-up to the
basic science one held in January 1982 but
will emphasize clinical science aspects of
bone growth. Again, a primary objective
of the conference is to update and inte
grate our understanding of the growth of
bone with new knowledge and to offer
directions for future clinical research.
Factors and mechanisms that influence
normal and abnormal prenatal and post
natal bone growth, both general and cra
niofacial, will be covered, from the subcellular to the gross level. Clinical expe
rimental approaches to bone growth will
be emphasized; limited attention will be
given to basic science aspects. English tit
les and abstracts, 100 to 200 words long,
are being solicited from various clinical
and other biologic disciplines including,
but not limited to, anthropology; compu
ter science; genetics; metabolism; morcontinued on page 87
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Rx Summary
Indications

A

The following infections when caused by susceptible
pathogens:
■ upper and lower respiratory tract (particularly chronic 4
bronchitis and including acute and chronic otitis
media)
■ urinary tract: acute, recurrent and chronic
A
■ genital tract: uncomplicated gonococcal urethritis
■ gastrointestinal tract
■ skin and soft tissue
A
■ Pneumocystis carinii pneumonitis in infants and
children.
Not indicated in infections due to Pseudomonas,
<
Mycoplasma or viruses.
Contraindications

«<

Evidence of marked liver damage or renal impairment
where repeated serum assays cannot be carried out;
blood dyscrasias; known hypersensitivity to trimethoprim*
or sulfonamides.
During pregnancy, and in newborn or premature infants
during first few weeks of life.
*
Precautions

Benefit should be critically appraised against risk in
-4
patients with liver damage, renal damage, urinary
obstruction, blood dyscrasias, allergies, or bronchial
asthma. Reduce dosage in patients with renal impair•«
ment. Do not administer if serum creatinine level is above
2 mg%. Consider possible superinfection with a non
sensitive organism.
4
Adverse reactions

Most frequent: nausea, vomiting, gastric intolerance,
4
and rash.
Less frequent: diarrhea, constipation, flatulence, anore
xia, pyrosis, gastritis, gastroenteritis, urticaria, heada
ache, and liver changes (abnormal elevations in alkaline
phosphatase and serum transaminase).
Occasionally reported: glossitis, oliguria, hematuria,
f
tremor, vertigo, alopecia, and elevated BUN, NPN, and
serum creatinine.
Hematological changes, primarily, neutropenia and
^
thrombocytopenia, and less frequently, leukopenia,
aplastic or hemolytic anemia, purpura, agranulocytosis,
and bone marrow depression; occur particularly in the
A
elderly and mostly prove reversible on withdrawal.
Dosage

Children: 6 mg trimethoprim / kg body weight per day,
plus 30 mg sulfamethoxazole/ kg body weight per day,
divided into two equal doses.
-4
Adults and children over 12 years of age:
Standard dosage:
1 Bactrim' DS Roche’ tablet or 2 adult tablets, twice
4
daily.
Minimum dosage and dosage for long-term treatment:
V2 Bactrim’ DS ’Roche’ tablet or 1 adult tablet, twice
4
daily.
^
Maximum dosage (overwhelming infections):
1'/2 Bactrim’ DS Roche' tablets or 3 adult tablets, twice 4
daily.
In acute infections treat for at least 5 days or until patient
is asymptomatic for 48 hours; in urinary tract infections, ^
until urine sterile.
”
Uncomplicated gonorrhea: 2 adult tablets or
1 Bactrim’ DS Roche' tablet four times daily for 2 days. ^
Pneumocystis carinii pneumonitis: 20 m g/kg/day tri
methoprim and 100 m g/kg/day sulfamethoxazole in four
divided doses for 14 days.
^
Supply

Adult tablets: White, capsule-shaped, biconvex tablet
1
with ROCHE C engraved on one face and BACTRIM and
indented score on the other, each containing 80 mg tri
methoprim and 400 mg sulfamethoxazole.
A
Bottles of 100 and 500. Unit dose, boxes of 100.
DS tablets: White, capsule-shaped, biconvex tablet with
ROCHE engraved on one face and BACTRIM DS and
4
indented score on the other, each containing 160 mg
trimethoprim and 800 mg sulfamethoxazole.
Bottles of 100 and 250.
4
Suspension: Cherry flavoured, 40 mg trimethoprim and
200 mg sulfamethoxazole per 5 ml.
Bottles of 100 and 400 ml.
v"
Pediatric tablets:
/—\
White, cylindrical biplane tablet w ith \R0C>y
engraved on one face, single scored on the other
A
with C above and below score line, each containing 20 mg
trimethoprim and 100 mg sulfamethoxazole.
Bottles of 100.
A
Solution for Infusion: 5 ml amber-coloured ampoules,
containing 80 mg trimethoprim (16 mg/ml) and 400 mg
sulfamethoxazole (80 mg/ml) for infusion with D5W,
Ringer's solution or NaCl 0.9% solution. Packs of
25 ampoules.
Product monograph available on request.
TM: Trade Mark of Hoffmann-La Roche Limited
RReg. Trade Mark
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Bactrim™ Roche
j (trimethoprim plus sulfamethoxazole)

the drug of
first choice in

the treatment
of pneumocystis
carinii pneumonitis
is a solution for
serious infections

‘Bactrim’ Solution for
Infusion has also produced
dramatic results in
■ severe urinary tract
infections
■ septicemia
■ meningitis
TMP-SMX “ ...has particularly
been useful against organisms
that are resistant to
ampicillin or are resistant
to the first and second
generation cephalosporins,
and it has been very active
against certain organisms
that appear to be resistant
to pretty much everything
we have ...”(1)
An important weapon when
aggressive antibacterial
measures are required.

Prescribing Information

Marcaine*
(bupivacaine hydrochloride injection)

Indications:
Peripheral nerve block including infiltration,
sympathetic blockade, caudal, epidural, para
cervical and pudendal blocks.

Contraindications:
Bupivacaine is contraindicated in persons with
known sensitivity to local anesthetics of the
amide type.
The use of bupivacaine is contraindicated in the
presence of sepsis near the site of proposed
injection, in severe shock and in heart block.

Warnings:
Usage in Pregnancy: Reproductive studies have
been performed in rats and rabbits and there is
no evidence of harm to the animal fetus. The
relevance to the human fetus is not known.
Safe use in pregnant women other than those
in labor has not been established.
The obstetrician is warned that severe persis
tent hypertension may occur after adminis
tration of certain oxytocic drugs, if vasopres
sors have already been used during labor (e.g.
in the local anesthetic solution or to correct
hypotension).
Until further experience is gained in children
younger than 12 years, administration of bupiva
caine in this age group is not recommended.

Precautions:
Marcaine should be used cautiously in persons
with known drug allergies or sensitivities, parti
cularly to the amide-type local anesthetics.
Caution is advised in administration of repeat
doses of bupivacaine to patients with severe
liver disease.
The lowest dosage that gives effective anes
thesia should be used, to avoid high plasma levels
and serious systemic side effects. Injection of
repeated doses of bupivacaine may cause
a significant increase in blood levels due to
accumulation of the drug or its metabolites or
slow metabolic degradation.
Tolerance varies with the status of the patient.
Debilitated, elderly and acutely ill patients may
require reduced doses commensurate with age
and physical condition.
Fetal bradycardia may follow paracervical block
with local anesthetics of the amide type and
may be associated with fetal acidosis. Fetal
heart rate should always be monitored during
paracervical anesthesia. Added risk appears to
be present in prematurity, toxemia of preg
nancy and fetal distress. The physician should
weigh the possible advantages against dangers
when considering paracervical block in these
conditions. When the recommended dose is
exceeded, the incidence of fetal bradycardia
increases. The incidence of fetal bradycardia
observed in clinical trials with bupivacaine in
which paracervical block was used, varied
between zero and 35%.
It should be remembered that solutions con
taining a vasopressor agent, e.g. epinephrine,
should be used with caution, if at all, in patients

who are receiving monoamine oxidase inhibi
tors or anti-depressants of the triptyline or
imipramine type, because severe, prolonged
hypertension may result. Dose related cardiac
arrhythmias may occur if preparations contain
ing epinephrine are employed in patients during
or immediately following the administration of
chloroform, halothane, cyclopropane, trichloro
ethylene or other related agents. In deciding
whether to use these products concurrently in
the same patient, the combined action of both
agents upon the myocardium, the concentration
and volume of vasoconstrictor used, and the
time since injection, when applicable, should be
taken into account.
The decision to use a local anesthetic contain
ing a vasoconstrictor in areas with a limited
blood supply or in patients with peripheral
vascular disease, will depend on the physician’s
appraisal of the relative advantages and risks.
Local anesthetics which contain preservatives,
i.e. those supplied in multiple dose vials, should
not be used for caudal or epidural anesthesia.

Adverse Reactions:
Reactions to bupivacaine are characteristic of
those associated with amide-type local anesthe
tics. A major cause of adverse reactions to this
group of drugs is excessive plasma levels,
which may be due to over- dosage, inadvertent
intravascular injection, or slow metabolic degra
dation. Other causes of reactions to these local
anesthetics may be hypersensitivity, idiosyn
crasy, or diminished tolerance.
Excessive plasma levels cause systemic reac
tions involving the central nervous system and
the cardiovascular system. The central nervous
system effects are characterized by excitation
or depression. The first manifestation may be
nervousness, dizziness, blurred vision, or
tremors, followed by drowsiness, convulsions,
unconsciousness, and possibly respiratory
arrest. Since excitement may be transient or
absent, the first manifestation may be drowsi
ness, sometimes merging into unconsciousness
and respiratory arrest. Other central nervous
system effects may be nausea, vomiting, chills,
constriction of the pupils, or tinnitus. The
cardiovascular manifestations of excessive
plasma levels may include depression of the
myocardium, blood pressure changes (usually
hypotension), and cardiac arrest.
Allergic reactions are characterized by cuta
neous lesions (e.g. urticaria, edema) and other
manifestations of allergy.
Reactions following epidural or caudal anes
thesia may include: high or total spinal block,
urinary retention; fecal incontinence, loss of
perineal sensation and sexual function; persis
tent analgesia, paresthesia, and paralysis of the
lower extremities; headache and backache; and
slowing of labor and increased incidence of
forceps delivery.
It should be noted that reactions due to
systemic absorption may be slow or rapid in
onset. Those of rapid onset include respiratory
depression, cardiovascular collapse and cardiac
arrest. This type of reaction necessitates a high
degree of preparedness since it can occur with
little warning.
In co-ordinated studies of 3200 procedures
carried out by 15 investigators, there were 2

severe systemic reactions. Both patients exf
rienced convulsions as a result of inadverter
vascular injection.
Fetal bradycardia has been observed w ith tt
use of bupivacaine. Most cases, including* f
fatalities, occurred when the paracervicah-oi
was used (see “Precautions”).
In some subjects bupivacaine may produce
marked peripheral vasoconstriction in unant
thetized areas which may last for severafcho

Dosage and Administration:

„

The duration of anesthesia with bupivacaine
such that, for most procedures, a single dos
sufficient. Maximum dosage limit must be in'
dualized in each case after evaluating tlw siz
and physical status of the patient, as well as
usual rate of systemic absorption from at>ai
cular injection site. Most experience to date
with single doses of bupivacaine up to 221) r
with epinephrine 1:200,000, and 175 m g<
without epinephrine; more or less drug may
used depending on individualization of qjch
case.
At present there is insufficient clinical eviden
with multiple dosage or intermittent dose tec
niques to permit precise recommendatiorts f
such procedures to be given. However, limit*
clinical experience in this area of use indicate
that bupivacaine may be repeated in 3 to 6
hours up to a maximum dose of 400 mg in
hours. In most cases the duration of ane^he
effect is prolonged by the addition of
(
epinephrine.
The following doses have generally proved
satisfactory for the average adult. They m«y
require adjustment in relation to age and the
physical condition of the patient.
*
Local infiltration: up to maximum dosage of
0.25% solution.
*
Peripheral nerve block: 5 to 30 mL of 0.50°/<
5 to 60 mL of 0.25% solution.
Sympathetic: 20 to 50 mL of a 0.25% soM i
Epidural: 10 to 20 mL of a 0.25%, 0.50% or
0. 7 5 . solution.
<
Caudal: 15 to 30 mL of a 0.25% or 0.50%
solution.
•<
Paracervical: 10 to 20 mL of a 0.25% solutio

Supplied:

*

Each 20 mL single dose vial contains: bupjva
caine 0.25%, 0.50% or 0.75% with or withoi
epinephrine 1:200,000. Boxes of 5 vials. «
Each 50 mL multiple dose vial contains: bupi
caine 0.25% or 0.50%. Boxes of 1 vial, v
Note: Bupivacaine solutions without epinephr
may be autoclaved.
*
Product Monograph available on request.
•4
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Intra-arterial Infusion Chemotherapy in Rectal Cancer

Chemotherapy by intra-arterial infusion,
»- using mitomycin C and 5-fluorouracil,
was administered to six patients with
* cancer of the rectum. In three patients
who presented initially with an in■* operable rectal tumour, medication was
. infused through the inferior mesenteric
’ artery. Tumour regression was
t documented in all three, allowing subse
quent resection in two. Of three other
patients with locally recurrent rectal
cancer, none showed tumour regression
after infusion, but two experienced
substantial relief of perineal pain, with
► improvement in the quality of life. Unex
pected complications occurred in the
^ form of a reversible ischemic colitis in
^ two patients and an arterioenteric fistula
in a third.
* Six patients porteurs d'un cancer du
► rectum ont suivi un protocole de
chimiotherapie par infusion intra-arterielle
r de mitomycine C et 5-fluorouracile. Chez
trois malades qui s'etaient presentes
r avec une neoplasie inoperable, I'infusion
^ a ete administree dans I'artere mesenterique inferieure. Une regression tumorale
, fut documentee dans les trois cas,
permettant ainsi I'exerdse chirurgicale
► chez deux de ces patients. Aucune
regression tumorale ne fut par contre
* observee chez les trois autres malades
s'etant presentes pour recidive locale
d'un cancer du rectum. Cependant, deux
de ces derniers rapporterent un soulagement significatif de la douleur perineale.
Des complications inattendues sont rapportees, soit deux colites isch6miques et
*une fistule arterio-enterique.
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The management of advanced pelvic
dissemination of colorectal cancer is com
plex. Patients may initially present with
an unresectable tumour. There may also
be recurrent disease confined to the pelvis
following surgical resection for cancer of
the rectum. Modest improvement has
been obtained by preoperative irradiation
designed to render fixed rectal lesions
resectable. The results of these measures
vary little from those obtained with
radiotherapy alone.1’2 The combination
of radiotherapy and intravenous chemo
therapy for locally inoperable rectal
cancer has not significantly improved
these results.3
Chemotherapy can be administered to
regionally confined tumours by direct
cannulation of the arterial tree. There are
several potential advantages of this
m ethod over systemic intravenous
therapy.4
Intra-arterial infusions of chemoactive
agents in patients with metastatic liver
disease secondary to carcinoma of the col
on have been effective and have improv
ed median survival.5-7 Some isolated
reports describe intra-arterial infusion
chemotherapy for palliation in inoperable
rectal cancer, or to decrease the bulk of
a tumour, permitting eventual resec
tion.8’9 The most logical and natural
route for intra-arterial infusion in cancer
of the rectum appears to be the inferior
mesenteric artery. The catheter may be in
serted directly during exploratory surgery
or remotely by the Seldinger catheteriza
tion technique.10
We have used intra-arterial chemo
therapy in initially inoperable and in
recurrent cancer of the rectum, in an at
tempt to make the tumour amenable to
surgery. Whenever possible, the inferior
mesenteric artery was used to deliver the
infusion. This approach to management,
its favourable influence on the course of
the disease and also the complications in
herent in the method of administration of
chemotherapy have prompted us to report

the findings on this small group of six
patients.
Patients and Methods
Six patients, three with initially in
operable rectal cancer (group 1) and three
with recurrent rectal cancer (group 2),
were entered into the study. They ranged
in age from 55 to 72 years. Three of the
six were men. Only two patients (in group
2) had had previous radiotherapy. Before
chemotherapy, a search was made for
metastatic disease.
In all group 1 patients and in one pa
tient of group 2, who had undergone a
low anterior resection of the rectum some
time before, the inferior mesenteric artery
was catheterized using a Cordis Head
Hunter (no. 6 French) catheter (Cordis
Corporation, Miami, Fla.) through the
left axillary artery. The catheter was posi
tioned in the vessel supplying the tumour,
but the infusion was not always restricted
to the tumour blood supply. In the two
other patients with locally recurrent rec
tal cancer who also had undergone rectal
resection, the catheter was placed in the
internal iliac artery.
The chemotherapy protocol was as
follows: mitomycin C 12 m g/m 2 in 500
ml of normal saline with 2000 units of
heparin given over 12 hours; 5-fluoro
uracil (5-FU) 1 g /m 2 given as a 24-hour
continuous infusion containing 5000 to
10 000 units of heparin daily for 5 days;
Abbott Life Care model II infusion pump
(Abbott Laboratories, North Chicago,
111.) was used for infusion; Aspirin (650
mg by mouth, twice daily) prevented
platelet clotting; catheter position was
verified daily either at fluoroscopy or with
a conventional roentgenogram of the ab
domen; the catheter was withdrawn after
the infusion was completed. Patients were
readmitted 1 month later for a second cy
cle of chemotherapy if there had been no
complications. Before each chemotherapy
cycle, angiography was repeated for
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assessment of the arterial supply and of
tumour stain or neovascularity.
Results

Tumour regression was evaluated
angiographically on the basis of decrease
in size of the feeding artery and of the
tumour stain, or of reduction in the splay
ing of arterial branches supplying the
tumour (Fig. 1).

tients subjected to resection, one was alive
and well 26 months after the infusion
therapy. He was the only patient to have
a second infusion. The other died of
widespread metastases 6 months after
operation. The third patient in this group
died in hospital, while awaiting arterio
graphy before undergoing a second cycle
of infusion chemotherapy. Autopsy
revealed stercoral peritonitis but the ex-

Group 1
Regression was documented in all three
patients in this group. At laparotomy in
two of the patients, the tumour had
become mobile and necrotic; the surgical
resection was completed. Of these two pa-

Fig. lb
FIG. 1—Inferior mesenteric arteriogram in
patient with inoperable rectal cancer. Infusion
into inferior mesenteric artery (a) before first
cycle of infusion, (b) after second cycle of in
fusion. Size of superior hemorrhoidal artery
(SHA) and inferior mesenteric artery (IMA)
has decreased by 30%. Tumour size had
decreased by 25% (decreased tumour stain also
evident on serial films). Note integrity of
vascular architecture of left colic artery (LCA)
and its branches.
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Group 2
None of the patients showed any ap-'*
preciable change in tumour size after in
fusion and none were operated upon; *
however, pain was relieved in two pa
tients. Two patients were still alive 19 and *
15 months after infusion; neither had any ^
evidence of disseminated disease. The
third patient, who died of metastases 1 ^
months after infusion, had no relief of
pain or other evidence of response to -i
therapy.
Complications
•«

FIG. 2—Roentgenogram after barium
enema into proximal loop of colostomy 1 week
after infusion therapy. There is segmental
stenosis and loss of normal mucosal pattern.

Fig. la

act site of perforation could not be iden
tified. However, substantial regression of
the rectal tumour was noted.
-4

Drug toxicity was minimal; two pa
tients had a mild transitory fall in the
blood platelet count and one had ^
vomiting that was easily controlled.
Two patients with recurrent disease had a
erythema and blisters in the gluteal area
when chem otherapy was delivered *■
through the internal iliac artery. These
toxic cutaneous reactions regressed spon- ^
taneously 2 weeks after the infusion was
interrupted.
Two patients had symptoms referrable
to ischemic colitis, 1 week after the infu
sion in one and 3 weeks after a second cy- ^
cle in the other. In both patients, scarr
ing of the affected area resulted in a stric- - i
tured bowel segment above the colostomy
site (Fig. 2). The stenotic segments were ^
resected and showed submucosal and
subserosal fibrosis; there was a remark
ably extensive fibrosis in the intima of

FIG. 3—Histology of involved colic segment shown in Fig. 2. There is extensive fibrosis
of intima of minute arteries and almost complete obliteration of vascular lumen. Submucosal
and subserosal fibrosis is also present (hematoxylin, phloxine, saffron stain, reduced by 31%
from xlO).
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minute arteries, causing almost complete
obliteration of small vessels (Fig. 3).
^
The other major complication was an
asymptomatic arterioenteric fistula,
demonstrated at arteriography before the
^.second cycle of infusion. The tumour and
the fistulous tract were removed at operaV tion (Fig. 4).
► Discussion
Two inoperable rectal tumours regress-

ed sufficiently after intra-arterial chemo
therapy to be resected. Although tumour
regression was documented in all three
patients with an initially inoperable rec
tal cancer, a similar response was not
observed in patients with locally recurrent
disease. Two patients with local recur
rence had received radiotherapy 12 and
5 months, respectively, before intra
arterial chemotherapy. Radiation-induced
microvascular alterations are well known
and probably prevented adequate delivery
of cytotoxic agents to the tumour bed.
However, the degree of pain relief obtain
ed in two of the three patients with local
ly recurrent rectal cancer was appreciable.
Even though the pain relief was tem
porary, there was improvement in the
quality of life for 2 and 3 months respec
tively; analgesic medication was required
less during that period.
For intra-arterial infusion, the cytotox
ic agents should be selectively adminis
tered into the distal artery supplying the
tumour exclusively; otherwise, sideeffects are bound to increase con
siderably. In cancer of the rectum, the
superior hemorrhoidal artery should be
selectively cannulated. If infusion is per
formed after extirpation with ligation of
the superior hemorrhoidal artery, the in
ternal iliac artery should be used.

►

Fig. 4a

►

v
►

r
►

In one of the two patients who subse
quently had ischemic colitis with stricture,
catheter displacement from the superior
hemorrhoidal artery into the inferior
mesenteric artery had occurred while the
infusion was in progress. In the other, the
catheter had initially been introduced no
further than the inferior mesenteric
artery. The subsequent colitis was not
secondary to simple thrombosis but was
more likely owing to a series of events
mediated by toxic effects of the drugs on
the micro vasculature. Faulty catheter
positioning could also be blamed for the
development of the arterioenteric fistula
(Fig. 4).

►

►

Fig. 4b
FIG. 4—Inferior mesenteric arteriogram in
* patient with inoperable rectal cancer, (a) Before
infusion. Because of high trifurcation of in* ferior mesenteric artery (IMA), selective, stable
catheterization of superior hemorrhoidal artery
*
(SHA) was not possible. Catheter was left in
sigmoid artery (SA). (b) After infusion. Ink ferior mesenteric artery and branches have
decreased in size with numerous irregularities;
there is opacification of cavity (arrow) which
freely communicates with segment of small
bowel (black pointer) and of large bowel (open
pointer). There were no symptoms at this stage.

According to Silverman and asso
ciates,11 the estimated median survival
for surgically treated patients with cancer
of the rectum, in a stage comparable to
that of our patients, ranges from 1.3 years
to 2.6 years. Of the three patients on
whom surgery was performed, only one
is alive after 26 months. We are aware
that our series is too small for any
statistical analysis of survival; however,
from our limited experience and given the
right indication, we believe that intra
arterial infusion chemotherapy may have
a number of advantages in the manage
ment of patients with inoperable cancer
of the rectum.
• The method is relatively simple to use
and its immediate side-effects or com
plications are manageable.

• In patients presenting with locally
recurrent tumour, the intra-arterial infu
sions can produce appreciable pain relief,
with a corresponding improvement in the
quality of life.
• In patients with initially inoperable
rectal cancer, the infusion of cytotoxic
agents by catheter in the inferior
mesenteric artery, rather than in the in
ternal iliac artery, can achieve tum our
regression, permitting subsequent resec
tion.
With appropriate supraselective place
ment and frequent monitoring of the
position of the catheter during the infu
sion period, we believe that the complica
tions of ischemic colitis and arterioenteric
fistula may be prevented.
We thank Miss Genevieve Vincent for
secretarial assistance.
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Immunosuppressive Effect of Surgery Evaluated by the
Multitest Cell-Mediated Immunity System
4

The immunosuppressive effect of surgery
in a series of 100 elective laparotomies
was determined by analysing the delayed
skin hypersensitivity, the most sensitive
in-vivo reflection of cell-mediated im
munity. For this purpose, a new method
(Multitest cell-mediated immunity sys
tem) for simultaneous, multiple, intradermal skin tests was used. This system
uses a plastic disposable device for
simultaneous intradermal injection of
seven immunologically standardized
recall antigens, offering the possibility of
assessing a patient's immunologic
capability in a manner that is painless,
rapid, safe, reproducible and quantifiable.
Patients were tested preoperatively
and on days 1, 3 and 7 after operation.
Twenty healthy volunteers, the control
group, were similarly tested.
Immunosuppression was observed in
all patients, reaching a peak on
postoperative day 3. Recovery occurred
between 7 and 10 days after operation.
Immunosuppression was more severe
and prolonged in patients with neoplastic
disease.
By continued immunologic monitoring
using the Multitest system, the authors
could confirm the suggested immunosup
pressive effect of operation and establish
that the phenomenon is temporary.
On a apprecie dans une serie de 100
laparotomies non urgentes les effets
immunosuppresseurs de la chirurgie en
analysant I'hypersensibilite cutanee retardee, reflet in vivo le plus sensible de
I'immunite a mediation cellulaire. A cette
fin, on a utilise une nouvelle methode (le
systeme Multitest de mesure de I'immunite a mediation cellulaire) pour pratiquer
simultanement des tests intradermiques
multiples. Ce systeme utilise un applica-
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teur de plastique a usage unique permettant I'injection intradermique simultanee
de sept antigenes de rappel immunologiquement standardises. II offre la possibi
lity d'evaluer sans douleur la capacity
immunologique du patient de facon
rapide, sure, reproductible et
quantifiable.
Les patients furent testes avant I'operation et 1, 3 et 7 jours apres [’interven
tion. Un groupe temoin de 20 volontaires
sains fut teste de la meme facon.
Une immunosuppression atteignant un
maximum au 3 e jour postoperatoire fut
observee chez tous les patients. Le retablissement s'effectua entre le 7e et le
10e jour postoperatoire. L'immunosuppression etait plus profonde et plus prolongee chez les malades cancereux.
En poursuivant la surveillance immuno
logique des patients a I'aide du systeme
Multitest les auteurs ont pu confirmer
I'hypothese d'un effet immunosuppresseur du a la chirurgie et etablir le caractere temporaire de ce phenomene.

M any studies have suggested th a t
postoperative surgical complications that
cannot be ascribed completely to the
mechanics o f the procedure itself are due
to immunosuppressive effects, resulting
in p o s to p e ra tiv e m o rb id ity an d
m ortality.1-5 The great interest in analys
ing and evaluating the immunologic
capability o f the surgical patient is thus
understandable.1,6'9
O f several methods of evaluation that
can be used to assess the immunologic
response to sepsis and traum a, in-vivo
evaluation o f cell-mediated immunity by
delayed skin hypersensitivity to recall an
tigens is the most indicative and the
easiest to p erfo rm .3’4’6’7’10' 15 In fact,
studies of delayed cutaneous hypersen
sitivity by conventional skin testing have
been used as a prognostic indicator of
postoperative morbidity and mortality,
but the results have been controver
sial.1’2'7’13'16' 18 Conventional skin testing
is unsatisfactory because of the lack of
a standardized method and results. A
review of the literature shows the great
differences between and diversity of the
recall antigens employed, the lack of

quality standardization (except for that of
tuberculin antigen) and their differing ^
biologic potency.5,19 Furtherm ore, conventional skin testing, usually perform 
ed by multiple intradermal injections of.,
several recall antigens, can be uncom for
table and painful for the patient and re- «
quires a skilled tester to achieve good
results. These criticisms have made it im- 4
possible to obtain com parable and
reproducible delayed skin hypersensitivity ^
determ inations using single sk in -test^
techniques. For these reasons, conven
tional means of assaying immunologic k
capability by the delayed skin testing of
recall antigens have not been used for
continued immunologic monitoring even
though delayed skin hypersensitivity is A
considered the most indicative clinical test
o f cell-mediated immunity.
The Multitest system, recently introduc
ed to clinical practice, appears to be a
safe, rapid, quantifiable and reproduci- <
ble method of evaluating delayed skin
hypersensitivity to multiple, standardiz- ^
ed recall antigens.8’16-18’20 The system can
simultaneously evaluate in man the 4
response to seven ubiquitous recall an 
tigens in a 70% glycerol solution, in a "f
reproducible and quantifiable m anner.
These properties are guaranteed (a) by us
ing chemically and biologically standar- ^
dized delayed hypersensitivity reactions
for each antigen, previously tested in sen- «
sitize d g u in ea p igs, (b) by th e
simultaneous intradermal injection o f ■*
seven recall antigens, supplied by a
multiple-puncture plastic device to ensure *
regular depth of injection, and (c) by the
possible quantification of the test result
(Multitest score).8,16,18’2° This system thus ^
avoids all the criticisms o f conventional
skin testing, offering the potential for „
detecting changes in cell-mediated im
m unity and evaluating the immunologic *
capability of patients.
The purpose of this presentation is to ■*
evaluate the changes in immunologic
capability before and after operation by
delayed skin hypersensitivity determination using the Multitest system to q uan
tify and establish the immunosuppressive 4
effect of operation and its recovery in the
postoperative period.
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Preoperative and postoperative im
munologic capability was measured in a
series of 100 patients who underwent elec
tive laparotomy performed by the same
surgical staff at the First Department of
Surgery, Genova University, Italy.
The series consisted of 45 men and 55
women, ranging in age from 18 to 81
years (mean 51 ± 17 years). Thirty-eight
patients had neoplastic disease. The
diagnoses and surgical procedures per
formed are reported in Tables I and II.
Im m unologic
capability
was
simultaneously determined in a control
group of 20 healthy volunteers (10 men
and 10 women) ranging in age from 21
to 60 years (mean 4 8 + 1 0 years). Both
groups were tested in the same way.
Immunologic capability was determin
ed by the Multitest system. The system
consists of a simultaneous intradermal in
jection of seven recall antigens with a
disposable eight-head plastic applicator
device (Multitest, CMI System; Institut
Mherieux, Lyon, France). The seven recall
antigens are tuberculin, tetanus toxoid,
diphtheria toxoid, Streptococcus, Can
dida, Trichophyton and Proteus. All are
biologically standardized for delayed skin

hypersensitivity in sensitized guinea pigs,
using a technique similar to that in the
standardization of tuberculin.16’17'20 All
antigens on the applicator are suspended
in a 70% glycerol solution. A 70%
glycerol solution is provided as a negative
control for nonspecific skin hypersen
sitivity on the eighth head of the ap
plicator, to ensure correct and easy
reading of the positive intradermal reac
tions. The applicator with the seven recall
antigens supplied and the glycerol solu
tion are stored at a temperature below
10°C but not frozen.
Delayed skin hypersensitivity was
determined using the Multitest 3 to 7 days
before operation then on days 1, 3 and
7 after operation. Healthy volunteers
were tested twice, 7 days apart, using the
same method. All patients were tested
twice on the volar surface of the right and
left forearms (four tests) in an arbitrary
sequence. The volar surface area of the
forearms used for the tests was not used
for the parenteral administration of fluids
or specific drugs.
Every induration reaction was read 48
hours after the intradermal injection
following Sokal’s c riteria.19 The
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Table 1-Diagnosis (N - IDO)

Diagnosis
► Peptic ulcer
Gallbladder stones
► Vascular disease
Morbid obesity
Crohn’s disease
k
Intestinal obstruction
Biliary tract stones
Acute pancreatitis
Large-bowel cancer
Gastric neoplasms
cancer
r Esophageal
Duodenal cancer
Ovarian cancer
► Renal cancer

No. of
patients
12
15
10
5
5
6
5
4
24
6
3
1
3
1

FIG. 1—Immunosuppressive effect of
operation evaluated by Multitest score analysis.
Decrease on postoperative day 3 in patients
who underwent operation (black bars) was
highly significant (p < 0.005). Variations in
control group (dotted bars) were not signifi
cant. Curve variance of surgical population was
highly significant (p < 0.001).

numerical test score (S) was the sum of
the mean diameter of every positive reac
tion greater than 2 mm of the seven intradermally injected recall antigens.
Results were given as the mean S value
± the standard error of the mean.
Statistical analysis was by Student’s ttest and analysis of variance. Values of
p < 0.1 were considered significant.
Results
Analysis of the Multitest S variations
after operation in the global study
population is reported in Fig. 1. In our
100 patients it was possible to observe a
decrease in S value from preoperative
score of 11.71 ± 0.9 to 8.18 ± 0.86,6.91
± 0.76 and 8.46 ± 0.87 on days 1, 3 and
7 after operation respectively. A greater
decrease was observed on postoperative
day 3 (p < 0.005). Analysis of variance
was highly significant (p < 0.001).
Evaluation of the scores in the control
group from the four consecutive tests,
hypothetically representing the test times
of the surgical population, was not
significant (p > 0.25).
Men and women had preoperative
scores of 17.44 ± 1.42 and 7.30 ± 0.81
respectively (p < 0.001) (Fig. 2).
Postoperatively, the most severe decrease
in S was observed on day 3, with values
of 9.92 ± 1.35 and 4.42 ± 0.69 for men
and women respectively (p < 0.001).
Following this, an increase in S values was
observed on day 7 of 11.70 ± 1.43 and
5.80 ± 0.45 in men and women respec
tively (p < 0.001). The S-curve variance
was highly significant both in men (p <
0.001) and women (p < 0.005). Com
parison of curve variances among men,
women and the global surgical population
showed no significant differences (p >
0.25).
Score variations in patients with and
without neoplastic disease are reported in
Fig. 3. Preoperatively, the scores were
9.77 ± 1.51 and 13.11 ± 1.15 in the
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Table II—Surgical Procedures (N - 100)
No. of
patients
Surgical procedure
10
Subtotal gastrectomy
6
Selective vagotomy
10
Vascular bypass
Intestinal bypass
5
11
Jejunoileal resection
Oddi's sphincterotomy
5
Anterior sigmoid resection
18
6
Miles' rectal amputation
2
Total gastrectomy
Distal esophageal resection
3
3
Ovariectomy
1
Nephrectomy
15
Cholecystectomy
5
Other

pr eop

FIG. 2—Multitest scores of men (black bars)
and women (shaded bars) were significantly
different (p < 0.001) for all tests. Curve
variances were highly significant in men (p <
0.001) and women (p < 0.005). Comparison
of two curve variances revealed no significant
difference.

1
3
d a y af t er su rge ry

7

FIG. 3—Multitest score in neoplastic (shad
ed bars) and non-neoplastic (black bars) pa
tients. There was no significant difference
preoperatively. Differences were not highly
significant on postoperative day 3 (p < 0.1).
Test on day 7 indicated more severe and pro
longed immunosuppression in neoplastic pa
tients (p < 0.05).
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neoplastic and non-neoplastic series
respectively. Differences were not signifi
cant (p > 0.5). The postoperative
decrease observed on day 1 was not
statistically significant in either series. The
maximal day 3 decrease was different in
the neoplastic and non-neoplastic series
— 5.35 ± 1.01 and 7.71 ± 1.06 respec
tively (p < 0.1). The increase on day 7
was 6.03 ± 1.18 and 9.80 ± 1.17 for the
neoplastic and non-neoplastic series
respectively (p < 0.05). Analysis of
variance was highly significant for the two
series (p < 0.001). Comparison of the
curve variance of the total study popula
tion, men, women, neoplastic and nonneoplastic patients showed no significant
differences, except for the day 7 S value
in the neoplastic series, where a
significantly lower increase was noted (p
< 0.05). An analysis of global results is
provided in Table III.

dization and reproducibility in the tests
used have been lacking.5’7-21’22 Even the
available data on delayed hypersensitivi
ty, the most widely used test for
evaluating immunity, are not sufficient
ly standardized to be considered in
dicative for assessing postoperative
immunosuppression.3'8,21
Our experience with the Multitest
system has dem onstrated that im
m unosuppression
occurs
from
postoperative day 1 and reaches a peak
on day 3 after operation. This effect was
temporary and recovery occurred between
7 and 10 days after operation. Curvevariance analysis was highly significant (p

T a b le 111-- M u lt it e s t S c o re s . C om paris on o f th e D iffe re n t S erie s
T im e o f te s t
P o s to p e ra tiv e d a y
C urve
T e s te d p o pu lation

Discussion

n - TOO
C o n tro ls , n -

20

M en, n - 4 5
W om en, n - 5 5
N o n -n e o p la s tic

1

P re o p e ra tiv e

S u rg ic a l po p u latio n , 1 1 .7 1

Several reports have shown that
surgical stress can induce multiple abnor
malities in conventional in-vivo and invitro assays of a patient’s immunologic
capability.1"7’9,21,22 The im m unosup
pressive effect of surgery has been sug
gested, but good assessment of this effect
has not been achieved because standar

< 0.001) in the total study population,
confirming the reproducibility of the test.
A further confirmation of the validity of 4
the Multitest was the lack of statistical
variations in the S curve in the control A
group.
Our results agreed with other ex- ^
periments using the Multitest system in
that the S values differed for men and
women, but postoperative curve variances ^
were not statistically different.18 This
difference between the S of men and ^
women was in other experiments con
sidered nonpathologic.8’1618
■*»
The immunosuppressive effect was
more severe and prolonged in the patients *
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Rational therapy for hemorrhoids,
proctitis and pruritus a n t
-»

+Darke, A.C., Rudd, W.W.H.: Reformulation ofTwo Hemorrhoidal Ointment Preparations: Double-blind Clinical
Comparison with Existing Formulations; Curr. Therap. Res. 30; 6:880-885,1981.
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with neoplasms, with less recovery at 7
days. This could be ascribed to the more
fc. destructive surgical procedures usually
performed on these patients and to more
V stressful anesthesia. Further, the more
severe postoperative immunosuppression
^ in neoplastic patients may in part account
^ for the higher incidence of postoperative
morbidity and mortality in these patients;
several studies are at present under way
to confirm this hypothesis.
>The easy clinical application of the
Multitest offers the possibility of a rapid,
u safe and painless method to obtain ac
curate immunologic monitoring. The
^ clinical importance of the system is
enhanced by the possibility of having a
clear knowledge of the host defences
y against sepsis and trauma preoperatively. The Multi test system could indicate
♦.whether action is required to increase
them by n u tritio n al support, im► munologic or other treatments, so as to
reduce postoperative septic complica* tions.2'4,6'7'9’10Furthermore, the effect of
these treatments on the immunologic
^ capability can easily be monitored,
j
Studies are presently under way to
establish whether the Multitest can be usa. ed as a preoperative screening test to
predict the occurrence of postoperative
septic complications.

We thank Dr. L.E. Derchi for his helpful
suggestions.
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Early Determinants of Outcome in Blunt Injury
A critical se t o f 1 3 5 p a tien ts and a
validation s e t o f 2 0 2 p a tie n ts w h o sus
tained blunt in ju ry w ere exam ined fo r in 
dices of o u tc o m e based on blood
chem istry and th e G lasgow com a scale.
In both sets th e non survivo rs had
sig n ifica n tly lo w e r scores on th e com a
scale, higher levels o f plasm a glucose
and increased le u ko cyte co u n ts.
Hypokalem ia w a s also n o ted and a tren d
to w a rd s lo w e r serum levels w ith increas
ing injury s e v e rity .
Logistic d is c rim in a n t analysis
dem onstrated th a t the m ost im p o rta n t
variables w e re the com a scale score (as
a continuous variable from 3 to 14) and
th e plasma g lu co se level (as a
dichotom ized variable w ith norm al being
defined as less than 10 m m o l/L [i.e ., th e
renal threshold] and abnorm al as being
above this le ve l). A com a scale score
c u t-o ff at 10 w ith an abnorm al plasma
glucose level, and a c u t-o ff at 8 w ith a
norm al plasma glucose level produced a
m axim um c o rre c t cla ssificatio n rate (into
survivals and deaths) o f 8 7 % . Low er
scores were a ssociated w ith an in cre a s
ing p robability o f death.
Serum po tassiu m levels and the
leukocyte c o u n t did n o t c o n trib u te
sign ifica n tly to th e d iscrim in a n t fu n c tio n ,
although b o th w ere related to ou tcom e .
T he reasons fo r the de tecte d abnor
m alities are discussed. M eta b o lic
m arkers, such as plasma g lucose and
serum potassium , in association w ith the
co m a scale s c o re are sim ple and early
determ inants o f o utcom e in b lu n t injury
and may be u s e fu l indices o f injury
severity.
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Une etude a ete e ffe ctu e e , co u vra n t
deux periodes de 6 m ois chacune, et
p o rta n t sur un groupe in itial de 135
malades et sur un groupe de validation
de 2 0 2 malades qui ava ie nt bte victim es
de blessures causees par un objet conto n d a n t. L 'etude visa it a analyser les
indices qui p e rm e ttra ie n t de connaitre les
consequences de la lesion d 'aprbs la chimie sanguine e t I'echelle G lasgow in d i
quant I'e ta t du com a. Pour les deux
groupes, lors du deces des victim e s, les
fa cte urs suivants o n t ete notes: les resultats de I'echelle in d iqu a n t I'e ta t comateux etaient n e tte m e n t inferieurs, la
teneur en glucose du plasm a 6 ta it superieure, et la n u m eration leucocytaire avait
augm ente. De plus, I'hyp o ka lie m ie s 'e ta it
prod u ite et, en general, la concentration
serique avait dim inue selon la gravite
croissante de la lesion.
L’ analyse lo g istiq u e des indices a m ontre que les variables les plus im portantes
com prenaient les resu lta ts de I'echelle
sur I’ e ta t com ateux (com m e variable
continue de 3 a 14), et le te n eu r en glu 
cose du plasma (com m e variable dichotom ique d o n t la norm ale se d e fin it com m e
m oins de 10 m m ol/L [c-a-d, le seuil
renal] et I'e ta t anorm al com m e plus de
10 m m ol/L). Un re su lta t de 10 sur
I'echelle indiquant I'e ta t co m a te u x avec
une teneur anorm ale en glucose du
plasma, et un re su lta t de 8 avec une
teneur norm ale en glucose du plasma o n t
donn6 une p ro p o rtion de classification
exacte m axim ale (entre su rviva n ts et
m orts) de 8 7 % . Des resu lta ts inferieurs
se rap p o rtaie n t a une p ro b a b ility accrue
du ta u x de m orta lity.
M em e si les ta u x du potassium dans le
serum et la n u m eration leucocytaire se
rattachaient aux consequences de la
lesion, ils n 'o n t pas co n trib u e de facon
sig n ifica tive a la fo n c tio n des indices.
On a exam ine les causes des anorm alites qui avaient 6te decelees. Les fa cte urs
m etaboliques. tels que la te n eu r en glu 
cose du plasm a et le ta u x de potassium
dans le serum , jo in ts au resultats de
I'echelle n o ta n t I'e ta t co m a te u x, sont
des prem iers indices bien sim ples pour
dyterm iner les consequences d ’ une

lesion causee par un o b je t conton d a n t,
et peuvent co n s titu e r des signes revyiateurs de la g ra v ity de la blessure.

Predicting outcome in trauma patients
has particular significance in the early
stages o f management: it can provide a
triage function, determine the level of
care that an individual patient should
receive and, in retrospect, will assist in
system audit and in allocating resources.
Assigning scores to individual injuries as
a method of defining injury severity ig
nores the variable capacity of each patient
to compensate for the trauma sustained.
It is the individual physiologic response
to trauma that should be quantified.
These responses have been extensively
investigated1-2 but have only rarely been
used to predict outcome.3-4 In the past,
attention has been paid to complex
substances such as hormones that may
relate to injury severity but require com
plicated measurement techniques. Also,
the exact timing o f the initial sampling is
important but has been essentially ig
nored. This study focuses on the initial
measurements o f simple blood chemical
levels within 6 hours o f injury, assuming
that abnorm al values reflect the
physiological state o f the patient. The
study also includes observations of the
Glasgow coma scale recorded within the
same period. The scale is easily applied
and has previously been noted to be of
significance in patients with head in
jury.5'7
Patients and Methods
Patients admitted to the Trauma Ser
vice at the Hamilton General Hospital
over two 6-month periods, from July 1
to Dec. 31, 1977 (critical set) and from
July 1 to Dec. 31, 1980 (validation set),
were reviewed. The patient sample includ
ed those with head injuries and victims
o f multiple trauma (defined as injury to
two or more body systems). Partly
because of this definition and partly
because of the pattern of injury in
southern Ontario, no patients with
penetrating knife wounds or gunshot in
juries were included in either set. Only pa-
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tients who had blood sampled at our in
stitution within 6 hours of the known time
* of injury were included. In the critical set
were 292 patients of whom 135 (100 men,
k 35 women) fulfilled the criteria for inclusion in the study. The validation set constained 202 patients (122 men, 80 women)
. who fitted the criteria for inclusion. The
initial sampling was done in the emergency department usually when intravenous
lines were established, except for patients
>- transferred from other institutions, who
arrived with lines already in place.
*- The following data were taken from the
records of each patient: age and sex;
whether a direct admission or a transfer;
premorbid history, if any; each injury
identified at admission; central nervous
v system status (using the Glasgow coma
scale) and time lapse from injury to blood
ksampling. The measurements made on the
blood sample included the following:
■ hemoglobin level, hematocrit, leukocyte
count, serum sodium , potassium ,
chloride, bicarbonate, plasma glucose and
blood urea nitrogen levels. Arterial blood
gases were measured in 32 of the patients
4 in the critical set. The patient outcome
was recorded, survivors being those
- discharged from the hospital or transfer
red to another institution.
The Glasgow coma scale was applied
routinely by the nursing staff when the
' patient was admitted to the emergency
departm ent. The three principle
* categories of the scale concern eye open> ing and motor and verbal responses. Each
category has several subsets that can be
v scored sequentially using a baseline of 1
for no response. Summing the three
v categories produces a coma scale score
with a range from 3 (being the most severe
' central nervous system deficit) to 14 (nor
mal). The original scale7 has subsequent’’ ly been modified by the addition of an extra category (withdrawal to pain) so that
the score now runs from 3 to 15.8
► Leukocyte counts were obtained using

a Coulter S counter (Coulter Electronics
lnc. , Hialeah, Fla.) which is accurate to
2% at a count of 20 x 109/L . Plasma
glucose was estimated on a KDA analyser
(American Monitor Corp., Indianapolis,
lnd. ) which is accurate to within 4% (3.0
+ 0.1 m m ol/L, 17.0 ± 0.5 mmol/L).
Patients admitted during daylight work
ing hours had plasma glucose estimated
on a Technicon autoanalyser mark I
(Technicon Instruments C orp., Tarrytown, NY) (3.0 ± 0.3 mmol/L, 17.0 ±
0.8 m m o l/L ). Serum potassium
measurements were obtained using a Klini
flame analyzer (Beckman Instruments,
Anaheim, Calif.) (± 0.1 m m ol/L within
the range from 2 to 6 mmol/L).
Initial analysis compared survivors and
nonsurvivors with respect to all variables
measured, using a one-tailed /-test. Subse
quent analysis dichotom ized the
biochemical variables into normal and ab
normal. The coma scale, however, was
kept as a continuous variable. The next
phase of the analysis was the use of a
logistic discriminant approach, which
assumes that a patient’s probability of
surviving can be derived mathematically
using a logistic equation derived from a
number of predictor variables. The
logistic equation for determining the pro
bability of a patient surviving has the
following form:
Ps = P(survive X ,,...X n) =

___________ 1___________
1 +

e - ( B 0 + B,X, + ...BnX„)

Where X j.—X,, are the predictor variables
for survival, e is the exponential function
and B0, B,,...Bn are the coefficients to be
estimated, based on the sample of
patients.9 In this study the predictor
variables are the metabolic markers
(serum potassium, plasma glucose and
leukocyte count), which take on values 0
and 1 for normal and abnormal respec
tively, and the coma scale score, which
ranges from 3 to 14, The maximum

>
y

>•

Variable

Serum potassium, mmol/L
Mean
Range
Leukocyte count, X 109/L
Mean
Range
Plasma glucose, mmol/L
Mean
Range
Coma scale score
Mean
A
Range
Age, yr
►
Mean
Range
Median

Table l-Critical Set Variables
Survivors
Nonsurvivors
(n = 24)
(n - 111)

Total
(n - 135)

p value

3.54 ± 0.40
2 .6 -4 .6

3.20 ± 0.62
2 .0 -4 .5

3.49 ± 0.46
2 .0 -4 .6

<0.01

14.85 ± 6.25
5.6-44.2

18.01 ± 7.62
5.1-33.3

15.41 ± 6.60
5.41-44.2

<0.05

8.34 ± 3.59
3.7-25.0

12.45 ± 5.30
4.8 -2 7 .0

9.10 ± 4.23
3.7-27.0

<0.01

12.13 ± 3.18
3 -1 4

5.25 ± 3.07
3 -1 4

10.90 ± 4.11
3 -1 4

<0.01

30.1 ± 19.1
3 -7 8
23.2

39.3 ± 20.0
13-81
40.5

31.7 ± 19.5
3-81
25.0

<0.05

likelihood estimates of the coefficients
B0, B1(...Bn were obtained using the
logist procedure in the statistical analysis
system (SAS) package.10 The backward
stepwise method was used.10
Results
Critical Set
Of the 135 patients, 24 (17.8%) died.
Ten deaths occurred within 48 hours,
another 9 within 12 days and the other 5
much later during the hospital stay. In
itial analysis of the biochemical and other
variables identified significant differences
between survivors and nonsurvivors for
the following variables: serum potassium
(p < 0.01), plasma glucose (p < 0.01),
leukocyte count (p < 0.05), coma scale
score (p < 0.01) and age (p < 0.05)
(Table I).
Validation Set
The above variables were specifically
noted in 238 patients during the second
6-month period. Of the 202 who filled our
criteria for inclusion in the study, 13
(6.4%) died. Six deaths occurred within
48 hours, six more within 15 days and one
much later in the hospital stay. Values for
serum potassium , plasm a glucose,
leukocyte count, coma scale score and age
are recorded in Table II. In this set there
was no significant difference between
serum potassium levels (in survivors and
nonsurvivors) or in the mean age.
Hypokalemia, however, occurred in 10 of
the 13 nonsurvivors.
Serum Potassium
Because o f the n a tu re o f the
biochemical variables, although measured
as continuous, it is more meaningful that
they be divided into normal and abnor
mal ranges. For serum potassium the
physiological cut-off point of 3.5 mmol/L
was used in these analyses; that is, pa
tients with a serum potassium level less
than 3.5 mmol/L were considered to have
abnormal levels while normal was con
sidered to range from 3.5 to 5.0 m mol/L.
Using serum potassium alone to predict
survival, we showed that at 3.5 m m ol/L
the sensitivity and specificity were higher
than at any other cut-off point. For the
clinical set, sensitivity and specificity were
71% and 63% respectively and 64% were
correctly classified into survivors or non
survivors. For the validation set, sensitivi
ty was 77%, specificity 59%, and 60%
were correctly classified.
Within the abnormal range there was
a significant (p < 0.05) correlation with
death among the patients in the critical
set. Thus, if a patient had a serum
potassium level lower than 3.5 m m ol/L,
the lower it was, the greater was the
likelihood that the patient would die.
Such a correlation was not observed
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within the normal range. This suggested
that the degree of abnormality of serum
potassium could increase our capability
to predict death.
Serum potassium was therefore
categorized into four groups: normal —
greater than or equal to 3.5 m mol/L,
mildly abnormal — 3.0 to 3.4 mmol/L,
moderately abnormal — 2.5 to 2.9
mmol/L and severely abnormal — below
2.5 mmol/L (Table III). The degree of ab
normality correlated with increasing mor
tality in the critical set. This correlation
was not significant in the validation set
among patients with abnormal serum
potassium levels, although 10 of the 13
patients who died were hypokalemic.
Plasma Glucose
The physiologic cut-off point for
plasma glucose is controversial but in this
analysis we accepted 10 m mol/L, which
is regarded as the renal threshold. With
this cut-off, in the critical set the sensitivi
ty and specificity were 63% and 84%
respectively, and 80% were correctly
classified. In the validation set, sensitivi
ty was 54%, specificity 90% and 88%
were correctly classified into survivors or
nonsurvivors. No patients with diabetes
mellitus were identified in the critical set.
Two patients were recognized in the
validation set, both with hyperglycemia
and both survived. They are included in
the study although they represent an in
herent error.
Leukocyte Count
Patients who died tended to have a
higher leukocyte count. However, there
is no determined physiologic cut-off point
for the leukocyte count which appears
logical. Analysis of our data showed the
best cut-off points were at 16 x 109/L
for the critical set and 19 x 109/L for
the validation set. The importance of
these levels is unclear, and therefore fur
ther analysis was deferred.
Arterial Blood Gases
Thirty-two patients in the critical set
had blood gases drawn for analysis within
6 hours of injury. The mortality in this
group of patients was 37.5%. Serum
potassium levels in the group ranged from
2.0 to 4.1 m m ol/L (mean 3.5 mmol/L).
Twenty of these patients had serum levels
less than 3.5 mmol/L and 9 of the 20
died. None of these patients, however,
demonstrated serious alkalosis, with the
mean pH for the whole group being 7.36
(range from 6.9 to 7.46) and for the
subset of 20, 7.37 (range from 7.26 to
7.46).
Coma Scale Score
Table IV demonstrates the distribution
of the coma scale score among survivors
66

and nonsurvivors for the critical and the
validation sets and the corresponding
cumulative percentages. The proportion
of survivors increases as the coma scale
score rises and vice versa for nonsur
vivors. Therefore, rather than dividing
the score into sections defining severe,
moderate and mild injury, it was kept as
a continuous variable ranging from 3 to
14 in all subsequent analyses. It was noted
that mortality appeared to rise in an ex
ponential fashion as the score dropped

Variable
Serum potassium, mmol/L
Mean
Range
Leukocyte count, X 109/L
Mean
Range
Plasma glucose, mmol/L
Mean
Range
Coma scale score
Mean
Range
Age, yr
Mean
Range
Median

(i.e., this scale was not linear for
outcome).
Relation between Coma Scale Score,
Metabolic Markers, Age and Outcome

11

The correlation coefficients of the
various markers with outcome were as •*
follows for the critical set and validation
set respectively: potassium, -0 .2 6 (p < A
0.01) and -0 .1 8 (p < 0.05), plasma
glucose +0.41 (p < 0.01) and +0.32 (p
< 0.01), coma scale score -0 .6 4 (p < ^

Table II—Validation Set Variables
Survivors
Nonsurvivors
(n = 189)
In = 13)

<
Total
In - 202)

p value
*

3.52 ± 0.45
2.3-5.1

3.30 ± 0.49
2 .6 -4 .7

3.50 ± 0.46
2.3-5.1

NS

15.91 ± 6.46
3.7-43.3

22.14 ± 11.08
7.5-48.0

16.31 ± 6.98
3.7-48.0

<0 .05

7.59 ± 2.32
4.3-18.5

12.09 ± 5.53
6.9-25.7

7.88 ± 2.84
4.3-25.7

<0.01

12.00 ± 2.80
3 -1 4

4.90 ± 2.90
3 -1 4

11.50 ± 3.30
3 -1 4

<0.01

28.9 ± 17.2
3 -8 2
24.0

36.3 ± 22.5
16 -7 2
22.0

29.4 ± 17.6
3 -8 2
23.9

NS

-i
<
*

V

K

4

Table Ill-Serum Potassium Levels and Outcome
Validation set (n - 202)
Critical set In = 135)
Serum potassium
Survivors Nonsurvivors
Nonsurvivors
Survivors
level, mmol/L
0
2
2
0
Severe hypokalemia, < 2 .5
2
7
16
Moderate hypokalemia, 2.5-2.9
9
8
32
60
8
Mild hypokalemia, 3 -3 .4
3
111
7
Normal, > 3 .4
70
Total

111

24

189

4

-*

13
A

Table IV-Coma Scale Score and Outcome*
Validation set (n - 202)
Critical set (n - 135)
Nonsurvivors,
Survivors,
Survivors,
Nonsurvivors,
Coma scale
no. (%)
no. (%)
no. (%)
score
no. (%)
4 (31)
2 (2)
11 (46)
2 (1)
3
2 14)
3 (54)
4
2 (54)
1 (2)
7 (5)
4 (85)
7 110)
3 (67)
5
3 (13)
2 (75)
8 (10)
6
1 (92)
0 (92)
3 (11)
2 (83)
1 (14)
7
5 (14)
0 (92)
0 (83)
4 (17)
8
2 (92)
8 (18)
0 (92)
9
1 (18)
8 (22)
0 (92)
10
0 (92)
1 (19)
11
3 (22)
0 (92)
10 (28)
0 (92)
6 (27)
19 (38)
0 (92)
12
1 (96)
13
18 (43)
0 (96)
29 (53)
0 (92)
14
63 (100)
1 (100)
1 (100)
89 (100)
24
Total
111
189
13
'Percentages are cumulative.
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0.01) and -0.52 (p < 0.01), age +0.18
(p < 0.05) and no correlation in the
validation set. Note that serum potassium
^ and plasma glucose levels were predictor
(0,1) variables, while the coma score and
V age were incorporated as continuous
variables. The effect of age is of par► ticular interest. In the critical set, a signifi
cant relation existed between age and out" come (p < 0.05); younger patients tend
ed to have a better chance of surviving
than older patients. A closer examination
of the data, however, led to the extrac
tion from the 135 patients of 15 patients
► aged 12 years or younger. All of these 15
patients survived and they were similar to
► the older survivors with respect to the
coma scale score and the metabolic
* markers, but not to the nonsurvivors;

Table V-Critical Set: Estimated Probability
of Survival, Using Coma Scale Score
and Plasma Glucose Level

0.41
0.51
0.61
0.70
0.78

0.19
0.26
0.34
0.44
0.54
0.64
0.73
I 0.80 I
0.86
0.90
0.93
0.96

oo

3
4
5
6
7
8
9
10
11
12
13
14

Plasma glucose level, mmollL
--------------------------------------------Normal, < 1 0 Abnormal, > 1 0

CD

Coma scale
score

0.89
0.92
0.95
0.97
0.98
0.98

r

therefore, age did not seem to be a deter
mining factor for survival amongst in
jured patients in this study. This was fur
ther established in our finding that there
was no relation between age and outcome
in the validation set.
Predicting Outcome

Using the logistic discriminant ap
proach, we found that the results from
the critical set indicated that only the
coma scale score and plasma glucose level
were important in predicting outcome.
Adding serum potasssium level (even
weighted for lower levels) or leukocyte
counts did not contribute to predictabili
ty. The maximum likelihood estimates of
the coefficients of the model are as
follows: a constant (B0) coefficient of
1.611 (p < 0.05), a coma scale score (B,)
coefficient of -0.412 (p < 0.01) and a
plasma glucose (B2) coefficient of 1.094
(p = 0.08). From this model we can
calculate the estimated probability of a
patient surviving for all combinations of
the coma scale score and plasma glucose
(Table V). For example, if an injured pa
tient has a coma scale score of 6 and a
normal plasma glucose level, then he has
a 70% chance of surviving. To
discriminate between nonsurvivors and
survivors we need to select a threshold
probability, a level at which we will
Table VIII—Combined Set (N - 3371:
Estimated Probability of Survival, Using
Coma Scale Score and Plasma Glucose Level
„
,
Coma scale
score

Plasma glucose level, mmollL
--------------------------------------------Normal, < 1 0 Abnormal, >10

y

T

Table VI—Critical Set: Actual and
Predicted Outcome

V

►

Actual
outcome

r

Survivors
Nonsurvivors
y

►

Predicted outcome
Survivors

Nonsurvivors Total

94
4
98

17
20
37

111
24

135
Total
Sensitivity, 83%; specificity, 85%; correctly
classified, 84%.

3
4
5
6
7
8
9
10
11
12
13
14

0.45
0.57
0.68
0.78
0.85
I 0 .9 0 1
0.94
0.96
0.98
0.98
0.99
0.99

0.23
0.33
0.44
0.56
0.67
0.77
0.84
I 0 .9 0 1
0.93
0.96
0.97
0.98

predict either death or survival. A patient
with a greater than 50% chance of sur
viving could be predicted to survive, but
this would not take into account the ex
pected or actual survival (or mortality) of
the population under study. The mortality
in the critical set is 17.8%. If we use,
therefore, 0.80 as our threshold probabili
ty, that is, classify a patient as a survivor
if his Ps is at least 0.80, then all those pa
tients with a high plasma glucose level and
a coma scale score of at least 8 would be
predicted to survive. The classification
tables obtained using these cut-off points
are shown in Tables VI and VII. In the
validation set (Table VII) using the same
criteria to predict survival or death, we
obtained a correct classification in 89%.
Note that the mortality in the validation
set is much lower than that of the critical
set (6.4% v. 17.8% [13/202 v. 24/135]).
Demographic data, however, in both sets
were compatible not only with respect to
age but also with respect to the
biochemical measurements and the coma
scale scores. The two sets were therefore
combined in the final analysis and a
logistic function was obtained.
The combined set had a total of 337 pa
tients with a mortality of 11%. Again, on
ly the coma scale score and plasma
glucose level were important predictors in
the logistic model. The maximum
likelihood estimates of the coefficients of
the model for the combined sets were as
follows: a constant (B0) of 1.633 (p <
0.01), a coma scale score coefficient (B[)
of -0.482 (p < 0.01) and a plasma
glucose coefficient (B2) of 1.014 (p <
0.05). The estimated probability of a pa
tient surviving can be seen in Table VIII.
If we take the 11 % mortality for the com
bined set and use 0.90 as the threshold
probability, that is, classify a patient as
a survivor if his estimated probability of
surviving is at least 0.90, we end up with
the same set of cut-off points as before
and a correct classification rate of 87%
(Table IX). Note that for any individual
patient, a lower coma scale score increases
the probability of death until it exceeds
50%.
Discussion

y-

y

y

y

►

Table VII -Validation Set: Actual and
Predicted Outcome
Predicted outcome
Actual
Survivors Nonsurvivors Total
outcome
167
Survivors
1
Nonsurvivors
168
Total
Sensitivity, 92%; specificity,
classified, 89%.

22
12
34

189
13
202

88%; correctly

Table IX--Combined Set: Actual and
Predicted Outcome (N - 337)
Actual
outcome

Predicted outcome
Survivors

Nonsurvivors Total
300
39
37
32
337
71

Survivors
261
5
Nonsurvivors
266
Total
Sensitivity, 87%; specificity,
classified, 87%.

86%; correctly

Predicting outcome has intrigued and
interested trauma physicians for many
years. It is evident that simple analyses
of the injuries sustained do not provide
indices with predictor capability. This oc
curs partly because some injuries remain
undetected for varying periods of time
and partly because each patient has a
response to injury that is individual. This
response depends on the reserve function
of each physiological system and the
overall capacity to compensate for the in
jury. Effects of the decompensated state,
for example, increased respiratory effort
or decreased capillary return, tend to
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reflect single-system rather than totalbody response. It seems logical, therefore,
to attempt to quantify the metabolic (total
body) response of the patient in order to
predict mortality (and also morbidity).
The response, however, is a mass
response with the release of many hor
mones interacting with each other. In the
past,
plasma cortisol,11 growth
hormone12 and insulin levels13'16 have all
been related to injury severity. Unfor
tunately, measuring individual hormone
levels is relatively esoteric, takes time and
has not resulted in data that are useful in
determining outcome. The ultimate
biochemical effects of the mass response
have only intermittently received
attention.1,3,17 Our results suggest that
the coma scale score, plasma glucose
levels, serum potassium levels and
leukocyte counts reflect hormonal
changes and appear to represent indirect
indices of an individualized, graded
metabolic response to trauma.
The Glasgow coma scale score appears
to be the single most reliable predictor of
outcome. Its development has been due
to the interest of Jennett and his
associates57 in the long-term recovery of
patients with head injury. That this score
is useful as an early determinant of out
come in injured patients is exemplified
not only by this study but also by its in
corporation into the triage index and
trauma score of Champion and his
colleagues.3,18 Low scores also relate to
outcome in patients without apparent
head injury,3,19 suggesting a universal
application in all cases of direct or indirect
cerebral insult.
The metabolic effect o f trauma,
resulting in high plasma glucose levels,
has been observed over the past centur y . 12,16,20-23 -phe extent of the hypergly
cemia has been related to different
degrees of injury severity as seen in
patients undergoing minor, moderate and
major surgery.23 The increase in plasma
glucose concentration has been explain
ed by increases in plasma cortisol, cate
cholamine and glucagon levels, associated
with insulin antagonism by growth hor
mone and possibly suppression of insulin
release by catecholamines.23 The insulin
response has given rise to controversy in
the recent literature. Earlier work sug
gested that a fall in plasma insulin level
and a rise in other hormones resulted in
an elevation of the plasma glucose
level.13,22,24 On the other hand, more re
cent evidence points to a relative lack of
insulin, not an absolute deficiency.14,15
Our study demonstrates a significant
cut-off in plasma glucose at approximate
ly the renal threshold with higher levels
coinciding with increased mortality. High
plasma glucose levels appear to be an ap
propriate homeostatic response in the in
jured animal assuring adequate substrate
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for brain and injured tissue. A rise of this
level above the renal threshold may repre
sent overcompensation and be indicative
of a more severe insult. This hypothesis
is supported by the fact that persistent
nonketotic hyperglycemia has been iden
tified as a grave prognostic sign in pa
tients with head injuries.25 One caveat to
be borne in mind relates to patients with
latent or overt diabetes mellitus, who will
invariably have exaggerated rises in
plasma glucose levels in response to
trauma. Other markers of injury severi
ty should be used in these patients.
The serum potassium has only recent
ly been noted to drop below normal levels
in severely traumatized patients.26 Our
results confirm this trend. Although they
did not contribute to our discriminant
function in terms of mortal outcome, we
suspect that low levels do correlate with
more intense physiologic responses.
Whether the low potassium level per se
results in myocardial or other muscle or
membrane dysfunction has not yet been
elucidated. Hypokalemia in any case ap
pears to be paradoxical. The classical
literature firmly states that hyperkalemia
should follow injury.27'29 This tendency
would be due to potassium release from
traumatized tissue30,31 and would be ac
centuated by hypovolemia and low flow
states with attendant metabolic acido
sis.27,31,32 For serum levels to drop, the
potassium ion would have to enter the
cell, pass into an extravascular fluid com
partment or be rapidly excreted into the
renal tubular system.33 Alkalosis would
normally be expected to effect an in
tracellular shift. However, in patients
with hypokalemia in which blood gases
were measured, acidosis commonly oc
curred, not alkalosis. Severe alkalosis
does appear in critically ill patients but
this is an ongoing problem and not related
to the immediate postinjury phase.34
Hyperinsulinemia also may affect the
transfer of potassium into the cells. Re
cent studies have confirmed that the
serum insulin level rises following
trauma,15,35 but its effect on the serum
potassium level has not yet been clarified.
Excessive urinary excretion of potassium
is also a possibility although concentra
tions would have to be remarkably high
in the face of low urine volumes secon
dary to the hypovolemic state, which
commonly occurs in severe injury.
It is traditional to expect leukocytosis
in response to trauma. This is mediated
by the catecholamine output.36,37 How
ever, there is no true steady state, and ex
perimental intramuscular injection with
epinephrine produces a two-phase re
sponse.37 Because of this variation over
time, we would not expect the leukocyte
count to be a good indicator of injury
severity, although an absolute leuko
cytosis may reflect sustained catechol
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amine output secondary to severe insult.
The timing of the blood sampling in
this study is of particular interest as
homeostatic responses are inevitably
modified by resuscitation. With direct ad
missions the data were collected before,
or in conjunction with, life-saving
measures. There was concern that giving
drugs and intravenous solutions before
arrival in our emergency department (as
in the case of transferred patients) would
affect the results of blood tests. In both
sets of data, however, it was observed that
although plasma glucose levels and
leukocyte counts were related to type of
admission, this association was not
related to outcome. Also, there was no
relation between direct admissions or
transfers and outcome.
In this paper, outcome is used as a
measure of injury severity. We note that
there are drawbacks to this method of
developing an injury severity scale, par
ticularly if the mortality is low. However,
the small number of deaths may reflect
the response of the institution to the
traumatized patient rather than the severi
ty of the injury. Controversy also exists
in identifying the best or most appropriate
cut-off point for each variable. We have
defined physiologic limits as being ap
propriate cut-off levels for the blood
chemistry; for example, the lower limit of
normal for potassium (3.5 mmol/L) and
the renal threshold for plasma glucose (10
mmol/L). We believe that physiological
ly inappropriate serum levels represent
overcompensation for increasing injury
severity. This belief is reinforced by the
data analysis, which confirms that our
cut-off points are close to optimum in
terms of sensitivity and specificity. At
present, however, we have no evidence
that the individual biochemical markers
identified in this study are indices of
detrimental metabolic reaction.
Unlike the biochemical markers, the
coma scale score requires clinical obser
vations and therefore is subject to observer error. Also, the score has no cut-off
point that can be explained on a
physiologic basis. The cut-off points
recorded here (8 and 10) were obtained
by analysis to provide optimal predictive
capability. These cut-off points allow the
physician to categorize his patient into a
high- or low-risk group. The coma scale
score combined with plasma glucose level
can be used as an index of injury severi
ty, with lower scores increasing the
likelihood of death in an exponential
fashion. Our data sample, however, is insufficient to indicate precisely the pro
bability of death or survival for use as a
clinical guide. Variations over time are no
doubt critical and it is evident that
dynamic indices of cellular metabolism
will inevitably be investigated to see which
are the most sensitive and reliable markers
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for outcome. On the other hand, a low
coma scale score and hyperglycemia, as
, well as hypokalemia and leukocytosis, can
be easily identified by any physician
> handling victims o f blunt injury.
Awareness of their possible significance
►is warranted.
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Product Monograph available on request.
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Complications evolutives associees a ('utilisation
d'une heterogreffe bovine comme abord vasculaire
4

Trois heterogreffes bovines utilisees
comme abord vasculaire ont ete analysees apres exerese suite a I'apparition de
formations anevrysmales (deux cas) et
au developpement d'une thrombose (un
cas). La premiere prothese, implantee
chez un homme de 17 ans presentant
une myasthenie grave et traite par plas
mapherese s'etait dilatee de fagon
notoire apres quelques mois et etait resequee 14 mois aprbs la mise en place. La
seconde greffe fut mise en place chez
une patiente de 31 ans tres fortement
deficiente en potassium et fut prelevee
16 mois plus tard alors qu'elle etait
thrombos£e. La troisieme heterogreffe
bovine mise en place chez un hemodialyse chronique de 48 ans presentait
une importante formation anevrysmale a
proximite de I'anastomose arterielle 3.5
mois apres I'implantation. Ces complica
tions evolutives associees aux hetero
greffes bovines illustrent les limites de ce
materiau comme derivation artdrioveineuse. Toutefois, avant de conclure a
la deficience conceptuelle de ce mate
riau, il convient de rapporter de telles faiblesses au pourcentage de greffes
implantees.

Three bovine carotid heterografts, used
for vascular access, were analysed after
removal following the development of
aneurysms in two cases and thrombosis
in one. The first prosthesis was implan
ted in a 17-year-old man who suffered
from myasthenia gravis and was under
going plasmapheresis. It became notably
dilated several months after implantation,
and resection was necessary 14 months
after insertion. The second graft was
placed in a 31-year-old woman being
treated for a severe chronic potassium
insufficiency. It was removed 16 months
after insertion because of thrombosis.
The third bovine carotid heterograft was
inserted in a 48-year-old patient on long
term hemodialysis and was removed 3.5
months later because of aneurysmal dila
tation adjacent to the arterial anastomo
sis. These evolutionary and degenerative
changes associated with the bovine
carotid heterograft illustrate the limita
tions of this material as an interpositional
limb for arteriovenous fistulas in angioaccess therapy. Small weaknesses have
sometimes been noted in the microstruc
ture of the graft material studied before
implantation.
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Universite Laval, et du laboratoire des
biomaterieux, HQpital St-Frangois d ‘A ssise,
Quebec, PQ
Le support financier a ete assure par le
Ministere de la Sante et du Bien-Etre Social
du Canada, la Fondation du Quebec des
Maladies du Coeur et I’Hopital St-Frangois
d ’Assise
*Hopital St-Frangois d ’Assise et Universite
Laval, Quebec, PQ
\H6pital de I’Enfant-Jisus et Universite
Laval, Quebec, PQ
tSir Mortimer B. Davis-Jewish General
Hospital et McGill University, Montreal, PQ
§Clinique Bizet, Paris, France
\H6pital du St-Sacrement et University
Laval, Quebec, PQ
Accepts pour publication le 22 mars, 1983
Les demandes de tires a part doivent etre
adressees au: Dr Robert Guidoin,
Laboratoire de chirurgie experimentale,
Pavilion Agriculture-Services, Local 0712,
University Laval, Quebec, PQ G1K 7P4

Quinton et collaborateurs1 et Brescia et
collaborateurs2 ont largement contribue
au developpement de l’hemodialyse a
long terme en permettant l’acces intermit
tent au sang chez les insuffisants renaux:
le premier a propose la derivation arterioveineuse en silicone immediatement utilisable et le second a developpe la fistule
arterio-veineuse qui requiert une periode
de maturation. Toutefois, ces possibility
peuvent s’epuiser; une derivation arterioveineuse est alors requise. La plethore des
substituts disponibles — heterogreffe
bovine, Teflon microporeux, homogreffe
veineuse, autogreffe veineuse, veine
ombilicale humaine traitee, SparksMandril et polyesters — atteste a l’evidence qu’aucun materiau ne s’impose de
lui-meme. Cette situation se presente non
seulement chez les hemodialyses chroniques mais encore chez tous les malades
pour lesquels un acces intermittent au
sang est requis.
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En effet, les derivations arterio- *
veineuses mises en place chez les hemo
dialyses presentent frequemment des 4
complications evolutives. Elies peuvent
cependant demeurer permeables tres longtemps, en partie a cause de 1’hypo4
coagulabilite associee a l’azotemie.3 Par
contre, les malades presentant des neo- 4
plasies sont susceptibles de developper des
coagulations vasculaires disseminees asso y
ciees a la thrombose de la greffe.4 Les
fistules des malades traites en chimiothe- K
rapie se dilatent rarement car les veines
A
sont tres frequemment sclerosees.5
Nous rapportons l’analyse de trois
heterogreffes bovines Artegraft (Johnson
& Johnson; New Brunswick, NJ) utilisees
comme derivations arterio-veineuses et A
analysees apres exerese. La premiere, •«
implantee chez un jeune homme presen
tant une myasthenie grave et traite par -*
plasmapherese s’etait dilatee. La seconde
mise en place chez une femme tres forte i
ment deficiente en potassium etait thrombosee. La troisieme, mise en place chez A
un homme traite par hemodialyse chro
nique presentait une formation anevris- i
male a proximite de I’anastomose arte
rielle.

Observations

Cas 1
Un homme, age de 17 ans, a presente une
myasthenie grave resistante a toute forme de
traitement medical aux steroides et aux
immuno-suppresseurs. Les plasmaphereses ont
ete alors entreprises en decembre 1978. Une
derivation arterio-veineuse a ete mise en place
au niveau du bras gauche pour permettre Fae
ces au sang. Un segment de 30 cm d ’heterogreffe bovine Artegraft fut implante le 4 avril
1979 entre l’artere axillaire et la veine cephalique. La partie restante de la prothese fut conservee comme reference. La derivation a ete utilisee lors de la serie de cinq seances quotidiennes de plasmapherese consecutives 1 mois plus
tard et toutes les 5 a 6 semaines par la suite.
Chaque seance necessitait l’insertion des deux
aiguilles au niveau de la prothese. Fin 1979,
la greffe presenta des dilatations anevrismales
et devint de plus en plus difficile a ponctionner. Elle fut alors resequee le 8 juin 1980 et preservee aux fins d ’analyse. Une greffe en Teflon
microporeux (GORE-TEX; W.L. Gore &
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Associates, Flagstaff, Ariz.) la remplaga. Elle
thrombosa en aout 1980 puis en septembre
1981; achaque episode, une thrombectomie et
une angioplastie permirent de retablir le flot
sanguin.

Cas 2
Cette patiente, agee de 31 ans, etait traitee
depuis 1972 pour une hypokaliemie profonde.
La premiere hospitalisation remontait a sep
tembre 1972; la patiente se plaignait de douleurs abdominales accompagnees de vomissements et presentait un probleme psychiatrique.
L’histoire de la malade montrait qu’elle avait
egalement ete traitee pour embolie pulmonaire.
L’hypokaliemie profonde a ete corrigee par une
administration abondante de potassium. Une
fistule arterio-veineuse fut mise en place entre
l’artere radiale droite et la veine. La fistule
demeura fonctionnelle jusqu’en 1976, periode
pendant laquelle la malade fut hospitalisee a
plusieurs reprises pour hypokaliemie persistante, vomissements et episodes de pneumonie. Les tentatives pour etablir une derivation

FIG. 1—Cas 1. Surplus de I’heterogreffe. Le
segment de 6 cm insere sur le mandrin de verre
comporte trois collaterals (A) (B), facilement
observables sur la surface luminale lorsque la
greffe est ouverte longitudinalement (C).

arterio-veineuse se succederent alors suite a de
nombreuses complications evolutives: en mai
1976 une heterogreffe bovine Artegraft (HB1)
fut mise en place entre l’artere brachiale gau
che et la veine axillaire. Elle s’infecta peu apres
et le chirurgien dut en pratiquer I’ablation. Une
seconde heterogreffe bovine (HB2) fut alors
mise en place entre l’artere femorale commune
droite et la veine femorale commune. En octobre 1977, a la suite d ’une reintervention chirurgicale au niveau de l’abdomen, la greffe
HB2 thrombosa. Une troisieme (HB3) fut mise
en place entre l’artere femorale gauche et la
veine femorale; elle resta fonctionnelle jusqu’en
septembre 1980, c’est-a-dire pendant pres de
3 ans. Lors de l’ablation, ce specimen fut rinse
et prepare afin d ’etre detaille en microscopie
optique et en microscopie electronique a
balayage (MEB).
Depuis lors, d ’autres methodes de mise en
place de derivations arterio-veineuses furent
tentees: GORE-TEX conique (“ tapered”
GO RE-TEX), GORE-TEX standard et egale
ment Microvel (Meadox Medical, Oakland,
NJ), cette derniere reliant l’artere axillaire gau
che a la veine droite. Quelle que soit l’approche choisie, des revisions furent frequemment
requises.

FIG. 2—Un faible grossissement en micro
scopie electronique a balayage (MEB) revele
des depressions a I’origine d’une collateral et
des plis perpendiculaires a I’axe de la prothese
(reduite par 50% de X 10).

Cas 3
Un homme ne en 1933 etait traite en hemodialyse chronique. Une heterogreffe bovine
Artegraft fut mise en place en juin 1981 sous
forme d ’anse a l’avant bras gauche entre l’ar
tere humerale et la veine cephalique afin d ’assurer l’acces au sang pour les seances d ’hemodialyse. On dut proceder a l’ablation de la
greffe en septembre 1981 suite au developpement d ’une formation anevrysmale favorisee
par les ponctions a proximite de l’anastomose
arterielle et d ’une formation stenotique au
niveau de l’anastomose veineuse.

Analyse pathologique

Les trois greffes furent regues au laboratoire des biomateriaux environ 1
semaine apres que l’exerese ait ete pratiquee dans les centres hospitaliers suivants;
l’Enfant-Jesus a Quebec, le Sir Mortimer
B. Davis-Jewish General Hospital, Mont
real, et la Clinique Bizet, Paris. Elies
furent alors photographiees. Des speci
mens representatifs furent preleves dans
chaque cas puis divises en deux sousspecimens afin de proceder aux prepara
tions suivantes.
• Le premier fut post-fixe dans une
solution de Bouin en vue de l’analyse histologique. Apres la preparation de rou
tine, les colorations suivantes furent pratiquees: a) hematoxyline, eosine et safran
pour Pidentification de la fibrine; b) trich
rome pour l’identification des cellules de
muscles lisse et du collagene; c) Weigert
pour les fibres d’elastine; d) Brown et
Brenn pour demontrer l’existence d’une
colonisation bacterienne; e) von Kossa
pour la mise en evidence d’une calcifica
tion eventuelle.
• Le second est depose dans une solu
tion tamponnee et isotonique de glutaraldehyde a 1.5% puis prepare pour examen

FIG. 3—Meme prothese qu’aux figs. 1 et 2. Segment dont la surface luminale comporte de nombreux plis toujours orientes perpendiculairement a I’axe de la prothese (A) et qui correspondent a une rupture dans la media de I’heterogreffe (B) (reduite par 20%
de x 15 [A], x 50 [B]).
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en MEB, par post-fixation a l’acide osmique, sechage au point critique et recouvrement a ror-palladium.

Resultats
Specimens provenant du cas 1
Controle.—II s’agit de la chute de l’heterogreffe bovine mesurant 6 cm et comportant trois collaterales parfaitement
liees (fig. 1). La surface luminale de la
greffe est parfaitement lisse a l’oeil nu a
l’exception de l’origine des collaterales qui
peuvent servir de point d’ancrage a des
coagulats (fig. 2). Toutefois, l’observation de la surface luminale en MEB
demontre la presence de plis selon un axe
perpendiculaire a la direction du flot sanguin; ces plis constituent des lignes de faiblesse (fig. 3).
Specimen obtenu apres exerese.—a
l’oeil nu, la greffe presente une section
tres irreguliere et les imperfections de sur
face sont nombreuses. Cette greffe ne pre
sente aucun manchon de fibrose a l’exterieur. En microscopie optique, on note
une importante sclerose sous-intimale,
tres irreguliere et qui donne un relief pro
nonce a la surface exposee au flot sanguin. Dans les zones particulierement
dilatee, on observe des depots lipidiques
dans la media; ceux-ci ont entraine une
distension de la structure. Notons egalement l’absence de calcification. La MEB
permet de confirmer ces observations. La
surface de la lumiere presente des aspects
variables; les debris de materiel thrombotique sont frequents mais peu importants.
Ils component essentiellement de la
fibrine et des elements figures. Notons
egalement la presence de plis perpendiculaires a l’axe de la greffe; a l’image de
ceux observes sur la prothese vierge, ils
correspondent a une media tres endommagee, done moins resistante au debit
pulse et susceptible de donner lieu a une
accumulation de materiaux lipidiques
(figs. 4 et 5).
Specimen HB3 obtenu dans le cas 2
Cette greffe a ete re?ue thrombosee.
Dans la majorite de la longueur, la sec
tion de la lumiere exposee au flot sanguin
est inferieure a 10% de la section originale. La paroi prothetique est plissee en
accordeon et presente une reaction fibreuse externe tres importante. La lu
miere est recouverte de fibrine compactee et de depots lipidiques abondants
(fig. 6).
Specimen obtenu dans le cas 3
II s’agit d ’un segment de quelques cen
timetres anastomose a l’artere humerale.
La surface luminale est depourvue d ’accumulation im portante de materiel
74

FIG. 4—Cas 1. Heterogreffe apres exerese. Diametre variable comportant de nombreuses
irregularites de surface (A). Depot de materiel cruorique dont la morphologie varie selon la
structure de la surface sous-jacente; lorsqu’elle est lisse, les depots sont peu adhesifs mais plus
importants (B, x 200); ils sont plus diffus lorsque la surface est plus irreguliere (C, x200).
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thrombotique. Les sillons perpendiculaires a l’axe de la prothese constituent des
^ sites privilegies sur lesquels se deposent
des plaquettes et de la fibrine sans qu’il
^ y ait veritablement accumulation. A
. proximite de l’anastomose, des llots de
^ cellules endotheliales s’etendent sur quelj, ques millimetres (fig. 7). La microscopie
optique confirme l’epaississement fibreux
v sous-intimal avec des foyers de sclerose.
II n’existe cependant ni calcification, ni
► colonisation bacterienne.
Discussion
v

L’acces au sang chez les hemodialyses
est deja fort complexe puisque les comk plications evolutives associees aux deriva
tions arterio-veineuses sont relativement
- frequentes. Les thromboses apparaissent
quel que soit le substitut choisi; les hemork ragies, les infections et les dilatations
anevrismales sont egalement rapportees.6 Par ailleurs, toute derivation
j arterio-veineuse peut entralner une sur

F

charge cardiaque si le debit sanguin est
trop eleve; ce dernier doit alors etre reduit
surtout en presence de cardiopathies
ischemiques ou d ’anemie, meme si les
derivations arterio-veineuses a debit
sanguin eleve sont susceptibles d ’avoir
une duree de vie prolongee.7
Neanmoins, meme si l’hemodialyse
constitue l’application majeure des
d erivations arterio-veineuses, les
plasmaphereses prennent une place
croissante parmi les approches therapeutiques employees: traitement des paraproteinemies, de certaines anemies hemolytiques, de maladies a complexes immuns,
ainsi que des affections ou elle a ete tentee
a titre plutot experimental et theorique
mais ou elle s’est souvent revelee relative
ment satisfaisante (asthme, maladie de
G u illain -B arre). Dans le cas de
myasthenie grave dont la pathogenese se
precise, il existe des anticorps circulants
diriges contre les recepteurs d ’acetylcholine. Dau et collaborateurs8 puis Pin
ching et collaborateurs,9 suite a la com
prehension de la pathogenese de la

myasthenie grave avec les anticorps antirecepteurs d ’acetylcholine, ont traite
des malades par echange plasmatique a
flux continu et immuno-suppression
(prednisone et azathioprine). II s’en est
suivi une diminution des taux des an
ticorps specifiques accompagnee d ’une
fonction electromyographique amelioree
avec augmentation de la capacite vitale et
de la force musculaire.10 Bien que le pronostic a long terme demeure inconnu, il
semble que les benefices de l’echange
plasmatique soient accrus par l’utilisation
simultanee d ’immuno-suppresseurs et de
substances cytotoxiques.
La chimiotherapie constitue une autre
application possible dont 1’importance est
difficile a evaluer; les catheters qui cons
tituent une alternative interessante presentent une certaine incidence de thrombophlebites. De plus, la derivation prothetique, pour ce type d ’application precise,
peut etre plus satisfaisante que la fistule
de Cimino-Brescia: la majorite des cancereux ont deja re?u de nombreux medi
caments sclerosants avant que la question

FIG. 5—Cas 1. Correlation entre I’etat de la surface luminale et I’epaississement des parois. L’importante sclerose sous-intimale tres
irreguliere donne un relief prononce a la surface exposee au flot sanguin qui comporte des depots thrombotiques irreguliers mais relativement
peu importants. Les lipides s'accumulent dans la paroi de I’heterogreffe, ce qui entraine une distension de la structure (reduite par 24%, de
x 20 [A], x 500 [B,C], x 1000 [D]).
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de Faeces au sang se soit posee. Alors que
le malade uremique est en general hypocoagulable, consequence de l’azotemie, le
cancereux, a l’inverse, developpe frequemment une tendance aux thromboses
veineuses ou une coagulation intravasculaire disseminee qui peut entrainer
des hemorragies ou des thromboses
arterielles.11
L’hyperalimentation intra-veineuse, le
traitement de deficiences diverses ou du
diabete apparaissent comme des applica
tions additionnelles des derivations
arterio-veineuses. La diversite des problemes poses, comme la variete des proprie
t y thrombo-hematologiques du receveur,
requierent des considerations particulieres lors de chaque mise en place de deri
vations prothetiques. Le bon jugement du
chirurgien vasculaire est alors essentiel.
Toute definition d ’une regie generate de
conduite serait presomptueuse car chaque
cas merite une reflexion particuliere.
Lorsque le besoin d ’un acces au sang a
ete reconnu, le chirurgien doit alors
rechercher la methode la mieux adaptee
au probleme a resoudre. La plethore des
moyens disponibles montre clairement
q u ’aucun d ’entre eux n ’offre toutes les
garanties requises. Un substitut ideal
devrait: a) etre immediatement utilisable,
b) etre resistant a la thrombose, c) etre
resistant a l’infection, d) presenter une
excellente capacite de cicatrisation, e) etre
stable et conserver son integrite physique
en particulier ne pas dechirer aux points
de penetration et f) etre tres etanche pour
permettre l’administration du substances
necrosantes.
A l’exception du shunt en elastomere
de siloxane propose par Quinton et
collaborateurs,1 toutes les autres greffes
qu’elles soient biologiques (autogreffe veineuse, homogreffe veineuse), biologiques
traitees (veine ombilicale humaine, heterogreffe bovine), allo-plastiques (polyes
ter ou Teflon microporeux) ou mixtes
(Sparks-Mandril) requierent un temps de
maturation minimale qui correspond a la
duree necessaire pour permettre la passi
vation de la surface luminale exposee au
flot sanguin.
Comment classer Theterogreffe bovine
dans la panoplie des differentes prothe
ses disponibles? S’agit-il d ’une prothese
conceptuellement defectueuse comme certaines publications devastatrices semblent
l’indiquer? En effet, plusieurs auteurs
s’attardent a rapporter cas par cas des for
mations anevrismales12 mais d ’autres
illustrent l’interet de cet abord13 malgre
ses faiblesses.14,15
Le probleme de base lorsqu’on utilise
du materiel biologique est de s’assurer que
Ton dispose d ’un materiel de qualite. Les
controles pathologiques et microbiologiques requierent peu de materiel et peuvent
se faire a partir des extremites. II s’agit
en fait d’examens par microscopie opti76

F1G. 6—Cas 2. Greffe thrombosee dont la section de la lumiere est considerablement reduite
(A, x 20). La paroi prothetique plissee en accordeon a suscite une reaction fibreuse importante
(B, x 100). Des depots de fibrine compactee recouvrent la surface luminale et comportent des
depots lipidiques abondants (C, x 1000).
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que et de controle de sterilite. Mais il faut
aller plus loin. II est important de connaitre la cytocompatibilite et la qualite de la
►
surface. L’examen avec des fibres optidevrait permettre de rejeter les pro
t ques
theses dont la surface luminale est endom► magee, qu’il s’agisse de traumatismes
consecutifs a la preparation ou d’une
mauvaise selection du materiel original.16
Par ailleurs, la mesure de [’impedance
electrique devrait permettre de selectionner les arteres recoltees a l’abattoir avec
b
plus de securite.17

C o n clu sio n s

De tels exemples de complications evolutives associees a [’utilisation d’heterogreffes bovines illustrent les limites de ce
materiau comme derivation arterioveineuse. Avant de conclure a sa deficience conceptuelle, il convient de rapporter de telles faiblesses au pourcentage de
greffes implantees. S’agit-il seulement
d’un controle de qualite insuffisant ou
inadapte? Il est difficile d’etre affirmatif
car le jugement du chirurgien et la tech

nique chirurgicale sont des elements deter
minants dans le succes ou l’echec d ’une
derivation arterio-veineuse.18
Nous tenons a exprimer notre plus vive gra
titude aux docteurs L. Levasseur, J. Couture,
G. Roy et G. Drouin pour leur encourage
ments. La collaboration technique de M.
Bedros, L. Berryman, S. Bourassa, A. Dion,
D. Lafreniere-Gagnon et A. Savard nous a ete
des plus utiles. Nous voulons egalement remercier le personnel infirmier de l’hopital de
l’Enfant-Jesus, du Sir Mortimer B. DavisJewish General Hospital et de la Clinique Bizet
pour leur aide.

b
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^.Musculo-Skeletal - Rarely, prolonged muscle relaxation.
Other-Superinfection, including candidiasis.
OSAGE AND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously by injec!on or infusion. Dosage and route of administration should be determined by the severity of the infection and
ondition of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a 20 to 30
linute infusion administered intravenously.
The maximum daily dose usually administered to adults is 24 g/day, although higher doses have been used.

DOSAGE
Type of Infection
Serious infections such as septicemia, nosocomial pneumonia, intraabdominal infections, aerobic and anaerobic gynecologic infections,
and skin soft-tissue infections.
Complicated urinary tract infections.
Uncomplicated urinary tract infections and most community-acquired
pneumonia.
Uncomplicated gonococcal urethritis.

Usual Total
Daily Dosage
12-18 gl.V.
(200-300 mg/kg)

Frequency of
Administration

8-16 gl.V.
(125-200 mg/kg)
6-8 g I.M. orl.V.
(100-125 mg/kg)
2 g I.M*

Every 6 to
8 hours
Every 6 to
12 hours
Single dose

Every 4 to
6 hours

*One gram of probenecid given orally 1/2 hour prior to injection.
Dosage In Renal Impairment
Creatinine
Clearance
mL/min.

Urinary Tract
Infection
(uncomplicated)

>40

No dosage adjustment necessary
No dosage adjustment necessary

20-40
<20

Urinary Tract
Infection
(complicated)

Serious Systemic
Infection

12 g/day 4 g every 8 hrs.
9 g/day 3 g every 8 hrs.
8 g/day 4 g every 12 hrs.
6 g/day 3 g every 12 hrs.
6 g/day 3 g every 12hrs.
•Hemodialysis removes 30-50% of piperacillin in 4 hours;
6 g/day 2 g every 8 hrs.
1 g additional dose should be administered following each dialysis period.

Patients on
Hemodialysis*
For patients with renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* will provide
additional guidance for adjusting dosage.
Infants and Children - Dosages in infants and children under 12 years of age have not been established.
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in which
it is from 3 to 10 days; the duration should be guided by the patient's clinical and bacteriological progress. For most
acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asympto
matic. Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 days to
reduce the risk of rheumatic fever of glomerulonephritis.
ADMINISTRATION
0 ^
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular administration of 6 to 8 g. daily
of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for mainte
nance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin sodium
treatment. Administration should not exceed 2 g. per injection at any one site. This route has been used primarily in
the treatment of patients with uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12 Years of Age: The reconstituted solution is given by deep intramuscular injection. The
preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also may be given in the
mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and then only with caution
to avoid radial nerve injury. Intramuscular injection should not be made into the lower or mid-third of the upper arm.
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted with 5 mL of suitable diluent listed below
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation.
Intravenous Infusion: A dilution of at least 15 m l per gram is recommended to reduce potential for vein irritation.
The reconstituted and diluted solution may be administered by intermittent or continuous drip. Intermittent infusion
should be administered over a period of about 30 minutes. During intermittent infusion it is desirable to discontinue
the primary intravenous solution Any unused portion must be discarded. For continuous infusion the solution may
be administered over a longer period of time.
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for Injection, or if required
•Bacteriostatic Water for Injection,
**Lidocaine HC1 0.5 or 1% (without epinephrine)- For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required,
'Bacteriostatic Water for Injection.
‘ Either parabens or benzyl alcohol.
**Lidocaine HC1 is contraindicated in patients with a known history of hypersensitivity to local anesthetics of
the amide type.
RECONSTITUTION TABLE
Approximate
Approximate
VOLUME OF
Product
Average Concentration
Available Volume
Diluent to be added
Size
1 g/2.5 mL
5.0 mL
4.0 mL
Vials 2 g
1 g/2.5 mL
7.5 mL
6.0 mL
3g
1 g/2.5 mL
10.0 mL
7.8 mL
4g
Infusion Bottles
17 mL
15 mL
3g
23 mL
20 mL
4g
The prepared solution may be further diluted to the desired volume with any of the solutions for intravenous
infusion listed below.
The contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram.
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing
any of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Admixtures:
Intravenous Solutions:
Normal Saline (+KCL 40 mEq).
5% Dextrose in Water [D5W]
5% Dextrose/Water [D5W] (-H(CL 40 mEq).
0.9% Sodium Chloride (Normal Saline) [NS].
5% Dextrose/Normal Saline [D5NS] (+KCL 40 mEq).
Dextrose 5% and 0.9% Sodium Chloride [D5NS].
Ringer’s Injection, U.S.P. (+KCL 40 mEq).
Lactated Ringer’s Injection, U.S.P.
Lactated Ringer’s Injection, U.S.P. (+KCL 40 mEq).
Dextran 6 % in 0.9% Sodium Chloride.
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted with recom
mended diluents and further diluted with the indicated intravenous solution and intravenous admixtures.
Stability studies have demonstrated chemical stability (pH, potency and clarity) through 24 hours at room
temperature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recom
mends discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated. If used
as a multi-dose container, the vials must be reconstituted only with the bacteriostatic diluents noted above.
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous administration with
solutions containing sodium bicarbonate
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently with aminoglycosides, it is recommended that both drugs be used in full
therapeutic doses, but administered separately. PIPRACIL* should not be mixed with an aminoglycoside in a
syringe or infusion bottle, since this can result in inactivation of the aminoglycoside.
DOSAGE FORMS: PIPRACIL* (sterile, lyophilized piperacillin sodium) is available in vials containing amounts of pipera
cillin sodium equivalent to 2 ,3 and 4 grams of piperacillin. Available in boxes of 12 vials.
Product Numbers: 2 g /v ia l-3879-48 3 g/vial- 3882-49 4 g/vial- 3880-50
Available in 100 mL size infusion ( "piggyback”) bottles, containing sterile, freeze-dried piperacillin sodium
powder equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles.
Product Numbers: 3 g/bottles - 3882-41 4 g/bottles- 3880-42
Piperacillin Sensitivity Discs impregnated with 100 ug of piperacillin are also available.
Storage:
PIPRACIL* vials and infusion bottles should be stored at controlled room temperatures of 15-30°C (59-86°F).
Piperacillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request.
‘ PIPRACIL is a trade mark of Lederle Piperacillin, Inc.
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Operative Myocardial Protection: Does an Elevated Level
of Creatine Phosphokinase-MB Isoenzyme Always Indicate
Myocardial Necrosis?
Creatine p h o sp h o k in a s e -M B isoenzym e
appears in the serum of virtually all pa
tients w ho ha ve un d ergon e cardiac
operations, but w hether it represents
m yocardial cellular n e cro sis rem ains c o n 
troversial. In 17 adult patients w h o
underw ent coron a ry artery b y p a ss graft
ing or valve replacement, serial deter
m inations o f the serum levels of creatine
p h o sp h o k in a se -M B isoenzym e, ultrastructural studies o f left ventricular m yocar
dium before aortic cross-cla m ping and
1 0 m inutes after reperfusion and
p ostoperative electrocardiographic
recordings w e re undertaken. The isoen
zym e w as detected in all patients; those
ha v in g valve replacem ent had higher
peak values than those w h o underw ent
coronary artery b y p a ss grafting. N o cor
relation w a s foun d betw een the duration
of aortic cro ss-cla m p in g and the peak
level of isoen zym e after reperfusion. In
spite of appreciable isoen zym e release
from the m yocardium , all the specim ens
obtained from this series of patients
after reperfusion sh o w e d m yocardial
ultrastructural c h a n g e s indicative of mild
to moderate ische m ic dam age, c o n 
sidered to be reversible according to the
criteria described by J e n n in g s and
Schaper. Excep t for one n e w Q w ave,
electrocardiographic c h a n g e s in this
series were no n sp e cific and transient. It
is postulated that w h en sufficient
m yocardial m a s s is involved, such a s in
global ischem ia during cardiac surgery,
the M B isoen zym e of creatine
p h o sp h o k in a se leaked from reversibly
dam aged m y o c y te s m ay becom e detect
able and elevated in the serum . Thus,
alth ough the iso e n zy m e rem ains a sen-
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sitive indicator of m yocardial protection,
its presence d o e s not necessarily
indicate irreversible dam age and
m yocardial necrosis.
L 'iso e n zym e creatine p h o sp h o k in a se -M B
apparait d a n s le serum de virtuellement
tous les patients qui ont subi une opera
tion cardiaque. S o n rapport possible avec
une ne crose d e s cellules m yocardiques
fait I’objet d 'u n debat. O n a pratique
chez 17 adultes qui ont subi un pontage
aorto-coronarien ou un remplacement
valvulaire, des determ inations sdriees de
concentrations seriques de l'isoe nzym e
creatine p h o sp h o k in ase -M B , des etudes
des ultrastructures du ventricule gauche
avant la circulation extracorporelle et 10
m inutes apres la reperfusion, et des
enregistrem ents electrocardiographiques.
L'iso e n zym e a ete decele chez tous les
patients; ceux qui ont subi un remplace
ment valvulaire avaient des concentra
tions m a xim u m s d 'iso e n zym e superieures
a celles des m alades qui ont subi un pon
tage aorto-coronarien. A u cu n e correlation
n 'a ete retrouvee entre la duree de la cir
culation extracorporelle et la concentra
tion m axim um d 'iso e n zy m e apres reper
fusion. En depit d 'u n e liberation
d 'iso e n zym e im portante du myocarde,
tous les echantillons obtenus apres
reperfusion ont m ontr6 des changem ents
des ultrastructures m yocardiques com pa
tibles avec des do m m age s ischem iques
legers a m oye ns, consideres com m e
reversibles d a p r e s les critdres decrits par
Jen ning s at Schaper. A I'e xception d 'u n e
nouvelle onde Q, to u s les changem ents
electrocardiographiques etaient non specifiques et transitoires. II est postule que
quand une m a sse suffisante du m yo 
carde est impliquee, com m e c 'e s t le cas
lorsqu'il y a une ischem ie globale durant
une operation cardiaque, I'iso e n zym e -M B
de la creatine p h o sp h o k in a se qui
s'e c h a p p e des m y o c y te s endom m ages
de facon reversible peut devenir decela
ble et atteindre une concentration elevee
dans le s£rum . En consequence, bien que
cet isoen zym e dem eure un indicateur
sensible de la protection m yocardique, sa
presence ne signifie pas n6cessairem ent

q u'il y ait eu des dom m age s irreversibles
et une ne crose myocardique.

Controversy persists as to whether an in
crease in the serum level o f the myo
cardial-specific creatine phosphokinaseMB (C K -M B ) isoenzyme always indicates
myocardial cellular necrosis, or if it may
also indicate certain reversible myocardial
damage.1-4
The serum level o f creatine phospho
kinase-MB isoenzyme has for a number
o f years been used to diagnose myocar
dial infarction.1-5 Mathematical formulas
have been derived to estimate infarct
size, using the amount o f isoenzyme in
the serum.6 Such formulas are based on
the hypothesis that serum creatine phos
phokinase-MB isoenzyme is released from
necrotic cells and not from viable
ischemic cells. However, in the recent
literature, there have been reports o f the
isoenzyme appearing with myocardial in
juries that may be reversible and
temporary,2'4 such as minor precordial
trauma, cardioversion, cardiac operations
and cardiomyopathy. In contrast, some
authors still maintain that its appearance
is pathognomonic o f myocardial infarc
tion and irreversible myocardial cell
death.57 This controversy prompted us
to re-examine the serum levels o f creatine
phosphokinase-MB isoenzyme in our pa
tients who underwent cardiac surgery. By
correlating the perioperative isoenzymatic, ultrastructural and electrophysiologic changes, we investigated the
relation o f this isoenzyme to reversible
versus irreversible injury and determined
its role as an index o f effective myocar
dial protection.
Patie n ts

Seventeen patients who underwent car
diac surgery were studied; 9 had coronary
artery bypass grafting for stenosis o f one
to three coronary arteries and 8 had either
mitral or aortic valve replacement. A ll 17
patients were placed on cardiopulmonary
bypass and the heart arrested with a cold
crystalloid solution, com posed o f
Norm osol-R (containing 0.69 mmol/L
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During the operations, full-thickness
myocardial specimens were taken from
the anterior left ventricle using a Baxter
“ T ru -C u t” biopsy needle (Baxter
Laboratories of Canada Ltd., Malton,
Ont.) just before aortic cross-clamping
and again 10 minutes after removal of the
clamp and coronary reperfusion. The
myocardial samples were immediately fix
ed in glutaraldehyde solution and process
ed for electron microscopic examination.
Serial blood samples were drawn for
determination of the serum creatine
phosphokinase-MB isoenzyme levels after
the induction of anesthesia, after
thoracotomy, at aortic cross-clamping, 10
minutes after reperfusion, then every
hour for 6 hours and again 24 to 36 hours
postoperatively. The Gelman CPK isoen
zyme electrophoresis system (Gelman
Sciences, Ann Arbor, Mich.) was used for
the determinations.8
Statistical analysis of the results was by
the unpaired Student’s /-test.

Mg++ and 7 mmol/L K +) 1000 ml;
potassium chloride 20 mmol; sodium
y bicarbonate 25 mmol; lidocaine 0.5 g and
dextrose 17 g; pH 7.4 and osmolarity 383
| mOsm/L.
After the aorta was cross-clamped, the
* cardioplegic solution was administered at
^ 4°C through the aortic root. In patients
undergoing aortic valve replacement, the
aorta was incised and the solution ad
ministered by direct cannulation of the
> coronary ostia. Both topical cooling and
additional cold cardioplegic solution were
used to maintain an intramyocardial
temperature of less than 25°C. The in
tramyocardial temperature was monitor, ed by thermistor probe and checked
periodically throughout the procedure.
,, Global ischemia in these patients ranged
from 36 to 159 minutes.
r
Electrocardiograms were obtained for
evaluation preoperatively, immediately
postoperatively and for 2 days after
, operation for signs of ischemia and in
farction. The electrocardiograms were
i analysed by cardiologists w ithout
knowledge of the study.

Results
All patients survived the study period.

Clinically, 15 patients did well post
operatively. Two patients required ino
tropic support during the early post
operative period.
Creatine Phosphokinase-MB Isoenzyme
The isoenzyme appeared in the serum
of all patients. There was a significant dif
ference (p < 0.001), however, between
the peak level of enzyme released by the
coronary graft and valve-replacement
procedures, that in the valve-replacement
group being much higher (Fig. 1).
There was also a significant difference
(p < 0.05) in the length of time it took
for the isoenzyme to reach its peak (Fig.
2 ).
The pattern for both procedures was
one in which the isoenzyme peaked and
dropped to a very low level or was
undetectable in the serum by 24 hours
after operation. In Fig. 3 we plotted each
patient’s peak level against the length of
time the aorta was cross-clamped. The pa
tients who underwent coronary artery
bypass showed a horizontal pattern on the
graph while those who had valve replace
ment had a vertical pattern. Both groups
showed poor correlation between the
peak isoenzyme levels and duration of
aortic occlusion.
Electrocardiography
Changes in the ST segment and T wave
indicative of ischemic episodes occurred
postoperatively in all patients. These
changes could also be related to pericar
ditis, electrolyte imbalances and drugs ad
ministered. Q waves already present from
older infarctions persisted. In only one
patient did a new Q wave appear.
Electron Microscopy

FIG. 1—Mean (± standard error) peak
r serum values of creatine phosphokinase-MB
isoenzyme (CPK-MB) for patients who underv went coronary artery bypass grafting (CABG)
and valve replacement (p < 0.001).

FIG. 2—Mean ( ± SEM) time (min) to
reach peak isoenzyme values after reperfusion
in patients who underwent CABG and valve
replacement (p < 0.05).
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FIG. 3—Aortic cross-clamp time (minutes) versus peak serum level (IU /L) o f CPK-MB
isoenzyme for two patient groups, r = correlation coefficient.

The prearrest and early reperfusion
biopsy specimens from all patients show
ed varying degrees of ultrastructural
change. The changes were classified as
reversible or irreversible, using as
guidelines the ultrastructural assessment
of the ischemic myocardium of Jennings
and colleagues9 and Schaper and
colleagues.10 Ultrastructural changes in
dicative of reversible injury were aggrega
tio n and m argination o f nuclear
chromatin, mitochondrial swelling, mild
sarcomere distortion and some in
tracellular edema. Criteria used for deter
mining irreversible injury were marked
aggregation and margination of the
nuclear chromatin to shrinkage of the
nucleus, clearing of the mitochondrial
matrix, disruption of the mitochondria,
amorphous densities or calcium deposits
in the mitochondria, contraction bands or
marked distortion of the sarcomeres and
vacuoles within the cell from increased
edema. In all our biopsy specimens, the
ultrastructural changes were graded from
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mild to moderately severe reversible
damage (Fig. 4).
Discussion

It is now known that serum creatine
phosphokinase-MB isoenzyme appears in
almost all patients after cardiac surgery.
However, if isoenzyme is released only
after irreversible damage or necrosis of
the cells, then we should find evidence of
cell death by either morphologic or elec
trocardiographic changes. In this study,
our findings were not consistent with the
hypothesis that creatine phosphokinaseMB isoenzyme release occurred only after
necrosis.
A possible answer to this controversy
is the hypothesis that the amount of
isoenzyme release per cell increases with
increased damage to that cell. The earlier
impression that the isoenzyme appeared
only after necrosis was probably due to
the lack of sensitivity in detecting it by the
early test techniques. The assay is now
more sensitive and much lower levels of
isoenzyme can be measured perioperatively, but its appearance is often found to
be o f no clinical importance. If a cell can,
in fact, release creatine phosphokinaseMB isoenzyme without being irreversibly
damaged, then the serum level should de
pend not only on the number of cells in
jured but also on the extent of injury.
Thus, conceptually: ECK-MB leaked =
(CK-MB leakage/cell) x (myocardial
mass involved). It follows that an increas
ed serum level of creatine phosphokinaseMB isoenzyme could be accounted for
either by localized but severe damage as
in clinical myocardial infarction, or by
diffuse yet reversible damage such as is
seen after global ischemia in cardiac
surgery. In regional myocardial ischemia
(angina) without necrosis, a relatively
small amount of isoenzyme leaking from
each cell and the limited myocardial mass
involved may render it difficult to detect
the isoenzyme in the serum. This may
have led many cardiologists to believe that
the isoenzyme cannot escape from
myocytes unless irreversible infarction has
occurred.
Why the patients who underwent valve
replacement had higher levels than cor
onary artery graft patients is not clear.
We speculated that left ventricular apical
venting used in our valve-replacement
cases might have been contributory. To
determine whether creatine phospho
kinase-MB isoenzyme could rise from a
small incision in the left ventricular
apex, a patient, not in this series, who
underwent a closed mitral valve com
missurotomy was studied. A valve dilator
was introduced from the left ven
tricular apex, with iatrogenic myocardial
injury comparable to that occurring with
left ventricular venting. No cardioplegia
was induced and no cardiopulmonary
82

bypass was used. The isoenzyme levels re
mained low (5 IU/L). Certainly before
any definite conclusion may be drawn
from this case, more such patients need
to be studied. Interestingly, in spite of
higher levels of isoenzyme found in valvereplacement cases, the ultrastructural
findings were comparable to those of cor
onary bypass cases and the postoperative
courses in each case were uncomplicated.
M easurem ent o f the creatine
phosphokinase-MB isoenzyme level has
been used by other investigators to assess
myocardial protection. Strom and
associates11 reported that the levels cor
related with the duration of aortic cross
clamping, and that after 70 minutes of
aortic occlusion the level increased con
siderably. We did not find such a correla
tion; the difference between our results
may be due to different techniques of
myocardial protection practised by
Strom’s group. In their study, the
myocardial protection was by systemic
moderate hypothermia, local cooling and
electrical fibrillation of the heart. In con
trast, findings similar to ours were
reported by van der Laarse and
associates.12
The one patient in this series who had
a new Q wave postoperatively recovered
well. His peak isoenzyme level was only
20 IU /L. Unmasking of old Q waves has
been described and this may be the ex
planation h ere.13 The electrocar
diographic change following most of
present-day cardiac surgery is too
nonspecific and insensitive for assessing

myocardial protection and quantifying
the amount of ischemic injury.13-16
Ultrastructural assessment of the
myocardial ischemic injury is extremely
sensitive. H owever, the inherent
drawbacks of this method markedly
reduce its usefulness as a routine clinical
tool. Biopsy of the myocardium is done
reluctantly and not without risk. Only
relatively few myofibres may be examined by electron microscopy, and even with
random sampling the possibility of missing lesions exists. Small focal lesions will
be found only by serendipity. The results
would be improved with multiple biop
sies, but such maneuvers are not clinically . desirable.
The cost o f electron
.
.
microscopy in time and money would
make it less suitable for routine use.
Conclusions
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Although the serum level of creatine <
phosphokinase-MB isoenzyme is known
to increase in irreversible myocardial in- *
juries, our findings are consistent with the ,
hypothesis that it may also be detected in
reversible damage if the myocardial mass u
involved is sufficiently large. It is still
possible that the serum isoenzyme levels ifound in our patients came from small ir
reversible focal injuries that are undetec
table with the diagnostic methods used in
this study. Further investigations using ra- T
dionuclide imaging are desirable. The MB
isoenzyme of creatine phosphokinase,
*
nevertheless, remains a sensitive indicator
of myocardial damage, but it should not

FIG. 4—Electron photomicrograph of left ventricle after 60 minutes of aortic cross-clamping J
and 10 minutes of reperfusion shows reversible injuries. There are swelling mitochondria, disrup
tion of cristae, early contraction band formation and slight edema. Peak level (11 IU/L) of
4
isoenzyme in this patient was at 3 hours 15 minutes after reperfusion. Electrocardiogram show
ed no sign of perioperative infarction (reduced by 18% from x 7250).
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be used alone to diagnose myocardial in
farction perioperatively.
The authors appreciate the cooperation of
Drs. H.J. Scott, P.E. Blundell and D.S.
7 Mulder in obtaining myocardial biopsy
specimens, and Ms. Connie Goodberry for the
►electron microscopic study.

*

References
1. R o b e r t s R, G o w d a KS, L u d b r o o k PA , S o b e l BE:
Specificity o f elevated serum M B-creatine phosphokinase
activity in the diagnosis o f acute m yocardial infarction.
A m J Cardiol 1975; 36: 433-7

y

►
2. M a r m o r a , A l p a n G , K e id a r S, G r e n a d ir E,
P a l a n t A : The M B isoenzym e o f creatine kinase as an
indicator o f severity o f m yocardial ischaemia. Lancet
1978; 2: 812

y

y

3. L in d s e y D, N a v in T , F in l e y P: M eaning o f elevated
CK-M B (C). A m Heart J 1979; 98: 405-6
V-

4. M a r m o r A , K e id a r S, G r e n a d ir E, P a la n t A : MB
isoenzym e o f creatine phosphokinase. Indicator o f
ischem ia in coronary arterial disease. Chest 1979; 75:
88-90

y

5. R o b e r t s R, S o b e l BE: C reatine kinase isoenzymes in
the assessm ent o f heart disease. A m Heart J 1978; 95:
521-8

4
6. R o b e r t s R , H e n r y PD , So b e l BE: A n improved basis
for enzymatic estimation o f infarct size. Circulation 1975;
52: 743-54

^

7. ROBERTS R: Meaning of elevated CK-MB (C). Am Heart
J 1979; 98: 406

^

^

y
*

y

r

^

y

y
^

An abstract, in both English and French, about 125 words long, should accom 
pany each article, on a separate page.
Authors will receive a copy o f the edited m anuscript for approval before publica
tion but will not receive galley proofs.

Directives aux collaborateurs
Les textes originaux des articles et des autres communications y compris un nombre limite de rapports sur des cas speciaux doivent etre rediges en triplicata, en
frangais ou en anglais, et accompagnes d ’une lettre demandant leur publication
dans le Journal. Veuillez les dactylographier sur une seule face d'une feuille non
reglee avec double interligne et grandes marges.

12. VAN DER LAARSE A , DAVIDS HA, HOLLAAR L, VAN DER
Va lk E J, W it t e v e e n SA, HERMENS WT: Recognition
and q uantification o f m yocardial injury by m eans o f
plasm a enzyme and isoenzyme activities after cardiac
surgery. Br Heart J 1979; 41: 660-7

13. B a ss a n m m , O a t f ie l d R, H o f f m a n I, M a t l o f f J,
S w a n H JC : New Q waves after aortocoronary bypass
surgery; unm asking o f an old infarction. N E ngl J Med
1974; 290: 349-53

>-

15. K l e in H O , GROSS H , R u b in IL: T ransient electrocardiographic changes simulating myocardial infarction d u r
ing open-heart surgery. Am Heart J 1970; 79: 463-70

*f

References should be cited by number in the text, in order of occurrence, and
listed at the end of the article in the style used in this issue of the Journal. In general,
references to journals should follow the style used in this issue.

9. J e n n in g s RB, H a w k in s HK , L o w e JE , H il l M L,
KLOTMAN S, REIMER KA: R elation between high energy
phosphate and lethal injury in m yocardial ischemia in the
dog. A m J Pathol 1978; 92: 187-214

14. RUCKER C M , DUGALL JC , GANTER E L, KARTUB MG:
T he detection o f perioperative m yocardial infarction in
aortocoronary bypass surgery. Chest 1979; 75: 300-5

A-

Tables, the design of which is best considered in regard to the rectangular form at
o f the Journal, should be submitted separate from the text, one to a page.

Toute communication initiate doit etre adressee aux coredacteurs, CP 8650,
Ottawa, Ont. K1G 0G8 sous la mention: “ Le journal canadien de chirurgie” .

11. S t r o m S, B e n d z R, O l in C , L u n d b e r g S: Serum en 
zymes with special reference to CK-M B following co r
onary bypass surgery. Scand J Thorac Cardiovasc Surg
1979; 13: 53-9

Y

All initial communications should be addressed to the Coeditors, PO Box 8650,
Ottawa, Ont. K1G 0G8 and marked The Canadian Journal of Surgery.
Manuscripts of original articles and other contributions, including a limited number
of case reports, should be submitted in triplicate, in English or French, with a cover
ing letter requesting consideration for publication. They should be typed on one
side o f plain paper, double spaced with wide margins. Measurements should be
expressed according to the Systeme internalional d'unites if possible.
Illustrations (e.g., photographs of clinical material, radiographs, photomicrographs,
graphs and diagrams), in triplicate, m ust be in the form o f glossy, unmounted and
untrimmed prints, not larger than 20 x 25 cm. A legend must be supplied for each;
the legend(s) should be typed on a page separate from the text of the article. For
a roentgenogram submit a print rather than the original; for a photomicrograph
include details of the stain and magnification in the legend. Lettering identifying
parts o f the illustration should be large enough to remain visible when the illustra
tion is reduced in size for publication. A patient must not be recognizable unless
the patient’s written consent has been obtained; otherwise facial features may
require blocking. Colour work can be published only at the author’s expense. If
an illustration is taken from a source other than the author’s, letters o f perm is
sion to reproduce the illustration must be obtained from the original publisher and
author.

8. ALEYASSINE H , TONKS D B , K a y e M: N a tu ra l
fluorescence in serum o f patients with chronic renal
failure not to be confused with creatine kinase-MB isoenzyme. Clin Chem 1978; 24: 492-4

10. Sc h a p e r J , M u l c h J, W in k l e r B, Sc h a p e r W:
U ltrastructural, functional, a nd biochem ical criteria for
r
estim ation o f reversibility o f ischem ic injury: a study on
the effects o f global ischemia on the isolated dog heart.
J M ol Cell Cardiol 1979; 11: 521-41

.

Instructions to Contributors

16. K l e in MS, C o l e m a n RE, W e l d o n CS, So bel BE,
ROBERTS R: C oncordance o f electrocardiographic and
scintigraphic criteria o f m yocardial injury after cardiac
surgery. J Thorac Cardiovasc Surg 1976; 71: 934-7

Les unites de mesure doivent etre exprimees selon le Systeme international d ’unites
si c 'est possible.
Les illustrations telles que des photographies d ’appareils cliniques, des radiographies, des photomicrographies, des graphiques et des diagrammes, en tripli
cata, doivent etre fournies sous la forme d ’epreuves sur papier glace sans mon
tage, les bordures intactes, d ’un format ne depassant pas 20 x 25 cm. Chaque
illustration doit etre munie d ’une legende dactylographiee sur une page separee
du texte de I ’article. S'il s'agit de radiographie, envoyez une copie et non I'origi
nal. S’i l s ’agit d ’une photomicrographie, indiquez le contraste et I’echelle de I'agrandissement. Les lettres qui servent a identifier les elements d ’une illustration doi
vent etre d ’une dimension suffisante afin de demeurer visibles lorsque les necessites de Timpression imposent une reduction de / ’image fournie. II ne faut pas
qu 'on puisse identifier un patient grace a une illustration a moins qu 11n 'y ait expressement consenti par ecrit; faute de permission les traits de sa physionomie doi
vent etre obliteres. Les illustrations en couleur ne seront publiees qu 'aux frais de
I ’auteur. Si / ’illustration provient d ’une autre source, il convient d ’obtenir tant de
I ’auteur que de i ’editeur de I'ouvrage dont elle est tiree, I ’autorisation de s 'en servir aux fins de la publication.
II faut que les tableaux soient conformes au form at rectangulaire du Journal et
rediges sur des feuilles separees du texte, un tableau par feuille.
Les references doivent etre citees dans le texte au moyen d'un chiffre et groupees dans i ’ordre a la fin de / ’article selon la maniere de faire adoptee par ce
Journal. Les references a des periodiques doivent etre conformes a celles dans
cette revue.
Un resume, en frangais et aussi en anglais, qui ne doit pas depasser 125 mots
doit accompagner chaque article sur une feuille separee.
A titre d ’approbation, un exemplaire du m anuscrit redige sera envoye a Tauteur
mais non les epreuves.

VOLUME 27, NO. 1, JANUARY 1984 / THE CANADIAN JOURNAL OF SURGERY

83

For pain relief that lasts
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■ Analgesia comparable to a
narcotic-containing preparation
■ Up to 12 hours of pain relief with a single dose
■ Generally well tolerated
■ Avoids many of the problems associated with
narcotic-containing analgesics
For relief o f m ild to m oderate pain

Stat dose...
The stat dose is the key
to faster pain relief for m ost patients
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* ® Trademark

Two 500 mg tablets stat
Then one 500 mg
tablet every 12 hours

Tablets 250 and 500 mg
ANALGESIC/ANTI-INFLAMMATORY

ACTION
Diflunisal is a non-steroidal drug with analgesic,
anti-inflammatory and antipyretic properties.
The precise mechanism of the analgesic and anti
inflammatory actions of diflunisal is not known, however,
it appears to be a peripherally-acting analgesic drug.
Diflunisal is a prostaglandin synthetase inhibitor.
In animals, prostaglandins sensitize afferent nerves and
potentiate the action of bradykinin in inducing pain.
Since prostaglandins are known to be among the
mediators of pain and inflammation, the mode of action
of diflunisal may be due in part to a decrease of
prostaglandins in peripheral tissues.
Pharmacokinetics and Metabolism
Diflunisal is rapidly and completely absorbed following
oral administration with peak plasma concentrations
occurring between 2 to 3 hours. The drug is excreted
in the urine as two soluble glucuronide conjugates
accounting for about 90% of the administered dose.
Little or no diflunisal is excreted in the feces. Diflunisal
appears in human milk in concentrations of 2 - 7 %
of those in plasma. More than 99% of diflunisal in
plasma is bound to proteins.
As is the case with salicylic acid, concentrationdependent pharmacokinetics prevail when diflunisal is
administered; a doubling of dosage produces a greater
than doubling of drug accumulation.
The effect becomes more apparent with repetitive doses.
Following single doses, peak plasma concentrations
of 41 ± 11 (xg/mL (mean ± S.D.) were observed
following 250 mg doses, 87 ± 17 ^g/m L were observed
following 500 mg and 124 ± 11 ^g/m L following single
1000 mg doses. However, following administration of
250 mg b i d., a mean peak level of 56 ± 14 fig/m L
was observed on day 8, while the mean peak level after
500 mg b.i.d. for 11 days was 190 ± 33 ng/mL.
The plasma half-life of diflunisal is 8 to 12 hours.
Because of its long half-life and nonlinear pharma
cokinetics, several days are required for diflunisal plasma
levels to reach steady state following multiple doses.
For this reason, an initial loading dose is necessary to
shorten the time to reach steady state levels, and 2 to
3 days of observation are necessary for evaluating
changes in treatment regimens if a loading dose is
not used.

INDICATIONS AND CLINICAL USE
DOLOBID* is indicated for:
- relief of mild to moderate pain accompanied by
inflammation in conditions such as musculoskeletal
trauma, post-dental extraction or post-episiotomy
- symptomatic relief of osteoarthritis.
DOLOBID* has slow onset and long duration of action.
DOLOBID* produces significant analgesia in one
hour and maximum analgesia in 2-4 hours. Analgesic
effect lasts 8 to 12 hours. These characteristics
should be considered when prescribing this drug.

CONTRAINDICATIONS
Patients who are hypersensitive to this product.
Patients in whom acute asthmatic attacks, urticaria, or
rhinitis are precipitated by acetylsalicylic acid or other
non-steroidal anti-inflammatory drugs.
Patients with active peptic ulcer or any other active
inflammatory disease of the gastrointestinal tract.

WARNINGS
When DOLOBID* is given to patients with a history of upper
gastrointestinal tract disease, it should be given only after
consulting the CONTRAINDICATIONS and ADVERSE
REACTIONS sections and under close supervision.
Pregnancy
The safety of this drug in pregnancy has not been
established, and its use during pregnancy is therefore
not recommended.
A dose of 60 mg/kg/day of diflunisal (equivalent to two
times the maximum human dose) was maternotoxic,

embryotoxic, and teratogenic in rabbits. In three of
six studies in rabbits, evidence of teratogenicity was
observed at doses ranging from 40 to 50 mg/kg/day.
Teratology studies in mice, at doses up to 50 m g/kg/
day, and in rats at doses up to 100 mg/kg/day,
revealed no harm to the fetus due to diflunisal. ASA
and other salicylates have been shown to be teratogenic
in a wide variety of species, including the rat and
rabbit, at doses ranging from 50 to 400 mg/kg/day
(approximately one to eight times the human dose).
In rats at a dose of one and one-half times the maximum
human dose, there was an increase in the average length
of gestation. Similar increases in the length of gesta
tion have been observed with ASA, indomethacin, and
phenylbutazone, and may be related to inhibition of
prostaglandin synthetase. Drugs of this class may
cause dystocia and delayed parturition in pregnant
animals.
Because of the known effect of drugs of this class on
the human fetal cardiovascular system (closure of ductus
arteriosus), use during the third trimester of pregnancy
is not recommended.
Nursing Mothers
Diflunisal is excreted in human milk in concentrations
of 2 - 7 % of those in plasma. Because of the potential
for serious adverse reactions in nursing infants from
DOLOBID*, a decision should be made whether to
initiate nursing or to administer the drug, taking into
account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness in infants and children have
not been established, and use of the drug in children
below the age of 12 years is not recommended.
(See TOXICOLOGY.)

PRECAUTIONS
Effect on Platelet Function
As an inhibitor of prostaglandin synthetase, diflunisal
has a dose-related effect on platelet function and
bleeding time. In normal volunteers, 250 mg b.i.d. for
8 days had no effect on platelet function, and 500 mg
b.i.d., had a slight effect. At 1000 mg b.i.d., diflunisal
inhibited platelet function. In contrast to acetylsalicylic
acid these effects of diflunisal were reversible. Bleeding
time was not altered by a dose of 250 mg b.i.d, but
was slightly increased at 500 mg b.i.d. At 1000 mg
b.i.d, a greater increase occurred, but was not statisti
cally significantly different from the change in the
placebo group. Therefore, patients who may be adversely
affected should be carefully observed when DOLOBID*
is administered.
Effect on Fecal Blood Loss
When diflunisal was given to normal volunteers at
500 mg twice daily, fecal blood loss was not significantly
different from placebo. Diflunisal at 1000 mg twice
daily caused a statistically significant increase in
fecal blood loss.
Effect on the Kidneys
Since diflunisal is eliminated primarily by the kidneys,
patients with significantly impaired renal function and
the elderly should be closely monitored; a lower daily
dosage should be anticipated to avoid excessive drug
accumulation.
Uricosuric Effect
In normal volunteers, an increase in the renal clearance
of uric acid and a decrease in serum uric acid was
observed when diflunisal was administered at 500 mg
or 750 mg daily in divided doses. Patients on long
term therapy taking diflunisal at 500 mg to 1000 mg
daily in divided doses showed a prompt and consistent
reduction in mean serum uric acid levels, which were
lowered as much as 1.4 mg%. It is not known whether
diflunisal interferes with the activity of other uricosuric
agents.
Edema
Peripheral edema has been observed in some patients
taking DOLOBID*. DOLOBID* should be used with caution
in patients with compromised cardiac function, hyper
tension, or other conditions predisposing to fluid
retention.
Effect on the Liver
As with other non-steroidal anti-inflammatory drugs,
borderline elevations of one or more liver tests may

occur in up to 15% of patients. These abnormalities
may progress, may remain essentially unchanged, or
may be transient with continued therapy. The SGPT
(ALT) test is probably the most sensitive indicator of
liver dysfunction. Meaningful (3 times the upper limit of *
normal) elevations of SGPT or SGOT (AST) occurred in
controlled clinical trials in less than 1% of patients.
■*
A patient with symptoms and/or signs suggesting liver
dysfunction, or in whom an abnormal liver test has
?
occurred, should be evaluated for evidence of the develop
ment of more severe hepatic reaction while on therapy f
with DOLOBID*. Severe hepatic reactions, including
jaundice and cases of fatal hepatitis, have been reported *
with non-steroidal anti-inflammatory drugs. Although such
reactions are rare, if abnormal liver tests persist or
A
worsen, if clinical signs and symptoms consistent with
liver disease develop, or if systemic manifestations
occur (e.g, eosinophilia, rash, etc.), DOLOBID* should
be discontinued.
4
Effect on the Eye
Because of reports of adverse eye findings with agents ,
of this class, it is recommended that patients who
develop eye complaints during treatment with DOLOBID*
have ophthalmologic studies.
""
Antipyretic Activity
Diflunisal is not recommended for use as an antipyretic ’
agent. In single 250 mg, 500 mg, or 750 mg doses,
diflunisal produced measurable but not clinically useful
decreases in temperature in patients with fever; however,
the possibility that it may mask fever in some patients, '
particularly with chronic or high doses, should be
considered.
*
Drug Interactions
Oral anticoagulants: In some normal volunteers, the
concomitant administration of DOLOBID* and warfarin
or acenocoumarol resulted in prolongation of prothrombin
time. This may occur because diflunisal competitively
displaces coumarins from protein binding sites.
Accordingly, when DOLOBID* is administered with oral
anticoagulants, the prothrombin time should be closely
monitored during and for several days after concomitant
drug administration. Adjustment of dosage of oral
anticoagulants may be required.
Tolbutamide: In diabetic patients receiving DOLOBID*
and tolbutamide, no significant effects were seen on
tolbutamide plasma levels or fasting blood glucose.
Hydrochlorothiazide: In normal volunteers, concomitant
administation of DOLOBID* and hydrochlorothiazide
resulted in significantly increased plasma levels of
hydrochlorothiazide. DOLOBID* decreased the hyperuricemic effect of hydrochlorothiazide.
Furosemide: In normal volunteers, the concomitant
administration of DOLOBID* and furosemide had no
effect on the diuretic activity of furosemide. DOLOBID*
decreased the hyperuricemic effect of furosemide.
Antacids: Concomitant administration of antacids may
reduce plasma levels of DOLOBID*. This effect is small
with occasional doses of antacids, but may be clinically
significant when antacids are used on a continuous
schedule.
Acetaminophen: Concomitant administration of DOLOBID*
and acetaminophen to normal volunteers resulted in
significantly increased plasma levels of acetaminophen.
Acetaminophen had no effect on plasma levels of
DOLOBID*.
Non-steroidal Anti-inflammatory Drugs
Since no clinical data are available about the safety
and effectiveness of DOLOBID* when used in combination with other non-steroidal anti-inflammatory drugs,
no recommendation for their concomitant use can be
made. The following information was obtained from
studies in normal volunteers.
Acetylsalicylic acid: In normal volunteers, a small
decrease in diflunisal levels was observed when
multiple doses of DOLOBID* and acetylsalicylic acid
were administered concomitantly.
Indomethacin: The administration of diflunisal to
normal volunteers receiving indomethacin decreased
the renal clearance and significantly increased the
plasma levels of indomethacin. Further, the combined
use of indomethacin and DOLOBID* has been associated
with fatal gastrointestinal hemorrhage. Therefore,
indomethacin and DOLOBID* should not be used
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concomitantly.
Sulindac: The concomitant administration of DOLOBID*
and sulindac in normal volunteers resulted in substantial
^b u t not statistically significant lowering of the plasma
levels of the active sulindac sulfide metabolite.
►Naproxen: The concomitant administration of DOLOBID*
and naproxen in normal volunteers had no effect on the
plasma levels of naproxen, but significantly decreased
The urinary excretion of naproxen and its glucuronide
metabolite. Naproxen had no effect on plasma levels of
* DOLOBID*.

v ADVERSE REACTIONS
The adverse reactions observed in controlled clinical
x- trial encompass observations in 2427 patients.
Listed below are the adverse reactions reported in the
>4314 of these patients who received long-term
treatment. Five hundred thirteen patients were treated
>- for at least 24 weeks, 255 patients were treated for at
least 48 weeks, and 46 patients were treated for
*. 96 weeks. Also listed are the adverse reactions reported
in 1113 patients who received short-term treatment
„ (one week or less).
PERCENTAGE INCIDENCE
►
SHORT-TERM LONG-TERM
TRIALS
TRIALS
* GASTROINTESTINAL
1.4
8.7
Gastrointestinal pain
8.4
0.8
a Dyspepsia
6.5
Nausea
4.3
0.7
5.4
^ Diarrhea
Vomiting
2.1
1.9
1.4
Constipation
0.1
1.4
Flatulence
0.1
0.7
0.0
Anorexia
0.2
Eructation
0.3
0.3
Gastrointestinal bleeding
0.1
0.0
0.1
Peptic ulcer
L DERMATOLOGIC
r Rash
0.3
4.0
0.1
1.0
Pruritis
0.4
0.8
r ' Sweating
Stomatitis
0.0
0.8
0.3
0.6
D ry mucous membranes
- CENTRAL NERVOUS SYSTEM
3.7
3.0
Headache
2.1
Dizziness
3.5
* Somnolence
3.9
1.6
0.4
1.4
Tinnitus
1.1
►Insomnia
0.2
0.1
0.9
Vertigo
0.7
0.3
^Nervousness
OTHER
1.1
* Fatigue/Tiredness
0.6
0.8
0.0
Edema
0.4
0.6
► Asthenia

v CAUSAL RELATIONSHIP UNKNOWN
Other reactions have been reported in clinical trials or
.since the drug was marketed abroad, but occurred under
circumstances where a causal relationship could not be
established. However, in these rarely reported events,
that possibility cannot be excluded. Therefore, these
observations are listed to serve as alerting information
to physicians.
DERMATOLOGIC: erythema multiforme and Stevens* Johnson Syndrome.
RESPIRATORY: dyspnea.
'CARDIOVASCULAR: palpitation, syncope.
SPECIAL SENSES: transient visual disturbances.
NERVOUS SYSTEM: paresthesias,
v MUSCULOSKELETAL: muscle cramps.
w PSYCHIATRIC: depression.
h GENITOURINARY: dysuria.
MISCELLANEOUS: chest pain, fever, malaise, cholestatic
jaundice, hypersensitivity (including interstitial nephritis
with renal failure), anaphylactic reaction with
bronchospasm.

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
Cases of overdosage have occurred and deaths have
been reported. Most patients recovered without

evidence of permanent sequelae. The most common signs
and symptoms observed with overdosage were drowsi
ness, disorientation or stupor. A dose that is usually
fatal has not yet been identified.
In the event of overdosage, the stomach should be
emptied by inducing vomiting or by gastric lavage, and
the patient carefully observed and given symptomatic
and supportive treatment. Because of the high degree
of protein binding, hemodialysis may not be effective.

DOSAGE AND ADMINISTRATION
For mild to moderate pain, an initial dose of 1000 mg
followed by 500 mg every 12 hours is recommended
for most patients.
A lower dosage may be appropriate depending on such
factors as pain severity, patient response, weight, or
advanced age; for example, 500 mg initially, followed
by 250 mg every 12 hours.
For osteoarthritis, the suggested dosage range is
500 mg to 1000 mg daily in two divided doses
according to patient response.
Maintenance doses higher than 1000 mg a day are not
recommended.
DOLOBID* may be administered with water, milk or
meals. Tablets should be swallowed whole, not crushed
or chewed.

AVAILABILITY
Tablets DOLOBID* are capsule-shaped, film-coated
tablets supplied as follows:
8891X - 250 mg, peach coloured, coded DOLOBID on
one side, supplied in bottles of 60 tablets.
8947 - 500 mg, orange coloured, coded DOLOBID on
one side, supplied in bottles of 60 tablets.
1, Forbes. J.A,

Shackleford. R.W: Three 12-hour evaluations of the analgesic
efficacy of diflunisal, Proceedings of International Symposium on Diflumsal.
Amsterdam. 1980. pp. 143-155.

2. Andrew. A .e ta L Diflunisal: six-month experience in osteoarthritis.
Br J Clin Pharmac 4 45S-52S. 1977
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NOTICES
continued from page 54

phology; oral, maxillofacial and plastic
surgery; orthodontics; orthopedics;
pediatrics and pedodontics. Abstracts
should include purpose, method and
material, results and conclusions. They
should be submitted for consideration as
soon as possible, but no later than June
30, 1984. Attendance will be limited. The
proceedings of the conference will be
published.
For more information write: Dr.
Andrew D. Dixon or Dr. Bernard G. Sarnat, Dental Research Institute, School of
Dentristry, School of Medicine, Center
for Health Sciences, University of Cali
fornia, Los Angeles, Los Angeles, CA
90024, USA.

National Institutes of Health
Consensus Development
Conference on Osteoporosis
A consensus development conference on
osteoporosis will be held at the National
Institutes of Health (NIH) in Bethesda,
Md., Apr. 2-4, 1984. The conference will
address questions such as: What is osteo
porosis? What are its clinical features and
how is it detected? Who is at risk? What
are the possible causes? How can it be
prevented and treated? What are the
directions for future research?
Consensus development conferences
bring together biomedical investigators,
practising physicians, consumers and
representatives of public interest groups
to provide a scientific assessment of cur
rent information on important biomedi
cal issues, such as osteoporosis.
On the first 2 days of the conference,
experts will give presentations on various
aspects of osteoporosis. Following this,
a consensus panel, comprised of specia
lists and generalists, will evaluate the evi
dence and issue a draft statement
responding to the key conference ques
tions. On the third day, the consensus
panel chairman will read this preliminary
consensus statement before the audience
and invite comments and questions.
The conference is open to the public
without charge. To register for the con
ference or obtain further information,
contact Mr. Peter Murphy, Prospect
Associates, Ste. 401, 2115 East Jefferson
St., Rockville, Md. 20852, USA; (301)
468-6555.

General Surgical Symposium
The Division of General Surgery at the
University of Ottawa School of Medicine
will hold its 5th annual general surgical
symposium Feb. 3-4, 1984 at the Westin
Hotel in Ottawa. The program will deal
continued on page 89
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Bleeding Small-Bowel Varices
A case of bleeding jejunal varices in a
27-year-old man is reported. Portal
hypertension resulted from portal vein
thrombosis and the varices were not
associated with portasystemic shunting.
Because mesenteric varices are rare,
they are seldom the cause of
gastrointestinal hemorrhage. However,
they should be suspected in patients
with an obscure source of bleeding and
portal hypertension. The pathogenesis,
roentgenographic criteria and surgical
management are discussed.
Les auteurs ddcrivent le cas d'un homme
de 27 ans qui a presente des saignements de varices jejunales. Une hyper
tension porte resultait d'une thrombose
de la veine porte et les varices n'etaient
pas reliees a une insuffisance du
systeme porte. Comme les varices
mesenteriques sont rares, elles sont rarement la cause d'hemorragies des voies
digestives. Toutefois, on devrait en
soupconner la presence chez les patients
dont les saignements sont d'origine obs
cure et qui souffrent d'hypertension
porte. La pathogenese de cette affection,
les crit&res radiologiques de son identifi
cation et son traitement chirurgical sont
commentes.

Bleeding from gastroesophageal varices
occurs commonly in patients with portal
hypertension. Infrequently, varices of
mesenteric veins arise at other sites in the
gastrointestinal tract. When these bleed
they present a difficult diagnostic pro
blem. A case o f bleeding jejunal varices
is reported and the diagnosis and manage
ment are discussed.

history of recurrent hematochezia without
hematemesis. Investigation during this period
included gastroscopy, colonoscopy, roent
genography with barium, technetium scanning
and superior mesenteric angiography. These
did not reveal a bleeding site but only gastritis
for which he was treated medically. Bleeding
persisted, requiring more than 30 units of
blood; eventually a laparotomy was carried out
in a community hospital. The bleeding site
could not be established conclusively and a
vagotomy with pyloroplasty was performed.
One week after the operation his bleeding
recurred and he was transferred to the Health
Sciences Centre in Winnipeg.
As a 3-week-old infant, the patient had
undergone laparotomy for peritonitis, thought
to be due to a perforated duodenum. No record
of umbilical catheterization or sepsis could be
obtained.
The patient was pale and tachycardic, but
otherwise healthy without any signs of chronic
liver disease. He continued to bleed, passing
maroon-coloured stools while the nasogastric
tube drained bile-stained juice. A triple-vessel
angiogram did not reveal an arterial source of
bleeding and the venous phase was too faint
to interpret.
At emergency laparotomy, extensive adhe
sions from previous surgery were lysed. There
was blood throughout the small and large
bowel from the ligament of Treitz to the rec
tum. There were large, soft, dilated veins in
the mesentery of the proximal half of the small
bowel. Intraoperative mesenteric venography
revealed “ cavernous transformation of the por-

tal vein” (Fig. 1). No intraluminal lesion could
be palpated and intraoperative gastroscopy
showed the bleeding to be distal to the
duodenum. The bleeding site was localized to
the proximal jejunum only by opening the
bowel with bracketting enterotomies. The in
volved small bowel was resected and primary
anastomosis performed. Bleeding immediate
ly ceased and did not recur. Gross examina
tion revealed a clot protruding from a ruptured
submucosal vessel (Fig. 2). On histologic ex
amination there were extensive, large, sub
mucosal veins with focal mucosal ulceration
and clot (Fig. 3). Postoperatively, the patient
experienced low-grade partial small-bowel
obstruction but was discharged on a solid diet
and there has been no recurrence of hemor
rhage.

Discussion
Following the report of a case of
bleeding small-bowel varices by Bloor and
Orr1 in 1961, several authors reported
their experience with this unusual clinical
entity.2-8 Thirty-four cases of bleeding
small-bowel varices are documented in the
literature o f which 16 are stomal varices
occurring in an ileostomy after proc
tocolectomy for inflammatory bowel
disease. This variant has been reviewed
recently by Ricci and associates.8 Cir
rhosis in these patients is usually the end
result o f pericholangitis associated with
inflammatory bowel disease. The portal
hypertension in most o f the other patients
is secondary to alcohol-related cirrhosis.
However, Moncure and associates4
reported two cases o f jejunal varices

Case Report
A 27-year-old man presented with a 6-week

From the Department o f Surgery, Health
Sciences Centre, University o f Manitoba,
Winnipeg, Man.
Accepted fo r publication Sept. 26, 1983
Reprint requests to: Dr. B. Ostrow, 91
Laburnham Ave., Etobicoke, Ont.
M 8W 1S6
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H G . 1—Intraoperative mesenteric venogram
shows cavernous transformation of collateral
hepatopetal inflow (arrows).

FIG. 2—Luminal surface of proximal je
junum. Clot can be seen extruding from
mucosal ulceration.
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associated with portal vein thrombosis,
one occurring in the neonatal period and
the other as a result of carcinoma of the
pancreas. Portal vein thrombosis is the
most common cause of portal hyperten
sion presenting in childhood and is usually associated with neonatal sepsis, omphalitis, exchange transfusion and ab
dominal trauma.9
Portal hypertension causes collaterals
between the portal and systemic circulation to open and varices are thus
formed. The most clinically important of
these occur around the gastroesophageal
junction, although shunting and varices
in the hemorrhoidal veins, retroperitoneal
collaterals and veins in the falciform liga
ment are all recognized.10 All the
reported cases of small-bowel varices have
been associated with portasystemic shunting. Usually, this occurs postoperatively
in vascularized adhesions. Intestinal
varices without associated shunt are rare
and we have been unable to find a description of them in the literature. Varices
arising solely because of venous hypertension are common in other systems, however, such as in the saphenous veins of the
leg.
Angiography plays a crucial role in the
diagnosis of mesenteric varices. The
roentgenographic features are (a)
retrograde (hepatofugal) flow in the
superior or inferior mesenteric veins, or
both, (b) visualization of the varices
themselves and (c) visualization of the
systemic venous system after mesenteric
injection in the absence of esophageal
varices.7 Extravasation of contrast into
the bowel lumen is unlikely to occur with
arterial injections, but can be seen with
transhepatic portography. To avoid missing the diagnosis during angiography, it

is essential that all three mesenteric vessels
are injected, that the entire bowel is vi
sualized, that enough contrast is injected
to opacify the veins adequately and that
filming is carried out well into the venous
phase, for at least 30 seconds.
Tolazoline has been used to enhance
the venous opacification.7 Failure to
adhere to these principles accounted for
the failure to make a preoperative
diagnosis in our case, despite two
angiograms.
Resection of the involved segment of
bowel or portasystemic shunting, or both,
have been used in the surgical manage
ment of these patients. While Ricci and
associates8 argued that shunting is the
preferred management in the case of ileostomal varices, there does not appear to
be a clear-cut difference, either in the
mortality, which approaches 50%, or in
recurrent bleeding, with either method.
As in bleeding esophageal varices, sur
vival depends more on the severity of the
liver disease.
The case reported, which required the
transfusion of over 40 units of blood and
two laparotomies, illustrates the difficulty
in diagnosing this entity. One unusual
feature of the case is that despite the
previous surgery and the extensive adhe
sions, the varices were not associated with
portasystemic shunting but were confined
entirely to the small bowel. No evidence
of shunting could be seen on either
arteriography or venography.
Since this case, we have seen two other
patients with Laennec’s cirrhosis and
bleeding mesenteric varices, one asso
ciated with a colostomy and the other
with shunting into the ovarian vein
through a postoperative adhesion.
Despite its infrequent occurrence,
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bleeding from mesenteric varices should
be suspected in any patient with
hematochezia without hematemesis, por
tal hypertension and who has had
previous abdominal surgery. An ag
gressive diagnostic and therapeutic ap
proach can often localize and stop the
bleeding.
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with management of a wide variety of
commonly encountered surgical pro
blems. In addition to local faculty, guests
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FIG. 3—Dilated submucosal veins with focal ulceration and visible clot (hematoxylin and
eosin, reduced by 31% from XlO).

On page 557 of the November 1983 issue
of the Journal, a line has been transposed
in the sentence preceding “ Results” . The
two sentences before “ Results” should read
as follows: “ Where a severe stenosis has
resulted in vortex formation or turbulence,
blue dots are displayed, representing Dop
pler shifts greater than 5000 Hz and
velocities greater than 132 cm /s.6'7 The
technician is guided by an audio represen
tation of the Doppler shift, which is also
subject to spectral analysis.”
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Treatment of Tuberculous Masses in the Neck
Tuberculous cervical lymphadenitis was
diagnosed in 23 patients from 1970 to
1980; 21 of them were immigrants. The
masses ranged in diameter from 1.5 to
5.5 cm. The posterior triangle was in
volved in 11 patients, the anterior trianble in 7 and both triangles in 5 (3
bilateral). Excisional node biopsy was
performed in all. Acid-fast bacilli were
identified on the smear in only 12 pa
tients. Caseation necrosis was present in
19 specimens; the other 4 were com
parable with sarcoidosis. However, all
cultures grew Mycobacterium tuber
culosis, which was corroborated in all by
guinea-pig inoculation. No chest roent
genograms showed active pulmonary
tuberculosis. Chemotherapy was given
for 12 to 18 months. In three patients
masses continued to enlarge for 5
months after initiation of chemotherapy,
but then regressed and disappeared com
pletely within 12 months. No recur
rences were present in any patients
(follow-up more than 2.5 years, mean
5.4 years).
De 1970 a 1980, un diagnostic de
lymphadenite cervicale tuberculeuse a
ete pose chez 23 malades; 21 d'entreeux etaient des immigrants. Le diametre
des masses variait de 1.5 b 5.5 cm. II y
avait atteinte du triangle posterieur chez
11 patients, du triangle anterieur chez 7
et des deux triangles chez 5 (3 bilateraux). Tous subirent une biopsie-exerese
ganglionnaire. L'identiflcation sur frottis
des bacilles acido-resistants ne fut possi
ble que chez 12 patients. Une necrose
de caseification etait presente dans 19
prelevements; les 4 autres ressemblaient
a une sarcoidose. Toutefois, toutes les
cultures permirent la croissance de

Mycobacterium tuberculosis, observation
corroboree chez tous par inoculation
chez le cobaye. Aucune radiographie thoracique ne revela de tuberculose pulmonaire active. Un traitement de chimiotherapie fut administre pendant 12 a 18
mois. Chez trois patients, les masses
continuerent a augmenter de volume
pendant 5 mois apres le debut du traite
ment, avant de regresser et de disparaitre completement en moins de 12 mois.
Aucune recidive n'a ete vue chez les
patients (observations des suites therapeutiques de plus de 2.5 ans; 5.4 ans en
moyenne).

In the past, surgical excision was often
recommended for tuberculous masses in
the neck,1,2 often after at least 2 weeks
of chemotherapy.3 In the presence of
adherent, matted, diseased nodes, injury
to the spinal accessory nerve, internal
jugular vein, phrenic nerve or brachial
plexus was a hazard. However, adequate
antituberculous chem otherapy has
resulted in regression of these cervical
masses, so that the need for surgical ex
tirpation is now questionable. We review
ed the treatm ent of cervical lymphadenopathy due to tuberculosis and
results over a 10-year period when
modern combination chemotherapy was
used.
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Joseph’s Health Centre in the 10 years
from July 1, 1970 to June 30, 1980. This
review permitted a follow-up of at least
2.5 years. There were 19 females and 4
males, ranging in age from 14 to 58 years
(mean 33.6 years) (Fig. 1). Of the 23 pa
tients, 21 (91.3%) had immigrated to
Canada (Table I) from 10 months to 23
years (mean 4.3 years) before the masses
in the neck were recognized (Fig. 2).
Tuberculin skin testing was done at an
intermediate strength (5 TU), with an in
duration of 10 mm or greater represent
ing a positive reaction. Chest roent
genograms included posteroanterior and
apical-lordotic views. Excisional biopsy
of the most superficial node was done,
usually under local anesthesia. The biopsy
incision was selected so that it could be
included in a possible future neck dissec
tion if the masses proved to be malignant.
A portion of the node was sent for
pathologic examination. The other por
tion was submitted to bacteriology and
stained with fluorescent and ZiehlNeelsen stains. Culture was performed on
Lowenstein-Jensen’s, Woolley’s and
American Thoracic Society media, and
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FIG. I—Age al presentation of cervical
masses.

FIG. 2—Length of time in Canada before
cervical masses were discovered.
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the results read at 2, 3, 5 and 8 weeks.
Sensitivity of the mycobacterium to drugs
was determ ined on tra n sp a re n t
Middlebrook-Cohn medium. A guinea
pig was inoculated in the thigh with
material from the node. If the lumbar
node was palpable at 4 weeks, autopsy
was performed then; otherwise, autopsy
was performed at 8 weeks. In two patients
who presented with a fluctuant mass (cold
abscess), incision and drainage was per
formed, as well as curettage of the wall
for biopsy specimens, and smears and
cultures of the caseous material.
No surgical extirpation o f the mass of
cervical lymph nodes was undertaken.
Each patient was treated with
chemotherapy individually. When a single
node appeared to be diseased, 12 months
of chemotherapy was given; with
multinodal, extensive involvement, an
18-month course was used. From 1970 to
1974, eight patients were treated with
streptomycin, para-aminosalicyclic acid
and isoniazid; from 1975 to 1980, six pa
tients received streptomycin, rifampin
and isoniazid, five patients received
rifampin, ethambutol and isoniazid and
four received rifampin and isoniazid.
Streptomycin (1.0 mg intramuscularly)
was given on alternate days for the first
month and twice weekly for the next 2
months. Isoniazid (300 m g/d) was given
for 12 to 18 months, rifampin (600 mg/d)
for 9 months, para-aminosalicyclic acid
(14 g/d) for 12 to 18 months and etham
butol (15 mg/kg daily) for 9 months.
Findings and Results

In 18 of the 23 patients, the presenting
complaint was painless enlargement of
cervical masses. Five patients complain
ed of mild pain in the region of the
masses; two of them were the patients
who presented with cold abscesses, one
Table It—Location of Masses
No. of
patients
Location
7
Anterior triangle alone
3
Upper jugular
3 (1 bilateral)
Submandibular triangle
1
Submental triangle
11
Posterior triangle alone
4
Supraclavicular alone
Supraclavicular extending
2
behind sternomastoid
Supraclavicular extending
2
behind clavicle
3
Posterior cervical
Anterior and posterior triangles 5
Submental and supraclavicular
extending behind clavicle 1 (bilateral)
Submandibular and posterior
2(1 bilateral)
cervical
Anterior cervical and
1
supraclavicular
Anterior and posterior
1
cervical

of whom had a discharging sinus follow
ing noncompliance with a prescribed drug
regimen at another centre. Malaise,
anorexia and weight loss or fever, or
both, were present in three patients. One
patient had concomitant chronic sup
purative otitis media. Two patients had
an upper respiratory tract infection,
which may have been responsible for the
pain in their nodes due to superadded in
fection, as the pain disappeared with an
tibiotic therapy.
Multiple cervical masses were palpable
in 18 patients (78.2%). In three they were
bilateral. The anatomic distribution of the
masses is shown in Table II. Nodes
anterior to the sternomastoid muscle have
been termed “ anterior cervical” and
nodes posterior to the sternomastoid have
been termed “ posterior cervical” ; these
nodes were often contiguous with nodes
deep to the sternomastoid, close to the in
ternal jugular vein.
On palpation, the diameter of the
masses varied from 1.5 to 5.5 cm (mean
2.4 cm). In 16 patients the masses were
palpably firm and discrete. In five pa
tients they were fixed and adherent to
each other and to adjacent tissues; these
masses had generally been recognized for
a longer period (approximately 1 year).
In all patients the overlying skin was
smooth and not reddened, except in the
patient who presented with a discharging
sinus.
The remainder of the physical examina
tion at the time of presentation, with em
phasis on the oral cavity and pharynx (in
cluding dental caries and tonsils), thyroid,
breast and axilla, revealed no associated
findings.
All patients had a positive reaction to
tuberculin (5 TU). In 16, a chest roent-

genogram showed no abnormality. In
seven patients, there was a vague densi
ty; three had apical scars suggestive of
healed tuberculous masses, and the other
four had nonspecific roentgenographic
findings of dubious importance. No
evidence of active pulmonary tuberculosis
was seen.
At the time of biopsy, the superficial
node selected was frequently observed to
be adherent to multiple underlying nodes
and fused with surrounding deeper tissues
by fibrous material, which could make
identification of tissue planes difficult. In
only 12 patients (52.2%) was the smear
for acid-fast bacilli positive. Histologic
exam ination
show ed
caseating
granulomatous lymphadenitis (Fig. 3)
with epithelioid and Langhans’ giant cells
in 19 patients (82.6%). In the other four
patients (17.4%), the specimens showed
noncaseating granulom atous changes
consistent with sarcoidosis (Fig. 4).
Culture was positive for M . tuberculosis
var. hominis in all 23 patients, and
guinea-pig inoculation was confirmatory
in all.
After 6 to 8 weeks of chemotherapy,
a remarkable regression o f the cervical
masses was discernible; however, in three
patients the masses continued to enlarge
for up to 5 months, but with continued
chemotherapy they regressed and disappeard completely by 12 months. Two pa
tients stopped taking the drugs on their
own and a fluctuant mass developed in
the neck, which was incised and drained.
It was impressed upon these two patients
that they must resume the chemotherapy;
they did so, continuing chemotherapy for
the prescribed course, and all cervical
disease disappeared. The masses in both
patients healed with a coarse, irregular,

FIG. 3—Caseating granuloma in cervical
lymph node (hematoxylin and eosin, reduced
by 52% from x20).

FIG. 4—Noncaseating granuloma, consis
tent with sarcoidosis (hematoxylin and eosin,
reduced by 52% from x20).

VOLUME 27, NO. 1, J A N U A R Y 1984 / THE CANADIAN JOURNAL OF SURGERY

91

depressed scar, which was revised in one
under local anesthesia with an excellent
cosmetic result. Follow-up to the present
(mean 5.4 years) in the 23 patients treated
from 1970 to 1980, all of whom complet
ed at least 12 months of chemotherapy,
has revealed no recurrence.
Discussion
This study indicates that tuberculous
cervical adenitis occurs mainly in the im
migrant population, especially Asians,3
primarily in young adults, with women
predominating. The posterior triangle in
this series was the commonest site of lymphadenopathy, and this is in agreement
with other reports.3,4 Tuberculosis of the
cervical nodes should be considered in the
differential diagnosis of a mass in the
neck, along with such conditions as reac
tive inflammation, lymphoma, metastatic
carcinoma, infectious mononucleosis and
sarcoidosis.
These masses may develop many years
after a person has immigrated (in this
study as long as 23 years). Newcombe3
noted a similar feature in his series, and
concluded that while many probably
came to the United Kingdom with the
disease, those in whom the masses
developed 8 years after immigration had
most likely become infected in the United
Kingdom. This may not be true, since in
fection, especially of the cervical lymph
nodes, may remain dormant for many
years.5 With tuberculosis, nodal involve
ment of a primary complex may not heal
completely, and the bacillus can remain
dormant and become active years later.5
We found, as did others,4,6 that constitu
tional symptoms were minimal. However,
other authors7,8 have recorded a higher
incidence o f constitutional symptoms.
In earlier decades when unpasteurized
milk was consumed, the commonest
etiologic agent in cervical tuberculosis was
M. bovisJ In recent years, as in our
study, M. tuberculosis (var. hominis) has
been the common species. However,
atypical mycobacteria in cervical nodes
are being increasingly rep o rted ,8
especially in children.9 It is important to
identify the atypical mycobacterium,
since its clinical presentation does not dif
fer from M. tuberculosis, but does differ
in its cu ltu ra l and biochem ical
Table III—Suggested Natural History
of Tuberculous Lymphadenitis_______
1. Enlarged, firm, mobile, discrete, slightly
tender nodes, showing noncaseating
granulomas.
2. Nodes larger, rubbery and fixed to surroun
ding tissue owing to periadenitis, showing
caseation.
3. Central abscess formation.
4. Collar-stud abscess formation.
5. Sinus formation.
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characteristics, and in the relatively poor
response to antituberculous drugs; this
variety may require excision.9
The cervical area is the commonest site
of tuberculous peripheral lymphadenitis.
This may be part of a generalized process,
with lymphohematogenous spread from
pulmonary infection being responsible.8
In our series, there had been no active
pulmonary tuberculosis in at least 70%
of patients, possibly in all; in only three
(13%) did apical scars suggest old, heal
ed tuberculous lesions. None of our pa
tients gave any past or present history of
pulmonary tuberculosis. However, in
three of our patients, a close relative had
had open pulmonary tuberculosis in the
distant past. It appears that in our pa
tients the oropharyngeal route could be
a portal of entry. The tonsil is considered
a route of infection in children,6,10 and in
many of our patients the bacillus may
have gained entry via the tonsils, pharynx,
an infected tooth or a break in the lining
of the oral cavity and remained dormant
in the cervical lymph nodes.
Much emphasis cannot be placed on
the identification of acid-fast bacilli on
staining of smears; in our patients only
52% (12) showed acid-fast bacilli.
Histologic examination provided a degree
of accuracy. However, in four patients
the biopsy specimen was compatible with
sarcoidosis (noncaseating granuloma),
and in these four, staining was negative
for acid-fast bacilli; culture and guineapig inoculation provided the correct
diagnosis. It is possible that in these non
caseating granulomas the disease was pre
sent in an earlier stage (Table III).
Before chemotherapy, when surgery
alone was used, recurrence was often
observed if the surgeon was unable to ex
cise all the involved nodes. Radiotherapy
to the area was often effective.11
However, in a 54-year-old woman we per
formed a total parotidectomy for chronic
scialadenitis of the superficial lobe and
for acinic cell carcinoma of the deep lobe
of the parotid 40 years after irradiation,
in Yugoslavia, of multiple subjacent cer
vical tuberculous masses. The association
of cervical irradiation and subsequent
neoplasms of thyroid, parathyroid and
parotid glands is well recognized.12,13
Earlier studies6,14 reported failure of
chemotherapy and advised surgical extir
pation of the involved nodes as a primary
treatm ent or in combination with
chemotherapy (often as an operative
“ cover” ). Earlier chemotherapy failed
when used for short periods. A British
series3 recommended early operation
after initial cover of at least 2 weeks of
standard therapy. Some14 have suggested
using antimicrobial agents until the inci
sion heals. A more recent prospective
study15 found that complete excision
followed by 18 months of chemotherapy

had no advantage over biopsy followed
by 18 months of chemotherapy. Likewise,
our study suggests that the use of
chemotherapy for a minimum of 12
months gives good results.
Recently, isoniazid and rifampin given
for 6 to 9 months were recommended as
an effective combination for pulmonary
tuberculosis.16 We have used this com
bination but have continued the isoniazid
for 12 to 18 months. We believe that a
longer course is necessary to control
disease in lymph nodes than in the lungs,
possibly because of poor blood supply in
caseating cervical lymph nodes. Failure to
respond to chemotherapy may be due to
inadequate dosage or because the patients
failed to take their drugs regularly,14 as
in the two patients in our study who
relapsed.
Chronic inflammatory reaction in and
around the nodes causes distortion of the
anatomy. Surgical dissection of the nodes
in the presence of fibrosed, adherent
tissue can be technically difficult. The
spinal accessory nerve, internal jugular
vein, phrenic nerve, brachial plexus
(especially with scalene triangle dissec
tion) and the marginal mandibular branch
of the facial nerve could be injured. At
the time of biopsy, what had appeared to
be a single mass on palpation was fre
quently found to be part of a mass of
deeper nodes, especially in the
supraclavicular fossa or deep to the sternomastoid muscle. These matted nodes
were occasionally adherent to the fibros
ed surrounding tissue, making identifica
tion of tissue planes difficult. For biop
sy, the most available node was selected.
We have had no experience with fineneedle aspiration for cytologic and
bacteriologic examinations in this disease,
but this method could be useful. The ac
curacy o f fine-needle aspiration biopsy
for benign granulomatous diseases has
not yet been evaluated.17
In our series, biopsy for diagnosis and
culture and chemotherapy have been
uniformly successful, with good patient
compliance. Cold abscesses were drain
ed when present. Thus, it is our conten
tion that modern chemotherapy, if given
an adequate opportunity, will generally
obviate the need for surgical dissection of
the lymph nodes.
We aknowledge the assistance of the Health
Records Department (Medical Audit and
Research) o f St. Joseph’s Health Centre, the
Nelson Arthur Hyland Foundation, Dr. Fred
Harris o f the Department of Pathology, Dr.
Edgardo Lim for assisting with patient follow
up and Miss Mary Howes, head of TB section,
Laboratory Services Branch (Toronto), Ont
ario Ministry o f Health.
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BOOK REVIEWS
BIOLOGIC AND SYNTHETIC VASCULAR
PROSTHESES. Edited by James C.
Stanley. 681 pp. Illust. Grune & Stratton,
Inc., New York, 1982. $79.50. ISBN
0-8089-1491-X.

This book has been compiled from papers
presented at a multidisciplinary symposium on
biologic and synthetic vascular prostheses held
at the University of Michigan in May 1982. It
comprises articles by 77 authors, all experts in
various aspects of this subject. It is a stepping
stone for further research in academic and in
dustrial sectors but also details the present
knowledge in this rapidly evolving field of
vascular conduits. Major recurring problems
that compromise graft function have been
discussed, including thrombogenic surfaces
especially of synthetic conduits used in smallvessel and venous reconstructions, deteriora
tion of biologic grafts with secondary
aneurysmal change and infection leading to
thrombosis and hemorrhage.
All aspects of graft function are described
in detail. These include a historical overview
of the problems solved in achieving satisfac
tory graft function; the principles of vascular
integrity, the roles of endothelial cells, platelets
and smooth-muscle cells and their interrelation
ship; and the pharmacologic control of arterial
thrombosis, detailing the search for plateletimmunosuppressive agents and reporting the
major prospective clinical trials involving these
drugs as well as the current experimental
antithrombotic agents being studied.
Six chapters discuss thoroughly the current
knowledge of blood-surface interaction, in
cluding the physical chemistry, graft thrombus
formation, ex-vivo and in-vivo evaluation and
flow patterns in model and natural vessels.
Prosthetic grafts are reviewed by a number of
authors who consider physical design and
durability, elasticity and compliance, and
biocompatibility as well as animal models for
testing vascular prostheses and methods for
macroscopic and microscopic analyses o f ex
perimentally implanted vascular grafts.
Of special interest to the clinical vascular
surgeon are chapters that discuss all aspects of
biological vascular prostheses with reviews of
the history, indications and long-term results
of autogenous arterial grafts, autogenous vein
grafts — both experimental and clinical — and
the use of arterial and venous allografts, and
the role of endothelial repopulation. The use
of human umbilical vein grafts is also described
in both experimental and clinical situations.
The third section of this volume concerns

synthetic vascular prostheses and is probably
the best current summary of this topic
available. The physical characteristics, func
tion and biologic fate of all prosthetic grafts,
and experimental evaluation in a variety of
research and clinical situations are presented,
including extensive reviews of clinical results
and long-term patency.
This book is written by numerous authors
with some resulting unevenness in the text, but
this is more than compensated for by their per
sonal observations and depth of knowledge,
since the contributors include most of the peo
ple responsible for the great developments in
this field. This volume outlines in great detail
the experimental work done to achieve con
tinued improvement in graft function in the last
30 years. It provides complete descriptions of
the physical and biologic characteristics of
these grafts. It is thus of great value to all those
working in the laboratory to improve graft
function, especially in small vessels and lowflow situations.
This book is a must for the clinical vascular
surgeon because it reviews the present state of
the art in detail and presents clinical results that
must influence the choice of graft material in
most clinical situations.

T. Keith Scobie , md , frcsic], facs
Chief,
Division of Vascular Surgery,
Ottawa Civic Hospital,
1053 Carling Ave.,
Ottawa, Ont.
K1Y 4E9

CONCEPTS IN PEDIATRIC NEUROSUR
GERY 3. American Society for Pediatric
Neurosurgery. Edited by Anthony J.
Raimondi. 224 pp. Illust. S. Karger AG,
Basel, 1983. $118.75. ISBN 3-8055-3580-5.

This volume published by members of the
American Society for Pediatric Neurosurgery,
consists of 18 papers on a variety of topics of
interest to pediatric neurosurgeons, including
a presidential address by H .J. Hoffman.
The first three papers deal with brain
tumours in children, with the initial one being
an extensive review of experience with cranio
pharyngioma by Raimondi and Rougerie.
Shorter papers follow, on analysis of 11 cases
of primary cerebral neuroblastoma and cisplatinum therapy in recurrent malignant in

tracranial tum ours in 25 children and
adolescents.
Four papers on unusual cerebrovascular pro
blems in children include an excellent review
of aneurysms of the vein of Galen at the
Hospital for Sick Children in Toronto during
the years 1950 to 1980.
The changes in local cerebral blood flow and
metabolism in the newborn Beagle puppy
model of intraventricular hemorrhage is fol
lowed by a review of the outcome o f 21 pre
term infants with intraventricular hemorrhage
and hydrocephalus.
One paper deals with intracranial fluid
dynamics and another with changes in the sub
dural space following the placement of
cerebrospinal fluid shunts. In the latter paper,
extracerebral fluid collections were identified
on computerized tomography in 7 of 129 pa
tients who had 200 shunt operations. The
authors discuss possible mechanisms for the
formation of this fluid, and point out that the
fluid collections often resolve spontaneously
and appear to be of little clinical importance.
Spinal cord astrocytomas of childhood and
spinal lipomas and lipomeningoceles are con
sidered in three papers. The one on the surgical
treatment of extensive spinal cord astrocytomas
is most interesting, but the follow-up is short.
An excellent paper on the outcome of severe
head injury in children is followed by two
papers on the use of the carbon dioxide laser
in pediatric neurosurgery. The paper on the use
of the laser in craniosynostosis surgery is poor,
with no scientific documentation of the sup
posed advantages o f this technique.
The final paper describes the intraoperative
use of ultrasonography during the placement
of the ventricular catheter in shunt operations.
The authors’ experience with 20 patients seems
encouraging, and this technique may become
much more widely used in the future.
The numerous spelling mistakes in this
volume are inexcusable.
The quality of the papers and illustrations
is variable, and I think that the relatively high
price will make this volume attractive to only
a small number of physicians who have a
special interest in children with nervous system
problems.

S. T erence M yles, md , m sc , frcsic ]
Ste. 701,
3031 Hospital Dr. NW,
South Tower,
Calgary, Alta.
T2N 2T8
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OPERATIVE UROLOGY. Lower Urinary
Tract, P elvic Structures and Male
Reproductive System. Edited by Bruce H.
Stewart. 411 pp. Dlusl. Williams & Wilkins,
Baltimore, 1982. $69.50. ISBN 0-68307896-8.

This book is divided into 29 chapters,
distributed in seven sections. The first deals
with anatomy, embryology and diagnostic pro
cedures. The following five sections are
devoted to surgery of the bladder, pelvic ureter,
prostate and urethra and the last section covers
scrotal and penile surgery. Twenty-one
authors, well known in their fields, have con
tributed to this book, but the editor has achiev
ed uniformity in the presentation of the
material.
As Stewart indicates in the preface, this book

is intended for residents in training. It is not
meant to be a reference book that describes
a ltern ativ e approaches with detailed
bibliography as in standard textbooks. The
authors have obviously written from personal
experience and presented the procedures in a
selective and practical fashion. The writing
style is clear and concise and a large volume
of generously illustrated material has been
covered, while keeping the size and cost accep
table. The concise descriptions of the operative
procedures and the clarity of illustrations make
it an ideal text for residents, particularly in the
early part of their training. Larger reference
texts dealing with specific subjects in greater
depth are already available. There is some
variation in the coverage of pre- and
postoperative aspects of the various surgical

procedures, and more uniformity in this regard
would have been desirable.
The editor and authors have succeeded in <
their mission and as a result many generations
of residents will benefit from this text. It should i
be available in every hospital participating in
residency training in urology.
-f
S .A . A

w ad,

MD, FRCS[C], FACS

<

Member,
Editorial Board.

y

Head,
Department of Urology,
Dalhousie University,
Victoria General Hospital,
Halifax, NS
B3H 2Y9
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NOTICES

Clinical Application
of Hyperbaric Oxygen
The 9th annual conference on the clinical
application o f hyperbaric oxygen will be
held June 11-15, 1984 at the Princess
Hotel, Acapulco, Mexico.
Abstracts are now being solicited for
original papers to be presented at the con

ference; they should be no longer than
200 words. The closing date for the
receipt o f abstracts is March 15, 1984.
For more information and submission
o f abstracts write: Dr. Michael B. Strauss,
Chairman, Program Committee, 9th Annual Conference on the Clinical Application o f Hyperbaric Oxygen, Baromedical
Department, Memorial Medical Center,
2801 Atlantic Ave., Long Beach, CA
90801-1428, USA; or call (213) 595-3613.
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As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The
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ORTHOPEDIC SURGEON: ON - required to join
a multispecialty group in Thunder Bay, Ontario.
Liberal guarantee, plus incentive formula and fringe
benefits. Clinic in modern office building complex
adjacent to city hospital with considerable scope for
orthopedic practice. Please write to: Executive
Chairman, The Spence Clinic, Ste. 500, 1265 Arthur St., E., Thunder Bay, ON P7E 6E7 — or —
tel: (807) 623-4335 collect.
—S83-030
OBSTETRICIAN/GYNECOLOGIST: ON - r e quired to join other obstetricians/gynecologists in a
multispecialty group in Thunder Bay, Ontario. Clinic
in modern office building complex adjacent to city
hospital. Liberal guarantee, plus incentive formula
and fringe benefits. Please write to: Executive
Chairman, The Spence Clinic, Ste. 500, 1265 Arthur St., E, Thunder Bay, ON P7E 6E7 — or —
tel: (807) 623-4335 collect.
—S83-031
PAN-PACIFIC SURGICAL ASSOCIATION Seventeenth Congress. Sydney, Australia. March
24-30, 1984. Sheraton-Wentworth Hotel. For fur
ther information contact: Mr. M el Neville,
Carefree Travel, 10846 Jasper Ave., Edmonton,
AB T5J 2B3 (403) 428-6933 - or - Dr. Elliot Gelfand, 550-8409-112 St., Edmonton, AB T5G 1K6
(403) 439-0045.
— S83-032
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ACADEM IC APPOINTMENT : ON - Head, Divi
sion of General Surgery, Toronto General Hospital.
An individual is required with established clinical
skills and the administrative ability to organize, coor
dinate and facilitate the clinical, research and educational activity in a variety of highly specialized and
developmental tertiary care programs. General
Surgery is the largest Division in the Toronto
General Hospital, Department of Surgery and is
comprised of three 38-bed services, staffed by 11
surgeons. Resources are available to support the
clinical and research needs of the various programs.
The division has a major responsibility for both the
undergraduate and postgraduate training programs
at the University of Toronto. Salary commensurate
with qualifications and experience. In accordance
with Canadian Immigration requirements, this
advertisement is directed to Canadian citizens and
permanent residents. Forward application by March
31, 1984 to : Dr. F.G. Pearson, Surgeon-in-Chief,
Toronto General Hospital, 101 College St.,
Toronto, ON M5G 1L7.
-S84-001

"H A N D S O N "

►

Teaching Sessions
T o ro n to W este rn H o sp ital
U n iversity o f T o ro n to
►
>-

A
A

1

The Department of Surgery, Toronto Western Hospital,
University of Toronto is conducting "Hands O n"
Teaching Sessions in upper and lower gastrointestinal
endoscopy.
This will involve intensive 1-day workshops with a max
imum of three participants.
For further information, please contact:
H.S. Himal, MD, FRCS(C), FACS
Toronto Western Medical Building
25 Leonard Ave., Suite 103
Toronto, ON M5T 2R2
Tel: (416) 366-0354
-S84-004

CLINICAL FELLOWSHIP - Ewart Angus
Surgical Intensive Care Unit. Wellesley
Hospital, Toronto. Available July 1, 1984 for a
period of one year in a multidisiplinary acute
surgical unit with 650 admissions per year.
Duties comprise clinical research in a strong
academic and teaching unit. Present research
includes metabolism, sepsis, and non-invasive
tissue oxygen monitoring. Reply to: Doctor
D.P. Jones, Director, Surgical ICU, Suite
219, E.K. Jones Bldg., 160 Wellesley St. E,
Toronto, ON M4Y 1J3, (416) 966-6656.
— S83-029

cellent location for someone w ho enjoys the out
doors. Remuneration to be negotiated. Early oppor
tunity for partnership. Please write, giving complete
resume, or tel: J.L. Pollock, Clinic A d
ministrator, 406 Lambert St., W hitehorse, YT
Y1A 1Z7, (403) 667-4421.
— S83-034

GENERAL SURGEON
NB
Required for
accredited 90-bed
general hospital.

GENERAL SURGEON - FRCS(C), wide ex
perience in vascular and thoracic surgery and en
doscopy wishes to relocate, solo or group. Reply:
BOX S103, CJS.
-S84-003
CERTIFIED GENERAL SURGEON: YT - Re
quired to join 10 family physicians/1 obstetriciangynecologist group for an extended period.
Emergency orthopedic experience a definite asset.
Located in Whitehorse, Yukon Territory, servicing a
population of 23 000 people and 26 doctors. Ex

McGill affiliation.
St. Joseph's Hospital
Dalhousie, NB
E0K 1B0
—S83-026

UNIVERSITY OF ALBERTA
HOSPITALS
DEPARTMENT OF SURGERY
THE POSITION : The Department of Surgery of the Univer
sity of Alberta Hospitals invites applications for a full-time
position in the field of Pediatric Cardiac Surgery. The posi
tion would carry an appropriate rank in the Faculty of
Medicine for the University of Alberta.
THE CAN DIDATE : Applicants
1. Should have completed a full training in general and
thoracic and cardiovascular surgery, and have ex
perience in the surgical management of complex con
genital heart lesions.
2. Should have a research interest related to the care of
patients with congenital heart disease and be prepared
to continue this endeavor.
3. Would be expected to participate in the teaching pro
grams at the University of Alberta.
THE HOSPITAL : The University of Alberta Hospitals is a
1400-bed acute care teaching facility and the major specialty
care referral centre for northern Alberta and the Territories.
Patient care, health education and clinical research activities
will soon be centered in its major new complex, the Walter C.
MacKenzie Health Sciences Centre.
Canadian residents and permanent citizens will be given
preference.
Remuneration and benefits are negotiable.
Please send a curriculum vitae and names o f
three references to :
Dr. H .T .G . W illia m s
P ro fesso r and C h airm an
D e p a rtm e n t o f S u rg ery
U n iversity o f A lb e rta
11-105 C linical S cie n c es B uilding
E D M O N T O N , A lb e rta , C anada
T6G 2G3
S84-002
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P rescrib in g In fo rm a tio n
ZANTAC® INJECTION (ranitidine hydrochloride)
PHARMACOLOGICAL CLASSIFICATION
Histamine Hj-receptor antagonist

ACTION
Ranitidine is a selective antagonist of histamine at gastric H2-receptor sites. Thus
ranitidine inhibits both basal gastric secretions and gastric acid secretion induced
by histamine, pentagastrin and other secretagogues. On a weight basis, ranitidine is
between 4 and 9 times more potent than cimetidine. Inhibition of gastric acid secre
tion has been observed following intravenous, intraduodenal and oral admin
istration of ranitidine and it is dose related, a maximum response being achieved at
an oral dose of 150 mg.
Pepsin secretion is also inhibited but secretion of gastric mucus is not affected.
Ranitidine does not alter the secretion of bicarbonate or enzymes from the pancreas
in response to secretin and pancreozymin.
Ranitidine is rapidly absorbed after oral administration, peak plasma concentra
tions being achieved within 2 to 3 hours. These plasma concentrations are not
significantly influenced by the presence of food in the stomach at the time of the
oral administration nor by regular doses of antacids.
Bioavailability of ranitidine administered orally is approximately 50%. Serum
protein binding of ranitidine in man is in the range of 10% to 19%. The elimina
tion half-life is approximately 3 hours. The principal route of excretion is the urine
(40% recovery of free and metabolised drug in 24 hours).
Intramuscular ranitidine is fully bioavailable in comparison to intravenous
ranitidine. The median elimination half-life of ranitidine injection 50 mg, adminis
tered intravenously or intramuscularly was found to be 140 minutes (range 120 to
160 minutes.) The half-life of ranitidine in patients with renal dysfunction is
prolonged. However, in a study of 27 patients with varying degrees of renal impair
ment therapeutic plasma levels of ranitidine were shown to be achieved without
risk of drug accumulation, using half the normal dose of ranitidine in patients with
plasma creatinine concentration greater than 300 ^mols/litre.
There is a significant linear correlation between the dose administered and the
inhibitory effect upon gastric acid secretion for doses up to 150 mg orally.
A plasma ranitidine concentration of 50 ng/mL has an inhibitory effect upon stimu
lated gastric acid secretion of approximately 50%. Estimates of the ICso range from
36 to 94 ng/mL. Following the administration of 150 mg ranitidine orally, plasma
concentrations in excess of this lasted for more than 8 hours and after 12 hours the
plasma concentrations were sufficiently high to have a significant inhibitory effect
upon gastric acid secretion. In patients with duodenal ulcer, 150 mg ranitidine
given by mouth every 12 hours significantly reduced mean 24 hour hydrogen ion
activity by 69% and nocturnal gastric acid output by 90%.
Following intramuscular injection of 50 mg ranitidine, plasma concentrations
in excess of 100 ng/mL were achieved within five minutes of administration and
remained above this level for 4 to 6 hours.
Intravenous infusion of ranitidine in seriously ill patients at a rate of
0.125 mg/kg/hour produced a rise of intragastric pH between 5.6 and 7.0 after two
hours and maintained this level over the test period. The volume of gastric secre
tion was reduced by more than 55%. Doubling the infusion rate to
0.25 mg/kg/hour produced no further increases in gastric acid inhibition.
A single 50 mg intravenous bolus dose of ranitidine produced significant acid
inhibition 8 to 9 hours after administration. When 13 seriously ill patients with two
or more risk factors (shock, sepsis, respiratory failure, jaundice, renal insufficiency
and peritonitis) were treated with a 50 mg intravenous bolus dose of ranitidine
followed by a continuous infusion of 0.2 mg/kg/hour the number o f ‘at risk’ days
when gastric pH was less than 3.5 on three consecutive four-hourly aliquots, was
approximately half that for placebo treated patients.
Furthermore, in respect of both 24 hour acidity and nocturnal acid output,
ranitidine, 150 mg twice daily was superior to cimetidine 200 mg three times daily
and 400 mg at night (P <0.001 and <0.05, respectively).
Ranitidine injection is well tolerated following intravenous administration at
dose levels of up to 100 mg four times daily for ten days. These levels are in excess
of those recommended for normal clinical use.
Treatment of volunteers with ranitidine 150 mg twice daily for 7 days did not
cause bacterial overgrowth in the stomach.
Volunteers treated with ranitidine have reported no significant gastrointestinal
or central nervous system side effects; moreover, pulse rate, blood pressure, electro
cardiogram and electroencephalogram were not significantly affected in man
following ranitidine administration.
In healthy human volunteers and patients, ranitidine did not influence plasma
levels of the following hormones: cortisol, testosterone, estrogens, growth
hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating
hormone, aldosterone or gastrin - although like cimetidine, ranitidine reduced
vasopressin output. Treatment for up to 6 weeks with ranitidine 150 mg twice
daily by mouth did not affect the human hypothalamic-pituitary-testicular-ovarian
or -adrenal axes.
At 50 mg intravenously, ranitidine had no effect on prolactin levels. Only at
the 300 mg i.v. dose level was an increase in prolactin secretion, equivalent to that
produced by 200 mg of cimetidine i.v., observed.
At the high dose levels used in the tolerance studies, minor, transient increases
in serum alanine transaminase (ALT/SGPT) and aspartate transaminase
(AST/SGOT) levels were observed in some patients. No other liver function tests
were abnormal for these subjects and the cause and clinical significance of these
findings are unknown.
Laboratory studies have shown that ranitidine has negligible affinity for the
cytochrome P4S0-linked hepatic mixed function oxidase system. In man, ranitidine
treatment has been shown not to impair the metabolism of antipyrine,
aminopyrine, warfarin or diazepam.

PRECAUTIONS
Use in pregnancy and nursing mothers - The safety of Zantac in the treatment
of conditions where a controlled reduction of gastric secretion is required during
pregnancy has not been established. Reproduction studies performed in rats and
rabbits have revealed no evidence of impaired fertility or harm to the fetus due to
Zantac. If the administration of Zantac during pregnancy is considered to be neces
sary, its use requires that the potential benefits be weighed against possible hazards
to the patient and to the fetus. However, therapeutic doses of Zantac administered
to obstetric patients in labour or undergoing caesarean section have been without
adverse effect on labour, delivery, or subsequent neonatal progress.
Ranitidine is secreted in breast milk in lactating mothers but the clinical
significance of this has not been fully evaluated.
Use in impaired renal function - Ranitidine is excreted via the kidney and in
the presence of severe renal impairment, plasma levels of ranitidine are increased
and prolonged. Accordingly, in the presence of severe renal impairment, clinicians
may wish to reduce the oral dose to half of the usual dose taken twice daily, simi
larly it is recommended that ranitidine injection be administered in doses of 25 mg
to patients with renal dysfunction.
Children - Experience with Zantac in children is limited and such use has not been
fully evaluated in clinical studies. It has however been used successfully in children
aged 8-18 years in doses up to 150 mg orally twice daily without adverse effect.

ADVERSE REACTIONS
No serious adverse effects have been reported to date in patients treated with
Zantac. There has been no clinically significant interference with endocrine,
gonadal or liver function, nor has the drug adversely affected the central nervous
system even in elderly patients.
The incidence of adverse events among Zantac-treated patients (8.1 %) was very
little greater than that among placebo-treated patients (7.7%). Only five adverse
events, namely, tiredness (0.38%), headache (0.90%), dizziness (0.32%), diarrhea
(0.52%) and skin rashes (0.52%) had a greater incidence in the ranitidine treated
group than in the control group.
A small proportion (1.99%) of patients treated with ranitidine injection experi
enced itching or burning at the injection site. This reaction was mild and usually
subsided within 10-15 minutes.
Headache was experienced by 2.54% of patients receiving ranitidine injection.
The majority of these cases were not thought to be treatment-related. In some in
stances the headache was thought to be due to over-rapid injection of ranitidine,
and did not recur on rechallenge with slow intravenous injection. Similarly, some
patients experienced nausea after rapid injection of the drug, but on subsequent
occasions with slow-intravenous injection, experienced no ill-effects.

OVERDOSAGE
Zantac is very specific in action and accordingly no particular problems are
expected following overdosage with the drug. Symptomatic and supportive therapy
should be given as appropriate. If need be, the drug may be removed from the
plasma by haemodialysis.

DOSAGE AND ADMINISTRATION
Adults: Zantac injection may be given either as a slow (over one minute) intra
venous injection of 50 mg, which may be repeated every six to eight hours; or as an
intravenous infusion at a rate of 25 mg per hour for two hours; the infusion may be
repeated at six to eight hour intervals.
In the prophylaxis of haemorrhage from stress ulceration in seriously ill
patients or the prophylaxis of recurrent haemorrhage in patients bleeding from
peptic ulceration, parenteral administration may be continued until oral feeding
commences. Patients considered to be still at risk may then be treated with Zantac
tablets 150 mg twice daily.
In patients considered to be at risk of developing acid aspiration syndrome
Zantac injection 50 mg may be given intramuscularly or by slow intravenous injec
tion (over one minute) 45-60 minutes before induction of general anaesthesia.
Experience with Zantac in children is limited and it has not been fully eval
uated in clinical studies - see PRECAUTIONS.

AVAILABILITY
Zantac Injection is available as 2mL ampoules each containing 50 mg ranitidine
(as hydrochloride) in 2mL solution for intravenous or intramuscular administra
tion. Packages of 10 ampoules.
Zantac Tablets are available as white film-coated engraved ZANTAC 150 on
one face and GLAXO on the other containing 150 mg ranitidine (as the
hydrochloride), in packs of 28 & 56 tablets.

REFERENCES
1. Morison, David H. et al: A Double-Blind Comparison of Cimetidine and
Ranitidine as Prophylaxis Against Gastric Aspiration Syndrome, Anesthesia and
Analgesia, Vol. 61, No: 12, December 1982.
2. van Blankenstein, M. and van den Berg, B., The Prevention of Stress-Induced
Upper Gastrointestinal Bleeding by Ranitidine in Critically 111 Patients,
In: Tytgat G.N. (ed) Ranitidine, The Selective New Hj-Receptor Antagonist,
Theracom 1982, Pages 41-45.

INDICATIONS AND CLINICAL USE
Zantac injection is indicated for the treatment of duodenal ulcer, benign gastric
ulcer, post-operative ulcer, reflux esophagitis, Zollinger-Ellison syndrome and
other conditions where reduction of gastric secretion and acid output is desirable.
These include the prophylaxis of gastrointestinal haemorrhage from stress ulcera
tion in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients
with bleeding peptic ulcers and before general anaesthesia in patients considered to
be at risk of acid aspiration (Mendelson’s) syndrome, particularly obstetric patients
during labour.
For appropriate cases Zantac Tablets are also available.

TH E BETTER (pS® ANTAGONIST.

CONTRAINDICATIONS
There are no known contraindications to the use of Zantac (Ranitidine).

WARNINGS
Gastric ulcer - Treatment with a histamine Hj-antagonist may mask symptoms
associated with carcinoma of the stomach and therefore may delay diagnosis of the
condition. Accordingly, where gastric ulcer is suspected the possibility of malig
nancy should be excluded before therapy with Zantac is instituted.
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Now,
control
hyperacidity
without drug
interactions.
INJECTION.
(RANITIDINE HC1)

(c®

Effectively treats hypersecretory conditions
with fewer patients at risk.®

(?®

“This study suggests that (Zantac)...increases
the mean gastric pH and decreases
the number of ‘at risk days’ in seriously ill
patients.”®

Prevents acid aspiration syndrome without
the hepatic drug interactions found with
other H 2 antagonists.

<P®

Effectively inhibits gastric acid secretion one of the major factors involved in the
pathogenesis of stress ulcers.
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Davis + Geek Introduces

SfTGlJT
Surgical Chromic Suture

Something
you’re used to
without
the problems
you’re used to
You told us that you liked using catgut but you didn’t like its
problems. So we took catgut and made it
•
•
•
•

soft and supple
easy to tie
less likely to curl, “pigtail” and tangle
easy to handle and control

In fact, we made it

S'FTGUT
Surgical Chromic Suture

Better than catgut — but still catgut

DAVIS+GECK
Cyanamid Canada Inc.

A TRADITION OF INNOVATION

Atria North, 2255 Sheppard Avenue East, Willowdale, (Ontario) M2J 4Y5
‘ Tradem ark A m erican C yanam id C om pany

